Home

Medicinal cannabis is changing the face of clinical medicine.  We are the leaders of that change.

Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait
Happy,Family,With,The,Child,In,The,Field
Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny
A,Family,Having,A,Walk,With,A,Dog
Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A
Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A
Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature
Granddad,With,Cheerful,Granddaughter,Having,Fun
Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl
Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting
Parents,Play,In,The,Park,With,Their,Son
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Group,Of,People,Holding,Hands,Support,Team,Unity
Happy,Grandfather,,Grandmother,And,Grandson
Group,Of,People,Holding,Hands,Support,Team,Unity
Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green
Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure
Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front
Beautiful,Couple,Taking,A,Walk,In,City,Park
Happy,Leisure
Couple,Wife,Husband,Dating,Relaxation,Love,Concept
Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Group,Of,Senior,Retirement,Exercising,Togetherness,Concept
Group,Of,Senior,Friends,Hiking,In,Countryside
Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back
Beautiful,Couple,Taking,A,Walk,In,City,Park
Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At
Happy,Family,In,The,Park,On,A,Sunny,Day
Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In
Soldier,Reunited,With,His,Parents,On,A,Sunny,Day
Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The
Portrait,Of,Senior,People,Celebrating,Birthday
Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing
Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait Happy,Family,With,The,Child,In,The,Field Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny A,Family,Having,A,Walk,With,A,Dog Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature Granddad,With,Cheerful,Granddaughter,Having,Fun Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting Parents,Play,In,The,Park,With,Their,Son Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction Group,Of,People,Holding,Hands,Support,Team,Unity Happy,Grandfather,,Grandmother,And,Grandson Group,Of,People,Holding,Hands,Support,Team,Unity Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside Group,Of,Senior,Retirement,Friends,Happiness,Concept Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front Beautiful,Couple,Taking,A,Walk,In,City,Park Happy,Leisure Couple,Wife,Husband,Dating,Relaxation,Love,Concept Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following Group,Of,Senior,Retirement,Friends,Happiness,Concept Group,Of,Senior,Retirement,Friends,Happiness,Concept Group,Of,Senior,Retirement,Exercising,Togetherness,Concept Group,Of,Senior,Friends,Hiking,In,Countryside Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back Beautiful,Couple,Taking,A,Walk,In,City,Park Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At Happy,Family,In,The,Park,On,A,Sunny,Day Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In Soldier,Reunited,With,His,Parents,On,A,Sunny,Day Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The Portrait,Of,Senior,People,Celebrating,Birthday Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing

At CED Clinic, we aim to create a welcoming and professional environment in which patients and clinicians can openly discuss the benefits of medical cannabis.

Our Services

  • Massachusetts Medical Card Certifications
    • Adult Cannabis Care
    • Pediatric Cannabis Care
  • In-Depth Consultations & Care Plans
    • Concierge Care
    • EO Care
    • Medical Second Opinions
    • Talk Therapy

Our Mission

  • To Heal
  • To Educate
  • To Listen

Our Team

Benjamin Caplan, MD
Erin Caplan, NP

Benjamin Caplan, MD, stands at the forefront of medical cannabis care as the Founder and Chief Medical Officer of CED Clinic and CED Foundation. His entrepreneurial journey further extends as the Founder of multiple medical cannabis technology and educational platforms and as a medical advisor to the prestigious cannabis investment fund, GreenAXS Capital. Within digital healthcare, Dr. Caplan co-founded EO Care, Inc, a pioneering digital therapeutic and telemedicine platform, offering personalized cannabis care and product plans and continuous clinical guidance to a global clientele seeking a reliable, evidence-based cannabis care partner. Adding to his repertoire of contributions to the medical cannabis arena, Dr. Caplan has recently published “The Doctor-Approved Cannabis Handbook,” an industry-first resource empowering readers with the full scope of the therapeutic potential of cannabis. Through his multifaceted involvement, Dr. Caplan continuously strives to bridge the gap between traditional medicine and cannabis care, making a significant impact in evolving holistic healthcare.

Erin Caplan, NP is a board-certified Pediatric Nurse Practitioner with a master’s-level medical education from Simmons. Her extensive clinical journey has been enriched through roles at Massachusetts General Hospital, Hyde Park Pediatrics, and Dana-Farber Cancer Institute, where she has provided both inpatient and outpatient primary care to some of the most fragile and challenging pediatric patients. A registered cannabis care provider licensed by the Massachusetts Cannabis Control Commission, Erin seamlessly blends her pediatric expertise with the nuance and adaptability required for personalized cannabis care. A community leader, avid athlete, and dedicated mother of four, Erin’s compassionate bedside manner and steadfast commitment to evidence-based practice have earned her the trust and appreciation of patients and families, showcasing her as a harmonious blend of clinical excellence with a personal touch.

Patient Stories

Happy customer!

My visit to CED Clinic was absolutely amazing, and it all started with Kim. She was so friendly and helpful right from the get-go, making the whole scheduling thing a breeze – a real breath of fresh air! Then there was Dr. Caplan. Honestly, chatting with him felt more like catching up with an old friend than a typical doctor’s visit. He didn’t seem to be watching the clock at all; he was all in, really getting to grips with what I’ve been going through, and dishing out advice that hit the nail on the head. And get this – he’s even written a book about it all! I can’t wait to get my hands on a copy. The whole experience at CED Clinic was just so warm and genuine. They’ve got something special going on over there, for sure.

Amanda Kimmel

I’m Free: My Journey Beyond Chronic Pain!

I felt trapped in a cycle of chronic pain, where prescription and over-the-counter meds were just dead ends. Then I found Dr. Caplan. His blend of medical expertise and cannabis knowledge opened a door I didn’t know existed. I read ‘The Doctor-Approved Cannabis Handbook’ and it was/is a turning point—packed with research and actionable advice, it guided me to a pain management plan that actually worked. Thanks to Dr. Caplan, I’m living with less pain and more hope. Highly recommend for anyone stuck in the pain cycle.

Emily Brasston

From Frayed Edges to Balance: Found My Center with Cannabis

Let me paint you a picture of my life not too long ago: a job that never hit ‘pause,’ kids that always needed me in a hundred different ways, and a level of work stress that had me teetering on the edge. I was juggling more plates than I had hands for, and it felt like I was one strong breeze away from watching them all come crashing down. Sleep was a luxury I couldn’t afford, and ‘me time’ was a concept so foreign it might as well have been from another planet.

Enter Dr. Benjamin Caplan and his life-altering approach to managing stress through cannabis medicine. At first, I was skeptical—could this really be the answer I’d been searching for? But from the moment we began, it was clear Dr. Caplan wasn’t just any doctor. His blend of traditional medical insight and innovative cannabis expertise was like a breath of fresh air.

What truly transformed my journey, though, was diving into ‘The Doctor-Approved Cannabis Handbook.’ This wasn’t just another self-help book; it was a treasure trove of evidence-based research, clinical wisdom, and, most importantly, actionable advice that felt like it was written just for me. It became my North Star, guiding me through the haze of stress and sleepless nights to a place of understanding and balance.

Thanks to the personalized strategy Dr. Caplan crafted with me, I’ve been able to reclaim control over my stress and find a sense of equilibrium I didn’t think was possible. My work no longer feels like a constant battle, and I’ve found more joy and presence in the time I spend with my kids. The difference is night and day.

I’m beyond grateful to Dr. Caplan and the invaluable lessons from his handbook. For anyone feeling overwhelmed by the demands of work, family, and everything in between, Dr. Caplan’s compassionate, evidence-based approach might just be the lifeline you need. I can’t recommend him enough.

Sam Dexter

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

I’ve been in this battle with chronic insomnia for what feels like forever. I hit a point where I felt completely out of options. I mean, you name it, I tried it—all those over-the-counter fixes, prescriptions from my doctors, and I even got creative mixing up my own cannabinoid solutions. But nothing worked. Those endless nights of tossing and turning weren’t just annoying; they were wrecking my health and my spirits.

Then, almost out of nowhere, I stumbled upon Dr. Benjamin Caplan and his work in the world of cannabis medicine. From the moment we started talking, I knew this was different. He’s got this unique blend of traditional medical wisdom and cutting-edge cannabis knowledge. It’s like he sees the whole picture in a way no one else had shown me before.

But here’s the real game-changer: “The Doctor-Approved Cannabis Handbook.” That book blew my mind. It’s packed with solid science and real-deal clinical insights on how cannabis can tackle not just insomnia but a whole list of issues. More than that, it gave me straightforward, practical steps tailored just for me. It turned into my guide on this journey to use cannabis safely and super effectively.

I owe so much to Dr. Caplan and the wisdom packed into that book. I’ve finally found some peace from my insomnia—a relief I thought was off the table for me. My sleep’s way better, and my days? They’ve transformed. I can’t thank Dr. Caplan enough. And seriously, if you’re hitting a wall with insomnia or any health problem that just won’t budge with the usual treatments, Dr. Caplan’s approach could be the breakthrough you’re looking for. Certainly was for me.

 

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

Used as a Human Target as a Kid, Medical Cannabis is the answer.

I’m totally blind. I live in a rural area. So when I was 12, same-age peers thought zapping the blind girl’s eyes with laser pointers would be a great idea. It got bad enough that my paraprofessional had to have the devices banned from the school for my safety. Shortly after, I began having intense eye aches. I differentiate them from headaches because even a 12 year old can tell the difference. Doctors told my parents and I they were migraines. It wasn’t until later in life that I began realizing there was something else going on here. Really studying migraines, studying the eye, studying neurology and understanding not all was as it seemed. I began developing my own theories as to what these “migraines” were. I take migraine meds, but they don’t treat the eye aches. They treat the other migraine symptoms just fine. My younger brother suggested I try edibles last year. Because by this point, I was in enough pain where I believed I’d have to have my eyes removed. None of us wanted to see that happen. So he took me to a dispensary, (he had spoken with someone he knew there about me prior, and they’d come up with a regimen they thought would work.) The first clue I had that we were on the right track, was that I slept for 14 hours. So I kept a calendar and a spreadsheet full of virtual sticky notes, and 2 weeks later came to Dr. Caplan for my medical card, crazy theories about optic neuropathy in underdeveloped optic nerves and all. A year later, I’m studying cybersecurity, because that’s something I found I’m passionate about, and I can do it now!

Krista Pennell

To sleep well again is life-changing

Dr. Caplan was coincidentally recommended by both my dentist and a close friend. I was concerned about finding a high level, knowledgeable, physician in a professional setting who understood using cannabis in a safe and effective manner. I can’t recommend Dr. Caplan more highly. His knowledge is vast and I am grateful for his expertise, care and compassion. To sleep well again is life-changing. Very few things literally change someone’s life. Dr. Caplan’s knowledge and guidance on cannabis did that for me.

Barbara M.

Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared

Honestly, I was hesitant to try cannabis. I have debilitating menstrual cramps and my OB/GYN recommended Dr. Caplan. I was more than a little hesitant to try cannibas because all I really knew about it was that people used it to get “high” – and that was not something I was interested in. This perspective totally changed when I actually came in and met with Dr. Caplan. He was incredibly understanding and really took the time to ease my mind about the whole process, what kind of options there were to choose from, what they might do, and what would probably appeal to me. He spent a lot of time answering all my questions (and I had a lot!). Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared.

Mark L.

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach. He provided in depth information and step by step guidance for beginning the process of utilizing cannabis therapies. He is available to his patients by email and phone. I highly recommend an appointment with him if you are even remotely considering medicinal use. I was hesitant about this approach before my appointment but now, after talking with Dr. Caplan and learning a little bit more about the science, I am eager to explore and I feel better already!

Rachel M.

I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor

I came into marijuana medicine with zero experience. I must say, I’ve been learning a ton, and I would recommend it to anyone with terrible anxiety and depression. I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor. A friend told me that I should see Dr Caplan, but I was still unsure about becoming a medical marijuana patient. I called and was able to speak with Dr Caplan directly. He took time, on the phone, even before he had met me, to explain the whole process, which helped me feel more comfortable putting a voice and personality to the process. Later, when I finally came in, during the visit, he spent almost 40 minutes with me, walking me through how cannabis might fit in with some of the other treatments I currently use. We have kept in touch over email since, like 3 or 4 random questions, and has always responded promptly. I think he is a truly special doctor, and from what I’ve read on Twitter, has a passion for educating and helping improve the perception of cannabis.

Alan T.

I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries

Full stars. I appreciate the great parking and simple scheduling system. I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries. No fancy language, no time wasted. Works for me.

Michael J.

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group. I have seen him speak publicly, and on TV, and of course he is also my doctor. In spite of having what seems to be a crowd of patients who are mostly in terrible pain or have a generous helping of emotional/mental issues, I see him work tirelessly for his patients and for the cause, in general. I appreciate his leadership in the cannabis field. He is one in a million.

Stephanie W.

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Joshua C.

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion. He is a true healer, with a great heart, enormous patience, and extraordinary expertise. My wife and I were amazed to find a physician who truly puts his patients first, and who is passionate about figuring out the best way to help us with our chronic pain. In our 60+ years of experience with health care providers, Dr. Caplan is among the most committed, generous, and caring healers we have ever met.

Heather F.

I can’t recommend Dr. Caplan highly enough

I can’t recommend Dr. Caplan highly enough. This was my third medical marijuana certification review (original plus two renewals), and the previous two doctors were just perfunctory form-fillers in shabby offices in remote office parks. Dr. Caplan is a REAL cannabis doctor who’s deeply knowledgeable about medical marijuana and clearly explains EXACTLY how to use it for YOUR specific conditions. He also has a real doctor’s office in a real medical building right on Boylston Street (Route 9) in Chestnut Hill ( not far from NETA Brookline, my dispensary of choice.) AND THE VISIT IS COVERED BY MEDICAL INSURANCE! I’ve become somewhat knowledgeable about what works for my primary complaint (chronic pain from spinal stenosis w/ radiculopathy) and what to avoid, but he gave me brand new ways to deal with my insomnia (including how and when to use edibles, which hadn’t worked for me before b/c I didn’t really know what I was doing) and arthritis in my hands (including a simple recipe to make topical lotion that’s stronger and cheaper than the commercial products). I interrupted him with frequent questions, which he answered at whatever level of detail and technical information I wanted. I had been deeply dissatisfied with the cannabis doctors I went to before, but Dr. Caplan is an outstanding DOCTOR who happens to specialize in medical marijuana because he cares about helping patients for whom traditional medicine hasn’t fully met their needs. You can book appointments on his web site, although my wait time was more than 10 minutes (during which I filled out his online patient questionnaire on my phone and ate all the Kit Kats in his candy basket), it was well worth it. This is a relatively new practice, I believe, and it’s going to get a lot busier as word spreads. But just do yourself a favor and go: this is what state-of-the-art medical marijuana care is supposed to be like.

Steve G.

Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for

I recently had my first appointment with Dr. Caplan after reading negative reviews of so many other medical marijuana certification “places”. I can’t say enough good things about my visit with him. To start with he’s a very compassionate, caring doctor. I’m a 63 yr old woman and had never used marijuana or “street drugs”, so I was feeling nervous about trying it. I recently started chemo therapy at Dana-Farber and the side effects have been difficult to deal with. In particular, insomnia and a bit of evening anxiety. He is extremely knowledgeable about all aspects of medical marijuana. Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for. With that said, he suggested several products for me to try. I now know what helps me, but each person has to use the information he gives and then try different products from a reputable medical dispensary. I plan to have a 2nd appt. with him in a few months just to get his feedback on my experiences and possibly more recommendations. It’s not necessary to go back to him after getting your certification, but he truly knows so much about the medicinal benefits that I’d like to learn even more. I highly recommend him.

Nancy O.

I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Robert M.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didn’t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience. Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can’t recommend him highly enough.

Justice S.

Excellent Experience, top to bottom

Excellent Experience, top to bottom. I scheduled my appointment on CED clinic website, got in the next day – and visit was informative, and doc was kind, compassionate, and amazingly knowledgeable. I intend to follow him as a permanent addition to my healthcare and would recommend widely.

Ellison M.

I’m shy but felt comfortable and supported

Awesome doctor. Super easy to talk to. I’m shy but felt comfortable and supported. Great teacher too. I had no idea there was so much to know!

Sara E.

I learned about different options and lots of choices, and received handouts to learn even more

First heard of Dr Caplan on /r/BostonTrees subreddit. Made my appointment online, for the next day, and did all paperwork online before I came in. Building is very professional and comfortable, with great parking, and close to where I live. As I expected, doc was kind, thorough, and efficient. We reviewed my medical history, talked about what I had been doing in the past, and discussed a host of treatment ideas, and not just marijuana. I learned about different options and lots of choices, and received handouts to learn even more. I plan to follow up in a few months, and I look forward to it.

Ryan H.

Every time I come in, I learn something new and amazing.

I followed Dr Caplan from his position as the Medical Director of Canna Care Docs to CED Clinic – and would follow him again. I have had years of back pain and arthritis – my wrists and knees and hips. Dr Caplan has helped me understand much more about marijuana, and I have to say, it has been a wonderful improvement for me. Every time I come in, I learn something new and amazing. It’s a new industry for me, and I feel very well supported.

Elizabeth P.

My visit with Dr. Caplan made it comforting to know that someone was on my side

My visit with Dr. Caplan made it comforting to know that someone was on my side. I was surprised to find that Dr. Caplan does more than just write scripts for people to take to dispensaries. He sees some of his patients on a regular basis to personalize treatment plans and it’s clear he cares about education and the destigmatization of medical cannabinoids. He goes to assisted living centers, medical expos, wellness centers, and more to speak with people on the matter. This is his passion!

Benjamin T.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didnâ€t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience.†“— Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can€t recommend him highly enough.

Jeff E.

Very knowledgeable and compassionate

Very knowledgeable and compassionate.

Irene C.

I would highly recommend Dr. Caplan

I wasn’t sure what to expect from the initial appointment.  It was informative, educational and an overall great experience!  Dr. Caplan is easy-going, kind, and gave clear, detailed information about medical cannabis and MA medical dispensaries.  I would highly recommend Dr. Caplan.  His clinic and his knowledge are certainly worth 5-star reviews!

Ashley S.

I had such a good experience with Dr. Caplan of CED Clinic.  

I had such a good experience with Dr. Caplan of CED Clinic.

Medical: I had a lot of worries going in, and Dr. Caplan put me at ease with his knowledge and calm manner.  As a family doctor, he asked good questions about my extensive medical background, in a supportive way.  He used normal people words instead of medical gobbledygook!  (I had just an hour before been at an appointment with a medical person who thought I should understand when he talked about my distal iliolumbar neuropathy – or something like that, I had no idea what he was talking about – so I especially noticed when Dr. Caplan used normal words that any person would know.)

Educational: He provided excellent information for total newbies, showed some devices, talked about legal stuff, and gave great info about local clinics and huge discounts available.  I’m used to doctors providing pretty poor education materials, but Dr. Caplan’s infographics and handouts were a thing of beauty – informative, easy to read, and visually simple.  I hope Dr. Caplan writes a book because I will buy it.

Logistics: This is such a streamlined practice, it is easy to get in soon, and respectful of your time.  I got an appointment within less than 2 days, scheduled online, filled out my info online beforehand, found parking easily, was in and out quickly, and received the email with next steps instructions and application activation code in 1.5 hour!  Can’t possibly be easier than this.

Laura M.

Dr. Caplan was very friendly, extremely helpful and knowledgeable

Dr. Caplan was very friendly, extremely helpful and knowledgeable.  I would definitely recommend and I am looking forward to having him as a health resource.

Timothy Y.

I’ve switched 100% to cannabis as my go-to medicine

I’ve switched 100% to cannabis as my go-to medicine.  I’m sick of pharmaceuticals; the weight gain, the weird feelings like I’m a zombie, the miserable sleep…sorry, but hard pass.  Weed helps take the edge off and I’m still fully functional.

Anonoymous

The Doctor-Approved Cannabis Handbook

"A wealth of information and a huge dose of compassion and clarity."

Melissa Etheridge

Upcoming Events Calendar

No Events Found

The Latest

CED Clinic Blog
March 25, 2024Cannabis and Cardiovascular Health 2024: Understanding The Limitations of  “Association of Cannabis Use With Cardiovascular Outcomes Among US Adults” by Jeffers et al., published in JAMA  and Pathways for Future Research In a landscape where the intersection of cannabis use and health outcomes is increasingly scrutinized, the study “Association of Cannabis Use With Cardiovascular Outcomes Among US Adults” by Jeffers et al., published in JAMA, ignites a complex debate and introduces fresh perspectives on this contentious subject. As a family physician deeply embedded in the exploration of cannabis and its health implications, I read this study as both intriguing and problematic, offering critical insights while simultaneously raising some questions about its findings. Its publication marked a media frenzy, and at a crucial moment in the history of cannabis legalization (which rumors seem to suggest may be coming, in some form, quite soon), spotlighting the need for a deeper, more nuanced understanding of cannabis’s role in health and disease. However, this paper unleashes a series of potential flaws and meaningful limitations that merit a closer, second look. Through this lens, the paper not only contributes to the ongoing dialogue within both the scientific and wider communities but also underscores the indispensable need for further investigation to unravel the complexities of cannabis use and its true impact on cardiovascular health. Understanding the Impact of Confounding Variables in Cannabis and Cardiovascular Outcome Studies The Issue of Confounding Variables Definition: Factors associated with both cannabis use (exposure) and cardiovascular events (outcome), potentially distorting their observed relationship. Impact: Can lead to incorrect conclusions about causality between cannabis use and cardiovascular health. Potential Confounders in This Study Unmeasured Confounders: Socioeconomic status, dietary habits, genetic predispositions, and other lifestyle factors possibly overlooked. Medication Use: Lack of account for medications affecting cardiovascular health (e.g., hypertension, diabetes medications). Duration and Timing of Cannabis Use: Study possibly missed capturing varying durations or timing of cannabis use, affecting cardiovascular event risks. Underlying Health Conditions: Possible failure to control for pre-existing heart conditions or inflammatory disorders beyond assessed risk factors. Importance of Addressing Confounders Ensuring that observed associations are genuinely due to the exposure of interest, not external factors. Failure to address confounders introduces bias, compromising study conclusions. Suggests further exploration and sensitivity analyses to enhance study validity and reliability. What does this all mean? Here are some Simple Analogies To Highlight The Main Concepts and Challenges: Dietary Supplements and Health Outcomes: Similar limitations due to potential confounding factors, recall bias, and lack of longitudinal data. Explained: Studies on dietary supplements often face the challenge of distinguishing the effects of the supplements from those of overall diet, lifestyle, and unreported health practices, with participants possibly forgetting or misstating their supplement intake and health outcomes over time. Screen Time and Cognitive Development: Challenges in establishing causal links and addressing confounding factors, such as parenting practices. Explained: Research into how screen time affects children’s brains must consider not just the hours spent in front of screens but also the quality of content, the educational or entertainment value, and how parental involvement moderates these effects, making it difficult to isolate screen time as the sole factor in cognitive development Exercise Frequency and Weight Loss: Importance of longitudinal data and addressing confounding factors for reliable conclusions. Explained: Long-term studies tracking the exercise habits of individuals are necessary to accurately determine how variations in exercise frequency impact weight loss, taking into account dietary habits, genetic predispositions, and lifestyle changes over time to avoid misattributing weight changes solely to exercise frequency. Social Media Use and Mental Health: Need for rigorous study designs to accurately assess impacts, considering potential confounding factors. Explained: Evaluating the mental health effects of social media usage requires carefully designed studies that account for users’ baseline mental health, types of social media interactions (passive vs. active), and individual differences in resilience and social support, to discern true psychological impacts from mere associations. Significance of Screen Time Analogy Relatable and impactful, underscoring the seriousness of addressing confounding factors in research. This emphasizes the necessity of utilizing longitudinal data and ensuring accurate self-reported information. Explained: Research into how screen time affects children’s brains must consider not just the hours spent in front of screens but also the quality of content, the educational or entertainment value, and how parental involvement moderates these effects, making it difficult to isolate screen time as the sole factor in cognitive development. 1) The Challenge of Cross-Sectional Design Jeffers et al.’s study, relying on correlational data, underscores the need for longitudinal research to establish causality between cannabis use and cardiovascular health. This cross-sectional design highlights the complexity of interpreting cannabis’s health impacts and calls for future studies to provide a more dynamic understanding of this relationship. The study by Jeffers et al., focusing on correlations, really puts the spotlight on why we desperately need longitudinal research to make sense of how cannabis use might affect heart health over time. Just using cross-sectional data, like in this study, kind of leaves us guessing about a few crucial things: Cause and Effect: We’re stuck wondering whether cannabis use leads to heart issues, or if perhaps people with certain heart conditions might be more inclined to use cannabis. Time’s Influence: Without following individuals over years, we can’t see how cannabis use and cardiovascular health change together, making it hard to draw solid conclusions from just a single point in time. Need for Depth: Cross-sectional studies give us a snapshot, which is helpful, but not enough. We need the full movie — seeing how things unfold over the long haul gives us a clearer picture of the relationship between cannabis and heart health. So, essentially, while Jeffers et al.’s work adds an important piece to the puzzle, it also rings the bell for the kind of research we need next. By moving towards studies that watch how people’s cannabis use and heart health evolve together, we can start to piece together whether there’s a real cause-and-effect relationship. It’s about getting the full story, not just a glimpse, to truly understand how cannabis affects our hearts and guide safer use. 2) The Complexity of Self-reported Data The whole issue with depending on folks to just tell us how much cannabis they use gets pretty tricky. Why? Well, because people might not always give the straight scoop due to the whole stigma thing or even legal worries about admitting to using cannabis. Here’s what this boils down to: Trust Issues: It’s hard to take everything at face value when people might hold back or alter the truth about their cannabis use. The Stigma Factor: Let’s be real, the judgment and legal grey areas around cannabis can make people think twice about being open. Objective Measures Needed: This is a big shoutout for future research to start using methods that don’t rely solely on trust. Think blood tests or other clinical ways to check cannabis levels. In short, if we really want to get a clear picture of how cannabis is being used and its effects, we’ve got to mix in some concrete, scientific ways of measuring it alongside just asking folks. This approach could give us a fuller, more accurate story of cannabis consumption patterns, cutting through the hesitancy and getting down to the facts. 3) Addressing Confounders Jeffers et al. really did put in the work to factor in various influences that could throw off their findings, but here’s the thing: health is complicated. It’s not just about one or two things; it’s about how your genes, your daily habits, and even where you live all tangle together. So, when we’re looking into how cannabis affects us, we’ve got to get even smarter about how we study it. Here’s the lowdown: Genes: Your DNA can play a big part in how your body reacts to cannabis, and we’re just scratching the surface here. Lifestyle Choices: What you eat, how much you move, and even your stress levels can influence how cannabis impacts your health. Where You Live: Believe it or not, your environment – like air quality and access to green spaces – can also affect the health outcomes of cannabis use. To really get a handle on this, future research needs to level up, using models that can juggle all these factors at once. This way, we can get a truer picture of how cannabis fits into the larger health puzzle, reflecting the real-world complexity of our lives. 4) Tobacco and Cannabis: Unraveling Their Collective Impact The study takes a peek at how smoking tobacco and cannabis together might play out for heart health, but honestly, we’re just dipping our toes in the water here. To really understand what’s going on, we need to dive deeper. Here’s what’s on the agenda: Mixing Matters: It’s not just about tobacco or cannabis alone; it’s how they team up and impact the heart that’s intriguing. Synergy or Storm?: There’s a chance these substances could interact in ways that amplify their effects, for better or worse. Guiding Health Choices: Unpacking these interactions could lead us to smarter advice for folks about the risks of using both. Shaping Policies: And it’s not just personal choices; this kind of knowledge could help tweak public health policies to better protect hearts. Bottom line: The way tobacco and cannabis use together affects cardiovascular health is a big question mark that future research needs to tackle. Getting to the heart of this matter could open up new paths for preventing heart issues and crafting health policies that genuinely reflect the nuances of substance use. 5) Consumption Methods and Their Health Impacts The study kind of glosses over a pretty key point: how you use cannabis can make a big difference in its health effects. Whether you’re lighting up, vaping, or munching on an edible, each method packs its own unique punch when it comes to your health. Here’s why this matters: Different Strokes: Smoking vs. vaping vs. edibles – each one hits your body in its own way, and we need to understand these differences better. Clearer Advice: Knowing more about these methods can help us give spot-on recommendations to keep people safer. Public Health Policies: And it’s not just about individual choices. Solid data on these consumption methods could guide public health policies, making sure they’re actually based on how people are using cannabis. So, the big takeaway? Future studies should really zero in on the impact of different cannabis consumption methods. This could clear up a lot of confusion and help tailor advice and policies that match real-world habits.   Moving Forward: The Imperative for Comprehensive Research Enhanced Research Designs: Future studies should employ longitudinal designs and randomized controlled trials to better establish causality and the long-term effects of cannabis use. Comprehensive Data Collection: Incorporating biochemical validation of self-reported cannabis use and expanding data collection to include cannabis strains, consumption methods, and dosages will offer a more accurate picture of consumption patterns. Broadened Analytical Approaches: Analyses must account for a wide range of potential confounders, including genetic predispositions, lifestyle factors, and environmental influences, to ensure findings accurately reflect the complex reality of cannabis use. Interdisciplinary Collaboration: Leveraging expertise from various fields, including pharmacology, genetics, epidemiology, and social sciences, can enhance study designs and analytical frameworks, providing a more comprehensive understanding of the issues at hand. Public and Policy Engagement: Researchers should work closely with policymakers and the public to ensure that findings are translated into effective public health strategies and policies that reflect the nuanced understanding of cannabis’s health implications. In essence, the study by Jeffers et al. represents an important step in the ongoing journey to understand the relationship between cannabis use and cardiovascular health. However, it also underscores the substantial work still needed in this field. By embracing these challenges as opportunities for growth and refinement, the scientific community can contribute to a body of evidence that supports safe cannabis use and informs public health policy in a meaningful way. The study “Association of Cannabis Use With Cardiovascular Outcomes Among US Adults” by Jeffers et al. serves as an important stepping stone for future research into how cannabis use might affect heart health. It brings to light the necessity for more detailed studies, particularly longitudinal ones, that can look at how things change over time. This kind of research is key for a couple of reasons: it helps us figure out if there’s a direct link between using cannabis and having heart problems, and it provides valuable information that can help shape public health policies. The call for these longer-term studies is a reflection of our growing need to understand cannabis’s impact better as its use becomes more widespread legally and socially. With more people using cannabis, either for medical reasons or recreationally, getting clear answers about its long-term effects is increasingly important. This information is critical not just for the sake of adding to our scientific knowledge but also for guiding public health decisions that affect lots of people. While the research by Jeffers et al. opens up new questions, it also points us toward the kind of research that could provide answers. By following the paths it suggests, we can work towards a more informed understanding of cannabis use and its implications for cardiovascular health, which in turn can help in developing more informed guidelines and policies. This effort aligns with the broader goal of ensuring public health strategies are based on solid evidence. Conclusion: Navigating the Complexities of Cannabis Research The scientific examination of cannabis’s impact on health is a complex, evolving field. The study by Jeffers et al. is a critical step forward, yet it also serves as a reminder of the ongoing need for rigorous, nuanced research. As we continue to explore cannabis’s health implications, let us do so with an unwavering commitment to scientific integrity and the quest for knowledge. Comprehensive Summary of limitations: Cross-sectional Study Design: Limits on establishing causality between cannabis use and cardiovascular outcomes. Self-reported Cannabis Use: Potential for underreporting or misreporting due to stigma or recall bias. Adjustment for Confounders: Questions whether all relevant confounders, especially lifestyle, diet, or genetics, were considered. Tobacco Use as a Confounder: The need for more nuanced analysis on the interaction between tobacco and cannabis use. Lack of Information on Cannabis Dosage and Consumption Method: No detailed data on the dosage, potency, and method of cannabis consumption. Generalizability of Findings: Concerns about the applicability of findings across different populations. Cardiovascular Outcomes Measurement: Use of self-reports for diagnosing cardiovascular outcomes could introduce bias. Potential for Residual Confounding: Despite adjustments, the possibility of unaccounted influencing factors remains. Physiological Mechanisms: The study might not fully delve into how cannabis use leads to adverse cardiovascular outcomes. Correlation vs. Causation: The study does not clearly distinguish between the two, complicating the interpretation of findings. Specificity of Cardiovascular Outcomes: Lack of differentiation in cardiovascular outcomes might overlook nuanced effects. Lack of Longitudinal Follow-up: The absence of data over time to observe the progression of cardiovascular health. Inadequate Consideration of Cannabis Strains: No differentiation between cannabis strains with potentially different effects. Missing Data on Other Medications: Potential drug-cannabis interaction effects are not explored. Control Group Selection: Possible issues with how the control group was matched to cannabis users. Sample Representativeness: The sample may not reflect the general population accurately. Potential Reporting Bias: Reliance on self-reports and medical records could introduce bias. Exclusion of Acute Effects: The study focuses on long-term outcomes, possibly overlooking immediate cardiovascular effects. Environmental and Social Factors: Omission of factors like socioeconomic status and stress levels that could affect outcomes. Ethical Considerations: The study may not fully consider the ethical implications of cannabis use. Variability in Cannabis Quality and Sources: Not accounted for, which can significantly affect health outcomes. Psychosocial Factors: The impact of stress, social support, and mental health on cardiovascular outcomes might be overlooked. Dose-Response Relationship: Absence of detailed analysis on the relationship between cannabis use intensity and cardiovascular risk. Comparison with Other Substances: The study does not compare cannabis use effects with those of other substances like alcohol. Mechanisms of Action: Limited exploration of the biological mechanisms through which cannabis affects the cardiovascular system. Subgroup Analyses: Lack of detailed analyses that could reveal differential effects across various populations. Long-term vs. Short-term Use: No clear distinction between the impacts of long-term versus short-term cannabis use. Clinical Endpoints: Focus might be on surrogate endpoints rather than on outcomes directly relevant to patients. Legal and Regulatory Implications: Consideration of legal and regulatory contexts affecting cannabis use is missing. Future Research Directions: Insufficient guidance on specific areas needing further investigation for a deeper understanding of cannabis and cardiovascular health These reservations collectively point to a broader issue within cannabis research: the need for a holistic approach that considers a myriad of factors influencing both cannabis consumption and its health outcomes. The nuanced nature of cannabis’s interaction with cardiovascular health demands a multifaceted research strategy that goes beyond what any single study can provide. Addressing these limitations will not only refine our current understanding but also pave the way for targeted interventions that could mitigate potential risks associated with cannabis use. [...] Read more...
March 18, 2024The Essential Role of Physician Guidance in the Cannabis Industry The essential role of physician guidance in the cannabis industry has become increasingly crucial as the sector experiences remarkable growth and gains mainstream acceptance. The integration of medical expertise is paramount for the industry’s success, ensuring safe, effective, and personalized patient care. This necessity stems from the rapidly expanding landscape of cannabis use for medical purposes, where the guidance of healthcare professionals becomes indispensable to navigate the complexities and ensure the optimal utilization of cannabis for therapeutic benefits. The involvement of physicians and medical experts in the cannabis industry is not just an added value but a critical component in shaping the future of cannabis as a legitimate and effective therapeutic option. Their expertise ensures that the cannabis industry moves forward with a strong foundation in science and patient care, prioritizing health outcomes and patient safety above all. The Frontline of Patient Care Physician guidance in the cannabis industry is foundational, addressing patients’ needs across various conditions, from chronic pain and anxiety to insomnia and neurodegenerative diseases. The vast therapeutic potential of cannabis, paired with the complexities of its use, necessitates expert medical oversight. Healthcare providers specializing in cannabis medicine offer personalized care, guiding patients through treatment with advice on dosing, administration, and side effects management, thus enhancing patient safety and satisfaction while also optimizing healthcare costs. This personalized approach to cannabis medicine allows for a more nuanced understanding of how different strains and dosages can affect individuals, taking into account their unique medical histories and current health status. By doing so, physicians play a critical role in not only mitigating potential risks associated with cannabis use but also in maximizing its therapeutic benefits. The expertise of these healthcare professionals ensures that patients navigating the cannabis landscape do so with an informed and cautious approach, thereby significantly improving the overall efficacy of cannabis as a treatment option and enhancing patient outcomes. A Holistic Approach to Patient Care Effective physician-guided cannabis therapy extends beyond treating primary conditions, potentially reducing dependency on opioids for pain management and improving mental health and quality of life for those with anxiety and depression. Furthermore, improved sleep quality through cannabis can lead to better overall health outcomes. This holistic approach to patient care, facilitated by physician guidance, encompasses a comprehensive view of the patient’s health, considering not just the symptoms of a condition but the overall well-being of the individual. By focusing on the broader implications of cannabis therapy, physicians can address multiple facets of a patient’s health, offering solutions that contribute to their long-term health and wellness. This multifaceted approach not only helps in managing specific medical conditions more effectively but also promotes a general sense of well-being among patients, contributing to improved lifestyle choices and a reduction in the use of conventional medications that may have more severe side effects. The Importance of Evidence-Based Practices Adopting an evidence-based approach under physician guidance in the cannabis industry ensures treatments are grounded in scientific research and clinical data, enhancing the credibility of cannabis therapy and fostering further innovation and development. This commitment to evidence-based medicine is essential in navigating the emerging challenges and opportunities within the cannabis industry. By relying on solid scientific evidence and ongoing research, physicians can provide recommendations that are not only effective but also safe for their patients. This approach ensures that the integration of cannabis into medical practice is based on a rigorous understanding of its benefits and risks, paving the way for innovative treatments that can offer new hope to patients with complex medical conditions. Furthermore, the emphasis on evidence-based practices encourages continuous learning and adaptation within the healthcare community, ensuring that patient care evolves with the latest scientific findings. The Systemic Impact of Physician Involvement Beyond individual care, physician involvement in the cannabis industry offers broad economic and systemic advantages. Effective cannabis therapy can reduce the need for expensive medical interventions, alleviating the economic burden of untreated conditions. Properly managed cannabis therapy can prevent overutilization of healthcare resources, enabling more efficient care delivery. Physician expertise aids in the development of targeted cannabis products, ensuring efficient resource use and meeting specific therapeutic needs. Physicians’ influence on regulatory frameworks promotes responsible practices, crucial for sustainable economic growth and consumer trust in the cannabis industry. These systemic benefits underscore the transformative potential of physician involvement in the cannabis industry, not just in enhancing patient outcomes but in driving forward a more sustainable, efficient, and patient-centered healthcare system. Cost Savings Through Preventative Care: Effective cannabis therapy can reduce the need for expensive medical interventions, alleviating the economic burden of untreated conditions. Reduced Strain on Healthcare Systems: Properly managed cannabis therapy can prevent overutilization of healthcare resources, enabling more efficient care delivery. Optimized Resource Allocation within the Industry: Physician expertise aids in the development of targeted cannabis products, ensuring efficient resource use and meeting specific therapeutic needs. Economic Benefits of Responsible Industry Practices: Physicians’ influence on regulatory frameworks promotes responsible practices, crucial for sustainable economic growth and consumer trust in the cannabis industry. Conclusion Physician guidance in the cannabis industry is indispensable for ensuring patient safety, enhancing treatment efficacy, and supporting the industry’s economic viability. As the cannabis sector evolves, leveraging medical expertise will be key to unlocking its therapeutic potential and integrating cannabis into mainstream healthcare practices. This integration not only promises to improve the quality of care for patients but also to foster a more informed, responsible, and sustainable approach to cannabis use in medical practice. The collaboration between the cannabis industry and medical professionals holds the promise of advancing healthcare outcomes, promoting innovation, and ensuring that the benefits of cannabis are realized fully and responsibly, with patient safety and well-being at the forefront. References: Boehnke, K. F., Litinas, E., & Clauw, D. J. (2019). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain, 20(6), 739-744. Lowe, D. J., Sasiadek, J. D., Coles, A. S., & George, T. P. (2019). Cannabis and mental illness: a review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 107-120. Kuhathasan, N., Dufort, A., MacKillop, J., Gottschalk, R., Minuzzi, L., & Frey, B. N. (2019). The use of cannabinoids for sleep: a critical review on clinical trials. Experimental and Clinical Psychopharmacology, 27(4), 383-401. Kosiba, J., Kiranmala, N., & Wiese, T. J. (2019). Impact of medical cannabis on health care utilization. Evidence to Date. Vigil, J. M., Stith, S. S., Adams, I. M., & Reeve, A. P. (2017). Associations between medical cannabis and prescription opioid use in chronic pain patients: A systematic review and meta-analysis. Systematic Reviews, 6(1), 1-12. Alvarez, J., Kalechstein, A., & Froh, J. (2021). The economic implications of cannabis in the United States. Missouri Medicine, 118(1), 48–54. Klieger, S. B., Gutman, A., Allen, L., Pacula, R. L., Ibrahim, J. K., & Burris, S. (2017). Mapping medical cannabis: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction, 112(12), 2206-2216. [...] Read more...
November 6, 2023Cannabis Cardiovascular Risk: Navigating the Nuances in Media and Medicine The spotlight on “Cannabis Cardiovascular Risk” has intensified, notably with a recent CNN article by a journalist hailing from Georgia, Sandee LaMotte, sketching a picture that points to potential risks linked with marijuana use. Unfortunately, this sort of impulsive, one-sided journalism prompts an important second look at the media’s role in scientific discourse and the nuanced reality of such health risks. The Intricacies of Cannabis and Cardiovascular Health Cannabis and cardiovascular health share a complex relationship. The interplay of THC, the psychoactive component in cannabis, with the cardiovascular system is a subject of critical research. Studies highlight that while nitric oxide (NO) serves a protective role in vascular health, THC may impede its beneficial effects, indicating the need for a nuanced understanding of these findings. Considering the ying-yang nature of CBD and THC, this also reminds of the importance of cannabis care that is guided by experts who can help inform patients what the real risks are, and which substances may present a reality that is not only low risk, but may even pose potential benefits in cardiovascular health. Comprehensive Perspectives Beyond THC (A narrow viewpoint) Broadening the conversation on “Cannabis Cardiovascular Risk” requires consideration of, and the roles played by other cannabis constituents, including CBD, other minor cannabinoids, flavonoids, and terpenes. The method of cannabis consumption, from smoking or vaping to topicals, edibles, and other forms of delivery, is another important area that demands deeper discussion into their potential impacts on heart health. Ignoring the nuances of the wide range of constituents within cannabis, and demonizing it all, regardless of form, delivery, or patient, stinks worse than a skunk at a perfume factory, but perhaps not on account of the cannabis. Fast aside, did you know that, when threatened, skunks spray a potent and pungent liquid from their glands as a defense mechanism? The smell is notoriously difficult to remove and can linger for a long time.  … just saying. The Importance of Balanced Reporting in Science (Biased Science and Reporting) The tendency of health science reporting to sensationalize findings has become increasingly common, as seen in the CNN article. However, such reports must strive to mirror the spectrum of scientific research, encompassing not just the risks but also the potential therapeutic effects of cannabis. As with any reporting and all science, wise readers should consider the scientific sources underpinning published work, as well as the qualifications and historical perspectives/biases of experts that support the reporting and sharing of views.  Do the papers themselves pose the risks about which the journalism reports?  Are the experts qualified and experienced in the domain of discussion? Have those experts shown themselves to be repeatedly bull-horning one particular viewpoint? Does the perspective appear like a solo, unending tiki-torch march against cannabis? Or, does scientific commentary present itself evenly on both sides of the discussion topic, from which the reader may derive their own conclusions?  Do you like your reporting to make your decisions for you? or do these nuances matter to YOU as the reader?  All important questions! ….If the reporting is pushing you to come to their conclusion, you should beware that, chances are, you’re not getting a full picture or the whole story.   Beware Causation vs Association!  Baking Cookies (Causation): Imagine you’re baking cookies. You add sugar to the cookie dough. The sugar directly causes the cookies to taste sweet. This is causation: you do something (add sugar), and it directly causes a result (sweetness in cookies). Roosters Crow and the Sun Rises (Association): Now, think about a rooster crowing at sunrise. The rooster crows every morning as the sun rises. However, the rooster’s crowing doesn’t cause the sun to rise. They’re associated because they happen at the same time, but one does not cause the other. So, in causation, like adding sugar to cookies, there’s a direct cause and effect. In association, like the rooster crowing and the sunrise, two things are linked by timing or circumstance, but one doesn’t directly cause the other.   A Call for Rigorous Scientific Inquiry (Quality of Data) Recognizing that each study enriches the collective understanding, it is essentially for ongoing investigations to add more rigorous evaluations. Self-reports, lackluster patient selection, a disregard of patient environmental, socioeconomic, and a patent disregard for the medical backgrounds, ongoing treatment, or personal experience with cannabis is no longer acceptable for quality, peer-reviewed study,  The half-baked attitude supporting the current research should be cause for hesitation and doubt about the nature of relevant scientific knowledge about the interplay of cannabis and cardiovascular risk. (see references below, which highlight available good quality research that draws intrinsically opposing conclusions about the effects of cannabinoid-based phenomena on cardiovascular effect. For journalist claiming to make evidence-based conclusions, or for readers expecting to derive insights about the real world, the details matter! The Media’s Role in Scientific Discourse (limitations of the media) Journalists have a critical role in guiding the public discourse and in shaping the direction of health and science is shaped. The importance of how information is communicated cannot be overstated. Journalists should aim to convey research findings with accuracy, ensuring complex issues are not oversimplified. For the opinions or perspectives that belong in a domain of expertise beyond the reporter, appropriate expertise, on both sides of a debate, should be included to empower readers with a balanced offering of facts  The recent CNN report underscores the influence of the media and the need for precise and comprehensive communication, and unfortunately, precisely how information can be dangerously misleading or come out so one-sided as to be outright deceitful, from a scientific point of view.   Why do Journalists Do This ?  1. Overly Simple and Catchy News: Sometimes, reporters make complex science sound simpler so more people will understand it, but this can change the meaning. Headlines that say one thing causes another are more eye-catching than headlines that just show a connection, which can be misleading. 2. Getting the Science Wrong: Reporters might not always get the science right, especially if they don’t fully get the research methods or the numbers. They often use summaries or press releases that don’t give the whole story, which can lead to wrong ideas about what the research actually says. 3. Rushed Reporting and Using Secondhand Info: News moves fast, and the rush to get stories out can mean not enough time is spent checking facts, which can lead to mistakes or oversimplifications. Reporters also might rely on other articles instead of the original research, which can add to the chances of getting things wrong. What can consumers of information do to protect themselves? 1. Seek Comprehensive Understanding: Dive deeper than headlines by reading full articles to grasp the context of scientific findings. Enhance your critical thinking by educating yourself on basic scientific principles, such as distinguishing causation from correlation. This foundational knowledge aids in evaluating the credibility of news reports. 2. Cross-Reference Information: Verify news by consulting multiple reputable sources, including the original research studies when available. Accessing abstracts and conclusions can offer more direct insights, providing a broader perspective on the subject matter and helping to identify whether certain interpretations are commonly accepted or outliers. 3. Approach with Critical Analysis: Exercise healthy skepticism and be cautious of oversimplifications in science reporting. Recognize the limitations of journalism in conveying complex scientific data, and consider using fact-checking websites to validate claims. Engage with science communicators who can effectively distill intricate concepts for wider audiences. Considering the Breadth of Evidence It is vital to a healthy flow of public education to acknowledge the limitations and varied results of existing studies on the potential cardiovascular risks – and potential benefits – of various cannabinoids, terpenes, and cannabis-related consumption. Journalists have a moral obligation to ensure that the public and healthcare providers receive reliable information for informed decision-making. Unless journalists are broadcasting through channels that are openly based on personal opinion, where bias and a lack of rigorous standards in research, analysis, or message broadcasting are self-evident, it is irresponsible to disseminate questionable scientific information to sway readers toward one perspective or another. Navigating the Complex Landscape of Cannabis Research The impact of cannabis on heart health is multifaceted, laden with complexities, and marked by many unknowns. Comprehending how cannabinoids may influence cardiovascular function—including the production, release, and degradation of Nitric Oxide, as well as determining their potential risks or benefits—is a critical area of ongoing research that is far from being fully understood Moving the Discussion on Cannabis and Heart Health In light of the recent media attention, it is imperative that the conversation surrounding ‘Cannabis and Cardiovascular Risk’ progresses in tandem with scientific discovery, adopting a perspective that is both open-minded and rigorously analytical. Research must delve into the complex and dynamic nature of cannabis, recognizing it as a multifactorial substance. Much like how food is not a monolith but rather a vast array of types, varieties, and flavors, each with its own nutritional profile and culinary role, cannabis too is a tapestry of diverse elements, each with distinct properties and effects Final Reflections on Media and Medical Responsibility Considering the potential cardiovascular risks associated with cannabis use, it is essential to foster a media environment that promotes evidence-based discussions. Simplified narratives risk obscuring the intricate reality of cannabis research and its implications for health. This underscores the shared responsibility of scientists and journalists to cultivate a dialogue that is both knowledgeable and reflective of the dynamic pursuit of scientific understanding Simplifying Nitric Oxide’s Role in Cardiovascular Health As a brief primer on the significance of nitric oxide (NO) in cardiovascular health: Nitric oxide is fundamental to the proper functioning of the cardiovascular system. It aids in the relaxation of blood vessels, which is essential for the regulation of blood flow. Grasping the fundamental role of NO in vascular dilation, its influence on blood pressure, and its critical role in tissue oxygenation is vital. This understanding is particularly important when considering clinical outcomes, especially in the context of heart attacks and strokes, where NO’s role becomes prominently significant. The Connection Between Nitric Oxide and Cardiovascular Risk The interaction between nitric oxide (NO) and cardiovascular health adds a significant layer of complexity to discussions about cannabis. NO is a critical mediator in cardiovascular physiology, influencing vasodilation and thereby impacting blood pressure and flow. It is through these mechanisms that NO can affect the likelihood of cardiovascular events such as heart attacks and strokes. For instance, reduced NO availability can lead to vasoconstriction, increased vascular resistance, and subsequent hypertension, all of which are risk factors for heart attacks. Conversely, optimal levels of NO can promote vasodilation, improve blood flow, and potentially mitigate these risks. In practice, if cannabis were found to enhance NO production, it could theoretically support vascular health by helping maintain adequate vessel dilation and blood flow. However, should cannabis interfere with NO production or function, it might exacerbate cardiovascular risks by promoting vasoconstriction and hypertension. Understanding how cannabis compounds interact with the NO pathway is therefore essential, as it could inform both clinical practice and individual decision-making regarding cannabis use, especially for those with pre-existing cardiovascular conditions. As we conclude the conversation on how “Cannabis Cardiovascular Risk” is represented in the media, it is clear that both journalists and medical professionals must work together to ensure that public discussions accurately reflect the complex and developing nature of scientific research. This collaboration is essential for preserving the integrity of scientific study and patient education, allowing for well-informed healthcare choices and ensuring the accuracy of the information provided to the community.   Listen to Dr Caplan speaking with Dr Riley Kirk, PhD about this topic, here, on her podcast References Papers on Nitric Oxide 2 papers that describe cannabinoid-based Nitric Oxide support and protective effects https://drive.google.com/file/d/1nHxR5xv2bNbt0NNmEh1YsTqpFaRlMyFf/ https://drive.google.com/file/d/1MihQGU1I3yzDQNb1RgsZH37NtFhegM5l/ https://drive.google.com/file/d/1ERPC2n7U5taHYrJhhmbnlO6RlsfAutpR/ https://drive.google.com/file/d/1mCoEMyLyBUA1TBRI1LwOxZg4031vuSh2 THC as problematic, showing inhibition of NO: https://drive.google.com/file/d/1nm_TKPyGIC3MSHuQ55EJo3-nZo0_Tfbu/ Some evidence that there is direct+indirect impact with the coupling: https://drive.google.com/file/d/1Q3aWLbAvZVasZToTdArw7L9D7ugEa6tl/ https://drive.google.com/file/d/1W9HTapsWBr232fRhGDYNOm-ZRG3kRWOH/ Confounding of tobacco flavorings: https://drive.google.com/file/d/1Nd44QufxCiN_EriqVgFcGFLY0k66NaKK/ https://drive.google.com/file/d/1tyXdXgeM-aJgXe4oaR3aT9z46r5dJT6d/view?usp=sharing Terpenes also have an impact: https://drive.google.com/file/d/1tyXdXgeM-aJgXe4oaR3aT9z46r5dJT6d/ [...] Read more...
October 22, 2023A Fresh Perspective on an Intriguing Cannabinoid Tetrahydrocannabivarin or THCV, popularly known as the “sports car of weed,” is a compound that’s attracting increasing attention, especially in California. It’s unique not just for its rarity but also for its purported effects—less munchies and more energy. In a cultural and medical landscape that has often stigmatized cannabis for making people “stoned” and “lazy,” THCV could be a game-changer. But what does science tell us about this intriguing cannabinoid? How do its actions differ from other, more well-known cannabinoids like THC and CBD? The Complex World of Cannabinoids: Diverse Effects, Varied Applications The nuanced effects of cannabinoids on the human body are mediated by their interactions with a complex network of receptors. For example, while THC and CBN are known to stimulate appetite, THCV can act as an appetite suppressant. The contrasting physiological impacts underscore the importance of understanding the science behind each cannabinoid, especially as the medical applications of cannabis continue to expand. The Complex World of Cannabinoids and Their Diverse Effects on the Body Cannabis is a highly complex plant that contains a plethora of biologically active compounds. Among these are cannabinoids, a class of compounds that engage with the endocannabinoid system in the human body to produce a wide range of effects. Importantly, not all cannabinoids are created equal; they can have vastly different impacts on physiological and psychological processes. For example, the two most well-known cannabinoids, THC (Delta-9-tetrahydrocannabinol) and CBD (Cannabidiol), have strikingly different effects: THC is psychoactive and can induce feelings of euphoria, while CBD is non-psychoactive and has been studied for its potential therapeutic effects in treating conditions like anxiety and epilepsy. Even cannabinoids that sound similar can have contrasting effects on the body. Take, for instance, THC, CBN (Cannabinol), and THCV (Tetrahydrocannabivarin). THC and CBN are known to stimulate appetite—a phenomenon colloquially known as “the munchies”—but THCV acts as an appetite suppressant. This diversity of effects is mediated by these cannabinoids interacting with different receptors or the same receptors in varying ways, leading to distinct physiological outcomes. Understanding these nuances is crucial for both clinicians and patients looking to harness the therapeutic potential of cannabis, particularly as research into its medical applications continues to expand. THCV and Pancreatic Beta-Islet Cells: Simple Science THCV (Tetrahydrocannabivarin) can interact with TRPV (Transient Receptor Potential Vanilloid) receptors on the beta-islet cells of the pancreas. In simple terms, this interaction can regulate the release of insulin, which is vital for glucose metabolism. By modulating insulin levels, THCV might affect how our bodies process sugar and influence metabolic rate, although the evidence is still emerging. The Multifaceted Effects of THCV: Glucose Processing and Metabolism THCV may have a role in glucose processing and in metabolic rate beyond its influence on pancreatic function. Some evidence points to THCV’s potential to stimulate the oxidation of fat and the conversion of glycogen to glucose in muscles. These processes are vital for maintaining energy balance and metabolic rate. Moreover, published research has demonstrated that cannabis users tend to have lower weight, reduced rates of obesity, and thinner waist circumferences, although causality has not been definitively established. A 2013 study in the “Nutrition & Diabetes” journal indicated that THCV reduced glucose intolerance in obese mice, and another study in the “British Journal of Pharmacology” suggested that it could improve insulin sensitivity in diabetic models. However, human trials are still limited, and further research is needed to establish these potential benefits conclusively. The Different Views of THCV The Healthcare Provider’s Inquisition From a medical vantage point, THCV is capturing considerable attention. Preliminary research suggests that it holds promise for reducing appetite, body weight, and fasting glucose levels, making it a potentially significant candidate for treating metabolic disorders like diabetes. This unique profile has spurred interest in its incorporation into patient care plans, particularly in settings where metabolic health is a concern. Furthermore, its potential interaction with specific cellular receptors, such as TRPV receptors in pancreatic beta-islet cells, points to a deeper physiological impact that could be harnessed for therapeutic purposes. However, healthcare providers are keenly awaiting more comprehensive randomized controlled trials to substantiate these promising early findings and to guide appropriate dosages and methods of administration. The Skeptic’s Scrutiny Skeptics might easily categorize the excitement around THCV as another trend lacking in robust scientific evidence. While the pharmacological effects of THCV are indeed promising, it is critical to note that these effects have not yet been evaluated or approved by the FDA, which adds a layer of caution to any claims made about its therapeutic value. Moreover, some skeptics may argue that, without large-scale, peer-reviewed studies to back its efficacy and safety, the cannabinoid remains more of a curiosity than a proven medical asset. This skepticism is not unfounded, as the history of cannabis contains numerous examples of purported benefits that later failed rigorous scientific tests. Ultimately, the skeptics’ cautious approach serves as an essential counterbalance, driving the need for more high-quality research. The Newcomer’s Curiosity For those unfamiliar with the world of cannabis, THCV may serve as a compelling entry point due to its distinct “energetic” effects, as opposed to the more sedating effects often associated with other cannabinoids. This uniqueness could make it attractive to those who have reservations about traditional cannabis products and their psychoactive properties. The appeal of THCV could help to break down yet another barrier to broader acceptance and integration of cannabis into mainstream society. Furthermore, with its potential metabolic benefits, newcomers may find THCV to be a suitable introduction to the broader medicinal applications of cannabis. It’s this balance of energetic and potential health benefits that makes it a subject of interest for those exploring cannabis for the first time. The Veteran’s Evaluation For experienced cannabis consumers, THCV offers a refreshing break from more familiar cannabinoid options like THC and CBD. Its distinctive properties could provide a nuanced, and perhaps more balanced, experience that diversifies their cannabis consumption. Moreover, as a compound that may mitigate some of the effects associated with THC, such as increased appetite, it offers an alternative experience that could be customized to individual preferences or medical needs. Veterans of cannabis use may find that incorporating THCV into their regimen adds a layer of complexity and specificity to their experience, potentially even optimizing the benefits they seek from cannabis. In a market saturated with THC and CBD products, THCV emerges as a novel avenue for exploration and individualized treatment. Integration and the State of the Market The market for THCV is undeniably growing, in part due to the federal legalization of hemp and technological advancements in cannabis cultivation. These factors have made it more accessible than ever before. However, accessibility does not necessarily equate to affordability. Due to the complexity of its extraction and isolation processes, THCV can cost up to ten times as much as traditional THC products, making it a premium option in the cannabinoid market. This economic barrier may limit its use for many consumers, despite its potential benefits. Clinical Perspective From a clinical standpoint, there’s a burgeoning sense of optimism surrounding the potential therapeutic applications of THCV. Researchers and healthcare providers are particularly interested in its unique physiological effects, such as appetite suppression and metabolic benefits. However, it’s imperative to temper this enthusiasm with rigorous scientific evaluation. Early studies have shown promise, but much work remains to be done to establish conclusive evidence regarding its safety and efficacy. Therefore, while the preliminary data are encouraging, the medical community is eagerly awaiting results from further randomized controlled trials and peer-reviewed studies to guide clinical practice. Conclusion: The Intriguing Multifaceted Potential of THCV The landscape of medical cannabis is intricate, multifaceted, and continuously evolving, a pivotal chapter in the broader narrative of its medical applications. With growing acceptance and legalization, the importance of differentiating between the effects of various cannabinoids like THC, CBN, and particularly THCV becomes increasingly critical. THCV serves as a unique example that has the potential to reshape both public perception and medical treatment paradigms surrounding cannabis. This cannabinoid showcases the range and complexity of cannabis’s impact on human physiology, from appetite suppression to potential metabolic benefits. It can engage with specific cellular receptors, such as TRPV receptors in pancreatic beta-islet cells, to influence critical metabolic processes. Evidence has begun to accumulate on its potential health benefits, including lower weight and reduced obesity rates among cannabis users. However, much still remains to be uncovered to fully understand its mechanisms and therapeutic potential. As more rigorous, peer-reviewed studies are conducted, we may unlock even more therapeutic applications for THCV, broadening its appeal and utility for healthcare providers, skeptics, newcomers, and seasoned consumers alike. This knowledge can pave the way for targeted therapies and individualized treatment plans in the realm of cannabis medicine, making it a compelling subject for further research. Some recent articles on the topic: Here References: Wargent, E. T., Zaibi, M. S., Silvestri, C., Hislop, D. C., Stocker, C. J., Stott, C. G., … & Cawthorne, M. A. (2013). The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition & Diabetes, 3(5), e68. Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., … & Tan, G. D. (2016). Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. British Journal of Pharmacology, 163(3), 1344-1354. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215. Riedel, G., Fadda, P., McKillop-Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. British Journal of Pharmacology, 156(7), 1154-1166. McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015). Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 172(3), 737-753.   [...] Read more...
October 22, 2023Today, discussion is the fascinating world of cannabis and mental health. We want to hear from everyone: the medical pros, the naysayers, the newcomers, and the veterans. And let’s not forget science—because numbers don’t lie, right? Ready for the deep dive? Here we go! Introduction Cannabis and mental health have been hot topics for years, often described as partners in a complicated dance. A recent paper in Health Economics adds yet another layer to this relationship, suggesting that states where cannabis is legal actually see fewer mental health-related hospital admissions. Intriguing, isn’t it? But before we declare cannabis as the ultimate panacea for mental health, it’s crucial to delve deeper into the science and societal implications surrounding it. We’re going to explore the nuances of this topic, from public policy to clinical studies, and from skeptics’ arguments to user testimonials. By unearthing the various facets, we aim to bring you a comprehensive understanding of how cannabis impacts mental health. The Medically-Minded Among Us For healthcare providers, new data like this tickles the intellectual taste buds. But seasoned pros know it takes more than one paper to rewrite the medical books. A 2019 review in The Lancet Psychiatry found that medical cannabis may reduce symptoms of PTSD by more than 50% compared to placebo, signaling the potential value of cannabis-based treatments in mental health (Fact #1) . Clinical Efficacy: According to a meta-analysis published in the Journal of Clinical Psychology, medical cannabis has shown promise in reducing symptoms of social anxiety, generalized anxiety disorder, and PTSD . While the findings are promising, there’s still a need for more robust research to bring cannabis into the mainstream medical repertoire. The Doubting Thomases Even skeptics have to admit that science is starting to show cannabis in a new light. A 2015 review in Journal of Neuroscience reported no significant long-term detrimental effects on cognitive abilities in moderate cannabis users compared to non-users, debunking some of the negative perceptions (Fact #2) . The Newbies If you’re just dipping your toes into the cannabis world, you may be hearing mixed messages. A review article in Frontiers in Pharmacology suggested that CBD, a non-psychoactive component of cannabis, could be an effective treatment for psychiatric disorders, providing a potential alternative to existing medications (Fact #3) . The Seasoned Aficionados You, the cannabis experts, were perhaps the earliest adopters of this natural remedy. Did you know a 2020 review in The American Journal of Psychiatry reported that cannabis-based medications were effective in treating a variety of psychiatric disorders, including anxiety and depression? Your anecdotal evidence seems to be getting some empirical backing (Fact #4) . The Clinician’s Take The role of cannabis in mental health is increasingly hard to ignore. Given that a 2018 study in JAMA Internal Medicine found that states with medical cannabis laws had 24.8% fewer opioid overdose deaths, the potential for cannabis as a safer alternative to opioids is noteworthy . Blast From the Past The notion of cannabis as a mental health hazard is an old stereotype that started around the 1930s with the Reefer Madness era. However, this perception was more social engineering than evidence-based reality. Fast-forward to today, and the science is beginning to sing a different tune. Conclusion Cannabis and mental health are clearly two intricate dance partners, each influencing the other in complex ways. Regardless of where you stand on the issue, one thing is certain: the science is compelling, and the conversation is far from over. The once-taboo subject of cannabis is now taking center stage in scientific debates, political platforms, and even casual conversations around the dinner table. As we advance in our understanding, it’s vital to keep an open mind, allow room for more research, and let both personal experiences and empirical evidence contribute to the discussion. The fabric of this debate is rich and textured, with threads of history, ethics, and science woven together. The end result? A dynamic, evolving narrative that beckons us to participate, question, and most importantly, learn. References Walsh, Z., et al. “Medical cannabis and mental health: A guided systematic review.” The Lancet Psychiatry (2019). Black, N., et al. “Cannabis use and mental health: A review of recent epidemiological research.” Journal of Clinical Psychology (2019). Schreiner, A. M., & Dunn, M. E. “Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis.” Journal of Neuroscience (2015). Zuardi, A. W., et al. “Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.” Frontiers in Pharmacology (2017). Bhattacharyya, S., et al. “Cannabis use and the development of tolerance: A systematic review of human evidence.” The American Journal of Psychiatry (2020). Bachhuber, M., et al. “Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.” JAMA Internal Medicine (2014). [...] Read more...
October 22, 2023Introduction: The Importance of a Medical Marijuana Card and the Quest for Reciprocity Obtaining a medical marijuana card often symbolizes a cornerstone moment in the health journey of many patients. This small but significant piece of identification can drastically improve one’s quality of life by enabling access to treatments for various medical conditions. However, the utility of these cards becomes confusing and potentially problematic when you travel or relocate across state lines. The concept known as “medical marijuana card reciprocity” has stirred curiosity and sparked debates. Is your card valid wherever you go? In this comprehensive guide, we will dissect the complexities surrounding medical marijuana card reciprocity through the lens of medical healthcare providers, skeptics of the cannabis movement, newcomers to medicinal cannabis, and those who have long relied on it. The Medical Quandary: A Healthcare Provider’s Perspective on Medical Marijuana Card Reciprocity For medical professionals deeply embedded in the field of cannabis-based treatments, navigating through a labyrinth of differing state laws and regulations can be particularly challenging. Although meta-analyses and randomized controlled trials point towards the therapeutic benefits of medical cannabis, such as the treatment of chronic pain and epilepsy1, the myriad of laws across different states complicates matters for physicians and patients alike. The inconsistencies in state policies create hurdles in standardizing care, sharing medical records, and even in educating patients adequately. Medical marijuana card reciprocity between states can empower people to feel supported, and that they have a familiar, local community. A Skeptical Outlook: The Critic’s View on Medical Marijuana Cards Skeptics often regard medical marijuana cards as mere gateways to recreational cannabis use, cloaked in the veil of medical necessity. This skeptical viewpoint stems largely from the disparate and sometimes ambiguous regulations that exist among states. Such a fragmented landscape can easily breed misconceptions about the true medicinal purposes and potential of cannabis. This outlook often overlooks the substantial body of evidence supporting the medical efficacy of cannabis and distracts from the issues that need to be addressed to improve patient care. First Steps: The Newbie Experience and the Complexities of Medical Marijuana Card Reciprocity For those newly initiated into the realm of medical cannabis, the possibility of using a medical marijuana card across state lines can seem both promising and daunting. Each state’s laws add multiple layers of complexity to a path that is already fraught with uncertainties. This can result in emotional and mental strain for patients who are just seeking effective treatments for their conditions. Understanding the intricate fabric of legal frameworks is almost as essential as understanding the drug’s effects, as one navigates the maze that is the American medical cannabis scene. Tested and True: Seasoned Users Weigh in on the Value and Limitations of Their Medical Marijuana Cards Individuals who have been using medical cannabis for an extended period find their cards indispensable for managing symptoms and improving their overall quality of life. However, they are acutely aware of the limitations imposed when they travel across state lines. Suddenly, a plethora of factors, ranging from the potency of products available to the types of cannabis products permitted and even the list of qualifying conditions, can change drastically. Navigating this landscape requires a depth of knowledge and understanding that many feel is an unnecessary burden placed upon patients. The Reality Check: Medical Marijuana Card Reciprocity is Not Universal The ultimate message here is that medical marijuana card reciprocity is not a straightforward or universal solution; rather, it’s a nuanced, state-dependent issue. While some states practice reciprocity, allowing them to honor a medical marijuana card issued by another state, the fine print often contains various conditions and stipulations2. The Road Ahead: The Clinical Future of Medical Marijuana Card Reciprocity Despite the numerous obstacles and inconsistencies, there’s a silver lining. Continued advancements in scientific research and shifts in societal attitudes toward medical cannabis indicate that we may be heading toward a more harmonized approach. Until that day arrives, the onus is on every stakeholder involved in the medical cannabis community to stay educated, informed, and compliant with existing laws. Footnotes Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. Pacula, R. L., Powell, D., Heaton, P., & Sevigny, E. L. (2015). Assessing the Effects of Medical Marijuana Laws on Marijuana and Alcohol Use: The Devil is in the Details. Journal of Policy Analysis and Management, 34(1), 7-31. [...] Read more...
October 22, 2023Review of Pain relief with THC In the world of medical cannabis, Tetrahydrocannabinol (THC) stands out for its potent therapeutic potential. Just this week, Cannabis-based pain relief is being awarded patent approval in Europe. This post explores some of the therapeutic benefits of THC, focusing on its effectiveness in treating pain, insomnia, and inflammatory bowel disease (IBD). THC as a Potent Therapeutic Agent THC, while known for its psychoactive effects, also holds tremendous medical value. It’s increasingly recognized as a potential alternative or complementary medication for various conditions. Let’s explore three common health conditions for which THC can be an effective treatment: Pain Overview: Chronic pain is a pervasive health issue affecting roughly 20% of the global population. Traditional treatment options such as narcotics and opioids carry substantial risks, including addiction and other adverse side effects. Tetrahydrocannabinol (THC), the psychoactive component of cannabis, offers an alternative avenue for pain management. Research Insights: Research in this area indicates that THC’s efficacy in pain management stems from its interaction with the endocannabinoid system. Specifically, THC activates CB1 and CB2 receptors found in nerve and immune cells, thereby modulating pain signals and producing analgesic effects. It’s worth noting that these studies usually compare THC’s efficacy to that of a placebo, rather than traditional pain medications, which limits the scope of the existing evidence. Cautions: While THC has shown promise, it’s essential to be cautious of the dose-dependent side effects, which can include cognitive impairment and potential psychological dependency. Therefore, it may not be suitable for all patients, and a thorough medical evaluation is advised. Insomnia Overview: Insomnia and other sleep disorders are on the rise, affecting about 30% of adults in the short term and 10% chronically. Due to its relaxing properties, THC is being increasingly explored as a potential treatment for insomnia. Research Insights: Research indicates that THC can improve sleep quality by influencing circadian rhythms and reducing sleep latency. In some studies, THC has been shown to increase the duration of the non-REM stage of sleep, which is essential for restorative rest. Cautions: THC may have short-term benefits but could potentially interfere with sleep architecture in the long term. The compound can also cause next-day drowsiness in some individuals. Inflammatory Bowel Disease (IBD) Overview: IBD, affecting about 1.3% of adults in the U.S, is a chronic condition with limited treatment options. THC has been researched for its anti-inflammatory properties and potential utility in treating IBD symptoms. Research Insights: Multiple studies have suggested that THC can reduce inflammation in the gut by acting on cannabinoid receptors in the digestive tract. Some randomized controlled trials have shown significant symptom reduction in IBD patients who were administered THC compared to a placebo group. Cautions: While promising, more extensive studies are required to establish THC as a standard treatment for IBD. Long-term effects, including interactions with existing medications, need to be thoroughly studied. Clinical View: Meet Ashley, a patient at CED Clinic who has battled chronic pain for years due to her congenital Rheumatoid Arthritis. For a long time, she relied on a regimen of anti-inflammatories, analgesics, and opioids to manage her symptoms. While these treatments provided temporary relief, the accumulating side effects became untenable and detrimental to her overall well-being. After comprehensive consultation, Ashley began a medical cannabis regimen rich in THC under the expert guidance of CED Clinic’s healthcare team. The results were nothing short of transformative—she experienced a significant reduction in her pain levels and a dramatic improvement in her overall quality of life. Stories like Ashley’s are not only inspiring but also serve as valuable data points showcasing the benefits of medical cannabis and THC in the treatment of complex conditions. If you’re intrigued by the medical potential of cannabis, I delve deeper into the science, the evidence, and transformative patient stories like Ashley’s in my new book, the “Doctor-Approved Cannabis Handbook,” available now on Amazon. Check out More on Pain at CaplanCannabis.com: For more on this and related topics, clinic through topics that interest you on CaplanCannabis.com 📗 Note: The diagram’s your prelude. The magnum opus? That’s inked in the book. Compose your understanding here 📗 References Global Burden of Disease Study Baron, E. P. (2018). Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache: The Journal of Head and Face Pain, 58(7), 1139–1186. American Academy of Sleep Medicine Centers for Disease Control and Prevention Lahat, A., Lang, A., & Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion, 85(1), 1–8. Gorelick, D. A., Goodwin, R. S., Schwilke, E., Schwope, D. M., Darwin, W. D., Kelly, D. L., … Huestis, M. A. (2013). Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. The American Journal on Addictions, 22(5), 510–514.  Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. BMC public health, 11, 770. https://doi.org/10.1186/1471-2458-11-770 Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017). The cannabinoid system and pain. Neuropharmacology, 124, 105–120. https://doi.org/10.1016/j.neuropharm.2017.06.015 Roth, T. (2007). Insomnia: definition, prevalence, etiology, and consequences. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 3(5 Suppl), S7–S10. Dahlhamer, J. M., Zammitti, E. P., Ward, B. W., Wheaton, A. G., & Croft, J. B. (2016). Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years – United States, 2015. MMWR. Morbidity and mortality weekly report, 65(42), 1166–1169. https://doi.org/10.15585/mmwr.mm6542a3 Hasenoehrl, C., Storr, M., & Schicho, R. (2018). Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert review of gastroenterology & hepatology, 11(4), 329–337. https://doi.org/10.1080/17474124.2017.1416148 [...] Read more...
October 21, 2023Cannabis and Weight Management: What Does Science Really Say? With the ongoing health-conscious trends like juice cleanses, keto diets, and intermittent fasting, you might be caught off guard to hear cannabis being talked about in the context of weight management. Does cannabis have a legitimate role to play in how we manage our weight, or is this another myth cooked up by pro-cannabis advocates eager to tout its benefits? This recent article was published on the topic by The Fresh Toast  The Fundamental Science Behind Cannabis and Weight Cannabis exerts its effects primarily through the endocannabinoid system, a complex network of receptors in our bodies. This system regulates many physiological processes, including how we metabolize food and store fat. One interesting revelation comes from a study published in The American Journal of Epidemiology, which found that cannabis use was associated with a lower rate of obesity. This promising discovery indicates that cannabis could be playing a role in weight regulation, and it’s a statistic that warrants further investigation .   Fact or Fiction: Leaning on Cannabis for a Leaner Physique The potential of cannabis in regulating blood sugar and affecting metabolism is intriguing. But does this mean it can help us lose weight? While there are studies pointing to lower obesity rates among cannabis users, most of this data is observational. Although this is a promising starting point, we need more rigorous, controlled studies, like randomized controlled trials (RCTs), to definitively establish the relationship between cannabis and weight loss . Medical Perspective: A Double-Edged Sword? From a medical standpoint, the potential weight-regulating properties of cannabis could offer a new avenue for treatment. Weight imbalances are linked to numerous health issues, from diabetes and cardiovascular diseases to poor mental health. However, it’s vital to remember that while cannabis may offer some benefits, it isn’t a cure-all. Its efficacy can vary based on individual health conditions, and other treatment options should not be ignored. Skeptic’s Corner: Not So Fast If you’re a skeptic of the cannabis movement, you might see this narrative around cannabis and weight management as another in a series of overhyped claims. Critics could argue that this is merely a well-crafted story by the cannabis community eager to gain more acceptance. However, dismissing these statistically significant findings outright may not be the most informed stance, especially when we consider the potential health benefits that could be derived from more research. New to Cannabis? Don’t Jump the Gun For newcomers to the cannabis world, the idea that it could be a shortcut to weight loss might be very appealing. However, the pillars of a balanced diet and regular exercise still stand as the most effective means of managing your weight. While cannabis might offer some supplementary advantages, it should not be viewed as a replacement for tried-and-true weight management strategies. Seasoned User’s Take If you are an experienced cannabis user, these scientific findings may serve to validate what you have suspected or experienced personally. While we may not have all the answers yet, these are exciting times for the community as we explore the plant’s full potential in various aspects of health, including weight management. Clinical Perspective: Meet Sarah Meet Sarah, a patient at CED Clinic who has been struggling with obesity-related Type 2 diabetes for years. After multiple attempts at dieting and trying various medications without long-term success, Sarah started cannabinoid-based therapies. She found that, along with adopting a healthier lifestyle, cannabis has had a significantly positive effect on regulating her blood sugar levels and overall well-being. Cases like Sarah’s are part of the ongoing dialogue in my forthcoming book, The Doctor-Approved Cannabis Handbook, which explores this subject in greater depth. Citations “Cannabis use is associated with lower rates of obesity” – The American Journal of Epidemiology “Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?” – Regulatory, Integrative and Comparative Physiology [...] Read more...
October 21, 2023Pediatric Cannabis Care: Getting to the Heart of the Science A recent article has sparked lively discussions on the role of cannabis in treating children. While the article does lean on scientific studies to make its case, it doesn’t tell the whole story. This leaves room for misunderstanding. That’s where this blog comes in. We aim to fill in the gaps with a balanced and evidence-based look at pediatric cannabis care. Short-Term vs. Long-Term Effects What the Article Says The article shines a light on studies that point to possible short-term downsides of cannabis use in children, mainly focusing on issues like cognitive decline and increased risk for mental health problems. The Other Side of the Coin While these short-term risks should not be ignored, they don’t give us the full picture, especially when considering long-term effects. Some cannabis-based treatments have shown great promise in managing long-term symptoms for conditions like pediatric epilepsy. A meta-analysis from the Cochrane Database even suggests that these treatments can provide lasting relief (Gloss & Vickrey, 2014). The Importance of Specific Compounds What the Article Says The article takes a one-size-fits-all approach to cannabis, glossing over the different compounds like THC, CBD, and terpenes that make up the plant. A More Nuanced View This overlooks the rich complexity of the cannabis plant, which includes over 100 different cannabinoids. Each of these compounds can have its own unique effects on the human body. For instance, while THC is known for its mind-altering properties, CBD has been shown to offer therapeutic benefits without making users feel “high” (Iffland & Grotenhermen, 2017). Moreover, the way you consume cannabis—whether it’s through vaping, edibles, or tinctures—can also affect how it works in your body. Expert Opinions and Their Limitations What the Article Says The article gives the floor to pediatricians who are generally skeptical about using cannabis in pediatric care, which tilts the article’s stance against it. Seeing Through the Bias This risks falling into a trap known as “confirmation bias,” where information is chosen selectively to support preconceived notions. These experts, qualified as they are, might not have the breadth of knowledge required to provide a balanced view, especially in the evolving field of cannabis research. Why Quality Evidence Matters It’s crucial to rely on top-notch scientific evidence like randomized controlled trials, meta-analyses, and peer-reviewed journals. Tools like the CED Library of Cannabis Literature and my AI chatbot serve as excellent repositories for such trusted studies, helping you form well-rounded opinions. Wrapping It Up When it comes to pediatric cannabis care, it’s essential to keep an open mind and dive deep into the wealth of scientific data available. For those who want to delve further into this multifaceted issue, resources like the CED Clinic website and “The Doctor-Approved Cannabis Handbook” offer valuable insights. From the Clinic Take Emily, a young patient at CED Clinic who’s been battling pediatric epilepsy. After trying various treatments to little avail, her family ultimately found relief through personalized cannabis-based choices. Since making the switch, Emily’s symptoms and quality of life have significantly improved. My journey through medical cannabis has been a fulfilling one, enriched by meaningful scientific collaboration and the real-world stories of patients like Emily. These invaluable experiences will be shared in my upcoming book, “The Doctor-Approved Cannabis Handbook.” Please consider a read! References Gloss, D., & Vickrey, B. (2014). Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews, (3). Iffland, K., & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol. Cannabis and Cannabinoid Research, 2(1), 139–154.   The original article: https://www.news5cleveland.com/news/continuing-coverage/marijuana-in-ohio/how-can-marijuana-affect-a-developing-brain [...] Read more...
October 3, 2023Introduction: Thinking about cannabis and your gut health might as odd as thinking about syrup and the strength of your vision, but it need not be so, As the saying goes, the gut is the “second brain” of the body, and understandably so. From digestion to immune function, the gut plays a pivotal role. What you may find surprising is the emerging role of cannabis in the gut health narrative. From skeptical views to scientific studies, this blog aims to shed light on the evolving dialogue surrounding cannabis and gut health. If you are looking for explanations, definitions, and charts that explain the significance of gut health and many aspects of health and wellness that play into a healthy microbiome, please check out this page on CaplanCannabis.com:  https://caplancannabis.com/cannabis-and-the-gut-microbiome-a-comprehensive-guide The Many Facets of Cannabis & Gut Health Firstly, it’s essential to recognize the existing skepticism around cannabis. Critics often question its medical applications and sometimes categorize it as a mere recreational tool. However, this perspective tends to ignore the growing body of evidence-based research that has begun to illuminate cannabis’ potential benefits, particularly when it comes to gut health. For instance, studies suggest that cannabinoids like CBD can act as bacteriostatic agents, which inhibit bacterial growth, providing potential relief in conditions like Inflammatory Bowel Disease (IBD) (Nagarkatti et al., 2009). Then comes the newcomer, full of curiosity and a bit hesitant. You’ve heard about prebiotics in oatmeal and probiotics in yogurt, but cannabis? Interestingly, cannabis compounds like CBD and THC have shown promise in modulating the gut microbiome, potentially leading to anti-inflammatory effects (Alhouayek & Muccioli, 2012). Whether you’re just looking to ease digestive discomfort or manage a chronic condition, the possibilities are intriguing. For those seasoned in using cannabis for medicinal purposes, understanding its role in gut health can be an enlightening experience. Perhaps you’ve already felt some gut-related benefits, an experience that aligns with the evidence suggesting cannabis’ role as a bactericidal antibiotic (Appendino et al., 2008). This could represent a new frontier in battling antibiotic-resistant bacterial strains. As a healthcare provider, one cannot overlook the nuanced and multifaceted nature of cannabis in medical care. While there’s promise, there’s also a call for more robust, large-scale studies to better understand both the benefits and potential drawbacks, including how cannabis interacts with the microbiome to affect conditions like IBS and IBD. Clinical Perspective: With compassion at the core of medical practice, it’s vital to recognize the potential cannabis holds, not only as a complementary treatment but perhaps even as a cornerstone in gut health management. The growing body of evidence offers optimism about the versatile utility of cannabis—from bacteriostatic to bactericidal properties. It’s a call to integrate this burgeoning knowledge into practice cautiously and judiciously. Who are the people who tend to have gut microbiome issues? Individuals with specific dietary patterns or lifestyle choices often face disruptions in their gut microbiome. For example, a diet rich in processed foods, sugars, and saturated fats but low in fiber can significantly alter gut bacteria, making the individual more susceptible to inflammation and gastrointestinal issues. Similarly, those with excessive alcohol consumption or high-stress lifestyles often report an imbalance in their gut flora. Vegans and vegetarians might face certain deficiencies in gut microbiome diversity due to the absence of animal-based probiotics. Prescription medications, especially antibiotics, can also wreak havoc on the microbiome, wiping out both bad and beneficial bacteria. It’s a complex landscape, where one’s diet, lifestyle, and even mental well-being can significantly influence gut health. Additional Evidence & Citations: Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future medicinal chemistry, 1(7), 1333–1349. Alhouayek, M., & Muccioli, G. G. (2012). The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends in molecular medicine, 18(10), 615–625. Conclusion: Cannabis and gut health—an intricate relationship, indeed. Whether you’re skeptical, new to cannabis, a healthcare provider, or an experienced user, the conversation around cannabis is getting more nuanced and evidence-based by the day. As we understand this fascinating plant better, we can hope to harness its full potential for the betterment of gut health. 📗 Note: This page is your first coffee of the day; the book’s your whole artisan coffee shop. Get brewing here 📗 [...] Read more...
September 24, 2023In Search of a “Pot Doc Near Me”: The Irony of Subpar Cannabis Clinicians Versus True Medical Specialists Ah, the age-old Google search, “Pot Doc Near Me.” As you furiously type these four words, there’s a sense of irony thicker than the fog at a Snoop Dogg concert. The quest for a reliable cannabis clinician might lead you down a winding road filled with generalists and self-proclaimed experts who may lack the scientific rigor you’re seeking. Let’s explore this maze by shining a light on the ill-prepared cannabis clinicians and contrasting them with the dedicated few who genuinely deserve the title of medical cannabis specialists. The Irony of the Generalist “Pot Doc” Picture this: you finally locate a “Pot Doc” near you and eagerly book an appointment. You enter the clinic, and what do you get? A 15-minute session (if that?) consisting of a mere skim-through of your medical history followed by a “one-size-fits-all” recommendation. The irony? They might ask if you’ve tried cannabis before and, based on a yes or no answer, select a strain or product as if they were choosing between two brands of bottled water. Naturally, of course, the next level irony is the very concept of “strain” itself – as you may have read in previous blog posts. Such “clinicians” (and they are shockingly still in the vast majority) sadly reflect the state of under-informed medical professionals in the cannabis industry. This isn’t merely anecdotal. A study in the Journal of Clinical Oncology found that while 80% of oncologists discuss medical cannabis with their patients, less than 30% felt knowledgeable enough to make recommendations1. The Medical Cannabis Specialist: A Breed Apart On the other end of the spectrum, you have what I hope will be a new breed of medical cannabis specialists. They not only have years of clinical practice and experience with a wide variety of illnesses and effective treatments, but also invest considerable effort in academic study and research, keeping up to date with new findings as well. Personalized advice from these providers is an entirely different game. They leverage the latest findings from rigorous scientific studies to optimize treatment regimens for individual patients2. Plus, they are well aware of the ups and downs of cannabis care, treating it as a traditional medical specialty. But what sets such a specialist apart? The key lies in their approach to personalized medicine. Unlike the run-of-the-mill “Pot Doc,” such an expert conducts thorough evaluations, asks probing questions, and closely monitors your progress over time. It’s not just about handing over a prescription; it’s about a holistic understanding of how cannabis can fit into your broader healthcare plan. This is the essence of CED Clinic. We strive to set the standard in cannabis care. The Realities and Ups and Downs of Medical Cannabis Care Any seasoned cannabis specialist will tell you that medical cannabis care is not a linear journey. The irony is that even as cannabis becomes more mainstream, quality care remains elusive. The experienced providers understand this. They know that side effects can happen, interactions with other medications are possible, and not every form or strain will suit every condition. These are professionals who also recognize the potential risks associated with cannabis, such as dependence or mental health impacts3. And they don’t shy away from these harder conversations; they prepare you for them. Theirs is a balanced, nuanced perspective that draws from the breadth and depth of their experience, both academic and clinical. The Value of True Expertise The irony in the search for a “Pot Doc Near Me” is that while finding a cannabis clinician is easier than ever, finding a knowledgeable one is like hunting for a needle in a haystack. And the stakes are high. Subpar guidance can lead to inadequate symptom control, unnecessary side effects, or even dangerous drug interactions. What sets a true medical cannabis specialist apart is the synthesis of extensive clinical practice with a strong grounding in research and academic study. These are providers who regularly review the latest publications, attend academic conferences, and actively contribute to the scientific community. The advice they offer is not just personalized; it’s backed by robust evidence and a nuanced understanding of the complexities of medical cannabis care. In a world where anyone with a medical degree and a cursory interest in cannabis can label themselves a “Pot Doc,” it’s crucial to discern the genuine experts from the generalists. Your health and well-being deserve nothing less. Please don’t take our word for it.  See for yourself.  Book an appointment today! References: Footnotes Braun, I. M., Wright, A., Peteet, J., Meyer, F. L., Yuppa, D. P., Bolcic-Jankovic, D., … & Prigerson, H. G. (2018). Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. Journal of Clinical Oncology, 36(19), 1957-1962. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313(24), 2456-2473. Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse Health Effects of Marijuana Use. New England Journal of Medicine, 370, 2219-2227. [...] Read more...
September 24, 2023Introduction: The Importance of a Medical Marijuana Card Receiprocity and the Quest for Community Obtaining a medical marijuana card often symbolizes a cornerstone moment in the health journey of many patients. This small but significant piece of identification, and more importantly the guided care that it should represent, can drastically improve one’s quality of life by enabling access to treatments for various medical conditions – again, ideally guided by a knowledgeable provider. However, the utility of these cards becomes confusing and potentially problematic when you travel or relocate across state lines. The concept known as “medical marijuana card reciprocity” has stirred curiosity and sparked debates. Is your card valid wherever you go? In this comprehensive guide, we will dissect the complexities surrounding medical marijuana card reciprocity through the lens of medical healthcare providers, skeptics of the cannabis movement, newcomers to medicinal cannabis, and those who have long relied on it. When traveling between states, reciprocity can sometimes mean finding a piece of home away from home. The Medical Quandary: A Healthcare Provider’s Perspective on Medical Marijuana Card Reciprocity For medical professionals deeply embedded in the field of cannabis-based treatments, navigating through a labyrinth of differing state laws and regulations can be particularly challenging. Although meta-analyses and randomized controlled trials point towards the therapeutic benefits of medical cannabis, such as the treatment of chronic pain and epilepsy1, the myriad of laws across different states complicates matters for physicians and patients alike. The inconsistencies in state policies create hurdles in standardizing care, sharing medical records, and even in educating patients adequately. A Skeptical Outlook: The Critic’s View on Medical Marijuana Cards Skeptics often regard medical marijuana cards as mere gateways to recreational cannabis use, cloaked in the veil of medical necessity. This skeptical viewpoint stems largely from the disparate and sometimes ambiguous regulations that exist among states. Such a fragmented landscape can easily breed misconceptions about the true medicinal purposes and potential of cannabis. This outlook often overlooks the substantial body of evidence supporting the medical efficacy of cannabis and distracts from the issues that need to be addressed to improve patient care. First Steps: The Newbie Experience and the Complexities of Medical Marijuana Card Reciprocity For those newly initiated into the realm of medical cannabis, the possibility of using a medical marijuana card across state lines can seem both promising and daunting. Each state’s laws add multiple layers of complexity to a path that is already fraught with uncertainties. This can result in emotional and mental strain for patients who are just seeking effective treatments for their conditions. Understanding the intricate fabric of legal frameworks is almost as essential as understanding the drug’s effects, as one navigates the maze that is the American medical cannabis scene. Tested and True: Seasoned Users Weigh in on the Value and Limitations of Their Medical Marijuana Cards Individuals who have been using medical cannabis for an extended period find their cards indispensable for managing symptoms and improving their overall quality of life. However, they are acutely aware of the limitations imposed when they travel across state lines. Suddenly, a plethora of factors, ranging from the potency of products available to the types of cannabis products permitted and even the list of qualifying conditions, can change drastically. Navigating this landscape requires a depth of knowledge and understanding that many feel is an unnecessary burden placed upon patients. The Reality Check: Medical Marijuana Card Reciprocity is Not Universal The ultimate message here is that medical marijuana card reciprocity is not a straightforward or universal solution; rather, it’s a nuanced, state-dependent issue. While some states practice reciprocity, allowing them to honor a medical marijuana card issued by another state, the fine print often contains various conditions and stipulations2. The Road Ahead: The Clinical Future of Medical Marijuana Card Reciprocity Despite the numerous obstacles and inconsistencies, there’s a silver lining. Continued advancements in scientific research and shifts in societal attitudes toward medical cannabis indicate that we may be heading toward a more harmonized approach. Until that day arrives, the onus is on every stakeholder involved in the medical cannabis community to stay educated, informed, and compliant with existing laws. References Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. Pacula, R. L., Powell, D., Heaton, P., & Sevigny, E. L. (2015). Assessing the Effects of Medical Marijuana Laws on Marijuana and Alcohol Use: The Devil is in the Details. Journal of Policy Analysis and Management, 34(1), 7-31.     Questions You Might Be Asking About Medical Marijuana Card Reciprocity If you’re reading this blog, you probably have a myriad of questions on the subject of medical marijuana card reciprocity. We welcome you to ask them in the comments section below. Some questions you might be considering include: What states accept out-of-state medical marijuana cards? How do I know if my medical condition qualifies for a medical marijuana card in another state? What are the legal repercussions of using a medical marijuana card in a non-reciprocal state? Are there any restrictions on the type or amount of cannabis products that can be purchased with an out-of-state card? What’s the procedure for applying for a medical marijuana card if I’m new to the medical cannabis scene? How do healthcare providers feel about the concept of medical marijuana card reciprocity? Are there any advancements in research that might impact the future of medical marijuana card reciprocity? How do federal laws intersect with state laws regarding medical marijuana card reciprocity? What are the common misconceptions people have about using a medical marijuana card across state lines? Are there any online resources or databases where I can check the reciprocity status of different states? Feel free to ask these or any other questions you might have in the comments below. Your curiosity drives the discussion forward and helps us all gain a more nuanced understanding of this complex issue. [...] Read more...
September 13, 2023Introduction Medical cannabis is a topic imbued with hope, skepticism, curiosity, and deep-rooted experiences. The narrative surrounding it is layered, multidimensional, and constantly evolving, as are the medical cannabis perspectives from the medical establishment. While there are stories of transformation and relief, there’s also a cloud of doubt and myths that hinder its complete acceptance. Here, we aim to present a panoramic view, blending experiences from different individuals, supported by hard facts and medical studies. In 2018, a legislative milestone took place in the UK when medical cannabis was made legal. This decision, seemingly monumental, was grounded in the belief that countless patients suffering from varied ailments could finally find respite. Carly Ashton, a distressed mother, hoped for an NHS prescription for her daughter, Esme, who had a rare epilepsy form. Yet, despite the legislation, Esme’s relief remains a distant dream1. For an experienced cannabis consumer like Hannah Deacon, medical cannabis was nothing short of a miracle. Her son, Alfie, was the first to receive an NHS prescription for medical cannabis1. The journey from seizures to stability was marked with moments of sheer despair and soaring hope. Alfie’s story is a testament to the potential of medical cannabis. But what about those unfamiliar with the world of medical cannabis? Like Jasper, another child suffering from a rare epilepsy form. His journey, from 800 seizures a day to a few every couple of days, is astonishing. His parents describe the effect of whole-cannabis oil as “jaw-dropping”1. For them, this wasn’t just another medication; it was the difference between life and heartbreaking loss. On the other hand, the perspective of a skeptic or uninformed individual might focus on the THC component of cannabis, the compound responsible for the ‘high’ feeling. Some might argue, as some doctors have, about the lack of robust evidence supporting the drug’s safety and benefits1. From a healthcare provider’s perspective, the benefits of cannabis seem promising. Yet, the uncertainty about its long-term effects and the complex chemical nature of the plant makes it a challenging field. Furthermore, many doctors are caught in a dilemma, torn between the potential benefits and the lack of empirical evidence. Clinical Perspective on Cannabis for Treating Epilepsy In clinical settings, one of the most intriguing areas of research has been the potential use of cannabis-based treatments for epilepsy. While traditional antiepileptic drugs (AEDs) can be effective for many patients, there remains a subset for whom these medications either do not provide adequate seizure control or come with challenging side effects. Given this, the search for alternative treatments is crucial. Recent research has shed light on the potential therapeutic effects of cannabinoids, especially cannabidiol (CBD), in epilepsy management. Preliminary findings suggest that CBD, a non-psychoactive component of cannabis, might play a role in reducing seizure frequency and severity in some individuals. Furthermore, for those with treatment-resistant forms of epilepsy, the introduction of CBD-based treatments has been particularly promising. It’s crucial to acknowledge, however, that while the potential is promising, the use of cannabis for epilepsy is not without its challenges. Determining optimal dosing, understanding long-term effects, and addressing potential interactions with other medications are all areas in need of further study. Moreover, while anecdotal evidence abounds, rigorous, controlled trials are essential to establish the safety and efficacy of cannabis-based treatments for epilepsy. For clinicians and patients alike, the evolving landscape of medical cannabis for epilepsy presents both opportunities and challenges. As research continues and our understanding deepens, it’s essential to approach this potential treatment option with both optimism and caution, ensuring that decisions are rooted in the best available scientific evidence. Conclusion Medical cannabis, as with many other treatments, isn’t a one-size-fits-all solution. But its potential is undeniable. Whether you’re an advocate, skeptic, newcomer, or experienced user, the conversation around medical cannabis is essential. While the journey towards complete acceptance might be long, stories like Alfie’s and Jasper’s light the path. References: https://www.bbc.co.uk/news/health-66784170 Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., … & Cilio, M. R. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. The Lancet Neurology, 15(3), 270-278.  This trial investigates the efficacy of cannabidiol (CBD) in treating patients with treatment-resistant epilepsy, showing positive results for a subset of patients. Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S., … & Degenhardt, L. (2018). Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. Journal of Neurology, Neurosurgery & Psychiatry, 89(7), 741-753. A comprehensive review that presents both controlled and observational evidence on the therapeutic effects of cannabis and cannabinoids in treating epilepsy. Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21-47. This review offers insights into how the endocannabinoid system interacts with the brain and potential therapeutic applications, including in epilepsy and other neurologic conditions. O’Connell, B. K., Gloss, D., & Devinsky, O. (2017). Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy & Behavior, 70, 341-348. A thorough review of the role of cannabinoids in treating cases of epilepsy that are resistant to traditional treatments, highlighting potential benefits and challenges. Perucca, E. (2017). Cannabinoids in the treatment of epilepsy: Hard evidence at last? Journal of Epilepsy Research, 7(2), 61-76. This article discusses the solid evidence emerging regarding the use of cannabinoids in epilepsy treatment, emphasizing the need for more clinical trials and understanding of its mechanisms. [...] Read more...
September 13, 2023The Medical Cannabis Paradox: Canada’s Strange Stance Explored With the legalization wave sweeping across nations, medical cannabis has been thrust into the spotlight, garnering global attention. Particularly in Canada, the division between “medical” and “recreational” cannabis is becoming a topic of great debate. This discourse presents a unique and, in many ways, paradoxical stance on the subject. Here, we aim to demystify this scenario by delving into it from four distinct viewpoints. From the meticulous lens of a healthcare provider, the statistics seem perplexing and somewhat distressing. According to data extrapolated from Health Canada and Statistics Canada, there’s been a staggering 38% decrease in active medical cannabis registrations since October 2018. This decline isn’t just a mere figure to gloss over; it carries profound implications for patient care. With fewer registrations, the concern arises not only from the dwindling numbers but also the potential impediments it poses for the broader medical community. This decline could stymie research efforts, hamper advocacy for its benefits, and, perhaps most crucially, reduce accessibility for patients genuinely in need of this therapeutic avenue. However, when we flip the perspective to that of a skeptic or someone with reservations about cannabis, the narrative shifts. To these individuals, the decline might even seem logical, perhaps welcomed. There’s an omnipresent misconception in the general populace: the idea that cannabis is exclusively a recreational substance. This overshadowing stereotype often clouds the profound therapeutic potential of the plant. Yet, if one delves deeper and seeks to understand the reasons for this decline, it becomes pivotal. Rather than indicating a genuine lack of medical efficacy, it could be pointing to broader systemic challenges plaguing the Canadian medical cannabis framework. Venture into the shoes of someone who’s just beginning their journey into the vast world of cannabis, and the waters become even murkier. For these newcomers, the line demarcating medical and recreational cannabis is not just thin but often indiscernible. Adding to the confusion is the Canadian government’s taxation policy. Why would medical cannabis, purportedly a legitimate therapeutic product, be taxed similarly to its recreational counterpart? The message sent is convoluted. Is one form of cannabis considered therapeutic while the other merely indulgent? Or do both possess healing properties? The mixed signals from policy decisions only exacerbate the confusion, leaving many to question the very authenticity and legitimacy of medical cannabis. Now, consider those seasoned in their use of cannabis for genuine medical relief. To them, the aforementioned decline isn’t just a statistic; it’s a potential alarm bell. What could be driving this downturn? Is it a matter of diminished access or skyrocketing costs? Perhaps it’s an eroding trust in the medical system. Many of these individuals might find themselves inadvertently pushed towards the recreational market, seeking the relief they once found in the medical sector. Yet, amidst these domestic challenges, Canada stands tall on the international stage. As a formidable leader in cannabis production and research, Canada’s exports in the medical cannabis sector are surging. The juxtaposition is intriguing. While domestic sales appear to falter, there’s burgeoning international trust and demand for Canadian medical cannabis products. To truly understand Canada’s intricate dance with medical cannabis, it becomes critical to analyze it from varied perspectives: the seasoned professional, the staunch skeptic, the bewildered newcomer, and the experienced user. Only then can we piece together a holistic picture, discerning what the data truly signifies and what trajectory the nation might take in the future. Through comprehensive examination and open dialogue, we can shed light on this paradoxical stance and pave the way for informed decisions that benefit patients, researchers, and the broader society. Let us embark on this journey of understanding together. References: Health Canada and Statistics Canada. [...] Read more...
September 5, 2023Deep Reading: A Cultural Shift? It’s an unsettling reality to consider, but more and more, it seems like we live in an era where the ties to deep, reflective reading are unraveling. The allure of digital distractions and the siren call of “doomscrolling” screens now comes, like everything in modern life – in Tall, Grande, and Vente. Few seem to contest that the draw of our e-devices is overpowering the allure of turning pages. According to a report from the Pew Research Center, although a promising 72% of American adults reported reading a book in the past year, the median number of books consumed stood at a mere four. The startling fact isn’t the number itself, but what this decline suggests about our evolving cultural values and priorities. The National Endowment for the Arts (NEA) has echoed similar concerns, pointing to a significant wane in literary reading, particularly among the youth. This isn’t merely a trend in leisure activities. It signifies a potential void in our collective ability to engage with complex arguments, narratives, and ideologies. The Double-Edged Sword of Short-Form Content Platforms like TikTok, YouTube, and Instagram have become monumental pillars in the world of information dissemination. These platforms, with their addictive bite-sized content, hold immense power in shaping public opinion. The primary strength of short-form videos lies in their accessibility and brevity. They’re convenient, quick, and cater to the modern dwindling attention span. However, their brief nature also stands as their inherent weakness. Dr. Maryanne Wolf of UCLA aptly warns, “The superficial way we read during the day is affecting us when we have to read with more in-depth processing.” The challenges posed by this format aren’t merely about retention. In the frantic race to condense information into seconds or minutes, much is lost in translation. Oversimplification or even misconstruction of facts becomes a real concern, particularly when these snippets become the primary sources of knowledge. Personally, I’ve begun to notice casual moments when people will talk about what they’ve learned on a Reel or in a Short – but as quickly as the interesting information has come, it becomes instantly apparent that there’s no depth to the DIY hack, or no knowledge of why some particular time-saver might work, or whether there might be relevant downsides. The bit-size knowledge simply isn’t enough to fulfill  minds that are hungry for more – or even a complete picture. Deep Engagement: Why It Matters in Complex Topics like Cannabis Over my career as a Family Physician specializing in medical cannabis patient care, I’ve encountered countless stories of transformation, relief, and hope. The spectrum of benefits that my patients have derived from cannabis-based therapies – most of which I’ve witnessed firsthand – is nothing short of remarkable. From individuals finding solace from debilitating chronic pain to those discovering a newfound balance in their mental health struggles, the therapeutic potential of cannabis stands undeniable. Yet, these profound narratives, intertwined with intricate medical research, mechanisms, and implications, can’t be compressed into bite-sized chunks without significant loss. It’s precisely the multifaceted nature of subjects like these that motivated my forthcoming manuscript on clinical cannabis care. The goal is not just dissemination but the deep, comprehensive illumination of a topic that demands more than superficial engagement. Evidence-Based Medicine in the Age of Tweets and TikToks In a landscape increasingly dominated by the influential voices of social media personalities, the call for evidence-based medicine becomes both challenging and imperative. With platforms that give everyone a microphone, the line between anecdotal evidence and scientific fact often blurs to almost unrecognizable. Social media influencers, many with minimal formal education in health or science, wield significant power in shaping public health perceptions. And worse yet, the value and significance of evidence and scientific rigor quickly fades in the memories of those flick-scrolling their way through what seems like an education. In my view, the danger lies not in sharing personal experiences, but in presenting them as universal truths. It’s in this difference that the irreplaceable value of evidence-based medicine shines. Decades of rigorous study, peer-reviewed research, and clinical trials offer a foundation of knowledge that is both credible and reliable. While it may not quite be “universal truth” it is certainly a different ballpark from what some famous actor/actress may wake up sharing on socials. To prioritize fleeting trends and unverified claims over this bedrock of evidence isn’t merely a matter of preference; it’s a question of public health, safety, and well-being. Add an element of time and human forgetfulness, and it could be reasonable to worry about the health of future generations. Final Thoughts While the digital age offers access to information like we’ve never seen before, there are critical challenges we still face to discern quality from quantity. Deep reading and comprehensive engagement, although seemingly antiquated in a world that overflows with snippets, remain crucial in fostering understanding, empathy, and critical thinking. As we stride further into this digital era, we must champion a balanced culture where both immediacy and depth are valued, ensuring that the allure of convenience doesn’t overshadow the quest for truth.   Citations: Pew Research Center. (2019). Who doesn’t read books in America? National Endowment for the Arts. (2007). To Read or Not To Read: A Question of National Consequence. Wolf, M. (2018). Reader, Come Home: The Reading Brain in a Digital World.   tl;dr: This blog considers the declining trend in deep reading, the rise and implications of short-form content across various media in contrast with longer form materials, and the value of evidence-based medicine in a digital landscape that is influenced by social media personalities. I try to champion the necessity of a well-rounded approach to information consumption, valuing both depth and brevity. And, hopefully anyone reading this will be that much more tempted to consider reading my own long-form book, The Doctor-Approved Cannabis Handbook [...] Read more...
August 30, 2023 Introduction Marijuana Positivity Rates in workplace drug tests have soared to a 25-year high, sparking a diverse range of views and approaches to cannabis use by employees. Let’s delve into four distinct perspectives: the medical viewpoint, the skeptical stance, the newcomer’s curiosity, and the experienced user’s wisdom. The Medical Perspective Recent studies indicate a general decline in opioid and barbiturate positivity rates in the same tests. This suggests a potentially momentous shift towards cannabinoid-based treatments, which often offer a more manageable side-effect profile than traditional pharmaceutical options The Skeptical Viewpoint about Rising Marijuana Positivity Rates For those skeptical about marijuana’s therapeutic potential, it’s important to note that a positive test doesn’t necessarily equate to on-the-job impairment. Drug screens can detect usage from as far back as a month. Employers have to navigate the labyrinthine mix of federal and state laws, which adds a layer of complexity to employee testing and subsequent actions. The Newcomer’s Curiosity Newcomers might be intrigued by the National Basketball Association’s new stance: removing marijuana from its prohibited-substance list starting the 2023-24 NBA season. For those unfamiliar with medicinal cannabis, this highlights the shift in social attitudes and may prompt further inquiry into the growing body of published cannabis research. The Experienced User’s Wisdom For veterans in the medicinal cannabis community, the increased rates of marijuana positivity are less of a ‘new phenomenon’ and more of a ‘return to normal’. Cannabis has been a part of human history, and the tide seems to be turning back towards natural, cannabinoid solutions over pharmaceutical ones. Clinical Perspective: Meet Sarah, a patient at CED Clinic struggling with chronic pain. For years, she relied on opioids, until the side effects became unbearable. With cannabinoid therapy, Sarah experienced symptomatic relief and improved quality of life. It’s a privilege to contribute to this field, alongside scientific collaborators and my patients. My forthcoming book, The Doctor-Approved Cannabis Handbook, aims to address these very issues.  Read Sarah’s story on page 249 of the book! Order here: https://a.co/d/3T6jYaQ  Summary: The Changing Landscape of Cannabis Use in the Workplace The dramatic rise in marijuana positivity rates in workplace drug tests to a 25-year high encapsulates a broader shift in attitudes and approaches to cannabis. This change is affecting everyone—from the medical community to employers, from cannabis newcomers to experienced users. From Opioids to Cannabinoids From a medical standpoint, this spike could indicate a cultural and medical shift away from traditional opioids and barbiturates towards cannabinoids. Multiple studies have shown that cannabinoids often present fewer side effects than these more traditional substances. Redefining Impairment Skeptics must grapple with the fact that marijuana positivity does not necessarily correlate with immediate impairment. Legal complexities at the federal and state levels add to the challenge of interpreting these tests. As cannabis legalization spreads, laws may need to adapt to better assess on-the-job impairment rather than historical use. Cultural Acceptance The NBA’s new policies on cannabis reflect changing social norms, influencing newcomers to cannabis and hinting at a broader societal acceptance. This may lead to greater interest and engagement in the scientific community’s growing body of cannabis research. A Return to Roots For experienced users, this trend is more of a return to normalcy than a radical change. The increasing preference for natural cannabinoid solutions is seen as a positive development that aligns with historical use and understanding of the plant. Bridging Gaps in Clinical Practice From a clinical perspective, the stories of patients like Sarah highlight the promising therapeutic potential of cannabis. Through published research, clinical experience, and educational resources like The Doctor-Approved Cannabis Handbook, healthcare providers and patients alike can make more informed decisions about cannabinoid therapies. In summary, the surge in workplace marijuana positivity rates is not an isolated phenomenon. Rather, it reflects evolving perspectives on cannabis, influenced by medical research, cultural shifts, and individual experiences. This change has implications for legal frameworks, workplace policies, and healthcare practices. References 1: “Decline in opioid and barbiturate positivity rates in workplace drug tests,” Journal of Occupational Medicine and Toxicology, 2021. 2: Moeller, K. E., Lee, K. C., & Kissack, J. C. (2008). Urine drug screening: Practical guide for clinicians. Mayo Clinic Proceedings. 3: Caplan, B. The Doctor-Approved Cannabis Handbook, 2023. 4: Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 5: “Marijuana Legalization and Workplace Safety: A Short Review of the Literature,” Journal of Occupational and Environmental Medicine, 2018. 6: “NBA Changes in Cannabis Policy and Public Perception,” Sports Medicine Journal, 2023. 7: Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. To find these articles: https://cedclinic.com/resources/cannabis-literature-library/   _______________________________________________________________________________________   Top 10 Takeaways from the Surge in Workplace Marijuana Positivity Rates Introduction: Marijuana positivity rates in workplace drug tests have hit a 25-year high, making headlines and leading to broader conversations about cannabis use among employees. Based on a news article by Anne Marie Chaker, published on May 18, 2023, we’re examining the top 10 things you need to know about this growing trend. 1. Record-Breaking Positivity Rates More than 6 million general workforce tests screened for marijuana in 2022 showed that 4.3% came back positive, which is the highest rate since 1997. 2. Post-Accident Rates Soar The percentage of employees testing positive for marijuana following an on-the-job accident rose sharply to 7.3% in 2022. 3. Opioid and Barbiturate Rates Decline Contrastingly, positivity rates for certain classes of opioids and barbiturates declined last year. 4. Rising Amphetamine Positivity Besides marijuana, tests for amphetamines also showed an increase in positivity, rising from 1.3% in 2021 to 1.5% in 2022. 5. State Vs. Federal Law Complications The growing number of U.S. states legalizing marijuana use adds complexity to workplace drug testing policies, as federal laws may still require testing. 6. Shift in Employer Screening Policies Companies like ManpowerGroup are starting to screen less often for marijuana, partly due to the challenges of hiring enough front-line workers. 7. NBA’s Progressive Stance The NBA is removing marijuana from its prohibited substance list for the 2023-24 season, signaling a shift in social attitudes towards marijuana use. 8. Amazon’s Inclusive Approach Amazon has stopped screening many job applicants for marijuana, citing that the tests disproportionately impact people of color. 9. Employee Impairment Challenges Because some drug screens can detect marijuana use that goes back days or even weeks, a positive test does not necessarily indicate on-the-job impairment1. 10. The Impact on Various Industries The rise in marijuana positivity rates isn’t restricted to one sector; it spans multiple industries including food services, retail, and accommodation. Summary The surge in workplace marijuana positivity rates reflects broader societal shifts in attitude towards cannabis, but it also introduces complexities for employers navigating drug testing policies. While some companies are reevaluating their approach to marijuana screening, debates around safety and legal liabilities continue. Overall, the rise poses challenges and opportunities in workforce management, health, and social policy. Citations Note Points 1-8 are extracted from the news article “American Workers Testing Positive for Marijuana Reaches 25-Year Record” by Anne Marie Chaker, published on May 18, 2023. Points 9-10 are supplemented with information from peer-reviewed literature. Footnotes National Safety Council: “Drug Testing Isn’t a Single Solution” – Katie Mueller, Senior Program Manager [...] Read more...
August 21, 2023Discover the potential of cannabinoids in pain management. Explore medical insights, opposition viewpoints, and real experiences. Learn how cannabinoids could reshape the future of pain treatment. Introduction: The opioid crisis has become a public health emergency in the United States, with over 130 people dying every day from opioid-related drug overdoses. As the medical community grapples with this crisis, a new frontier in pain management is emerging: cannabinoids. Recent research suggests that medicinal cannabis may offer a promising alternative to opioids for pain relief. This blog post will explore the medical perspective on cannabinoids, address common misconceptions, and consider the viewpoints of both new and experienced users of medicinal cannabis. The Medical Perspective on Cannabinoids From a medical standpoint, cannabinoids present an exciting opportunity to address the opioid epidemic. Studies have shown that medicinal cannabis can significantly reduce opioid consumption, with some patients finding cannabis alone more effective than a combination of cannabis and opioids. However, the integration of cannabinoids into medical practice requires careful consideration of dosing, legal regulations, and patient education. Continued research and development of prescribing guidelines are essential to ensure safe and effective treatment. The opioid crisis has led to a search for alternatives, and cannabinoids present a promising solution. Research supports the use of medicinal cannabis to reduce opioid consumption and provide effective pain relief. The medical community is urged to consider this option, recognizing the need for proper guidelines and continued research. Misconceptions and Opposition to Medical Cannabis Despite the promising evidence, some individuals remain opposed to medicinal cannabis. Common misconceptions include fears about its psychoactive effects, potential for abuse, and lack of regulation. Clear, evidence-based communication is vital to dispel these myths and provide accurate information about the therapeutic benefits of medicinal cannabis. Addressing legal and ethical concerns also requires collaboration between lawmakers, healthcare providers, and the community. Some individuals remain skeptical of medicinal cannabis, often due to misunderstandings about its effects and potential for abuse. Education and transparent communication about the scientific evidence supporting cannabis as a treatment option are essential to address these concerns. The Experience of New and Seasoned Cannabis Users For those new to medicinal cannabis, initial apprehensions may include concerns about side effects, social stigma, and legal issues. Comprehensive education and support can help alleviate these concerns. On the other hand, individuals experienced with medicinal cannabis often report significant benefits, including reduced opioid consumption and improved quality of life. Their insights and advocacy can foster acceptance and understanding within the broader community. Policy and Regulatory Considerations The legal status of medicinal cannabis varies across states, creating a complex regulatory environment. Developing consistent, evidence-based regulations is crucial to ensure safe and equitable access to this treatment option. Engaging with various stakeholders, including healthcare providers, researchers, policymakers, and patients, is essential to create a regulatory framework that supports responsible use.   The exploration of cannabinoids as an alternative to opioids for pain management is a multifaceted issue that requires a nuanced approach. By considering various perspectives and engaging in open dialogue, we can work towards a future where pain management is more effective, compassionate, and personalized. The potential of cannabinoids in reshaping pain treatment is promising, but realizing its full potential requires collaboration, education, research, and empathy.     This blog post delves into the medical viewpoint, opposition to medical cannabis, and the experiences of both new and seasoned medicinal cannabis users, but check out The Doctor-Approved Cannabis Handbook for this and more: https://amzn.to/3QFToba          [...] Read more...
August 7, 2023The Impact of Alcohol and Cocaine Misuse on Cognitive Flexibility: Multiple Perspectives The Medical Perspective From a clinical standpoint, the intricacies of how alcohol and cocaine misuse affects cognitive flexibility is a matter of profound interest. The brain is a complex organ, with multiple pathways and neural connections that control not only our physical actions but also our thoughts, decisions, and emotions. The recent study provides a compelling look at the neural pathways, such as the impact on striatal cholinergic interneurons and the activity of direct-pathway medium spiny neurons, which are altered by these substances. Medical professionals are particularly interested in these findings as they can guide the development of therapeutics to treat substance use disorders. Furthermore, understanding the decline in cognitive flexibility can assist clinicians in devising therapeutic interventions, which might include cognitive-behavioral strategies, medications, or even neurofeedback sessions, to boost or restore this vital cognitive function. The Skeptical Perspective Some individuals remain wary of the current science, often comparing the misuse of substances like alcohol and cocaine to medical cannabis. This skepticism usually stems from preconceived notions, past experiences, or misinformation. They might argue that drawing conclusions from a rodent study might not translate effectively to humans, making such studies less definitive. In comparing it to medical cannabis, these individuals often point out the lack of long-term studies or the possible risks of misuse and addiction, even if used for medical purposes. While their concerns cannot be entirely dismissed, it’s essential to differentiate between misuse and medical application, and to stay updated with evolving scientific research. Newbie’s Perspective For someone new to cannabis or the broader discourse on substance misuse, the intricate details of how alcohol and cocaine affect the brain might be overwhelming. They might wonder: “How does this relate to cannabis? Is it equally harmful, or does it offer medicinal benefits?” These individuals often seek rudimentary understanding. They might find the concept of cognitive flexibility intriguing, especially if they can relate it to their daily life experiences. Perhaps they’ve noticed changes in their behavior or thought patterns after consuming alcohol or know someone battling cocaine addiction. Being new to the subject, they’re open to learning but might be vulnerable to misconceptions or biases, making it crucial to present them with clear, accurate, and digestible information. Experienced Cannabis User’s Perspective For those who consume cannabis for medical purposes, such a study on alcohol and cocaine might provide a dual reaction. On the one hand, they might be curious about how different substances can influence the brain in varied ways. On the other, they might feel defensive, anticipating that detractors could lump medical cannabis into the same category as alcohol and cocaine. These individuals have firsthand experience of the therapeutic benefits of cannabis. They know that when used judiciously and under medical supervision, cannabis can provide relief from pain, anxiety, and various other ailments. When juxtaposing their experience against the backdrop of the study on alcohol and cocaine, they might assert the importance of distinguishing between “use” and “misuse”. For them, the underlying theme remains: everything in moderation, and under the right guidance. Conclusion:   the subject of substance misuse, brain health, and cognitive flexibility is multi-faceted. By looking at it from various perspectives, we can appreciate the nuances and complexities of this vital topic. Every viewpoint offers a piece of the larger puzzle, emphasizing the importance of open dialogue and continuous research. [...] Read more...
August 1, 2023In a surprising turn of events, more than a third of people aged 65 or older have tried marijuana, a figure that’s tripled since 2009. This trend is explored in depth in a recent article from The Washington Post, which also delves into the question of whether these older cannabis users are more likely to be NPR listeners. The article provides a wealth of information on the topic, including data from the National Survey on Drug Use and Health, and insights from researchers and experts in the field. It also highlights the potential influence of legalization on the increased use of cannabis among older adults. What are your thoughts on this trend? Are you surprised to see the older generation embracing cannabis? And do you know any NPR-listening, cannabis-loving seniors? Read the full article here: https://wapo.st/3Kc4QXO [...] Read more...
July 31, 2023Introduction The name Shawn Collins may not have been a household name a decade ago, but in recent years, it has become synonymous with the burgeoning Massachusetts cannabis industry. As the Executive Director of the Cannabis Control Commission, Collins has played an instrumental role in the development and regulation of the industry, drawing both praise and criticism from various quarters. In this blog, we delve deeper into the impact of Shawn Collins’ work, examining it from the perspectives of medical professionals, typical customers, and those indifferent or new to cannabis. Section 1: A Medical Perspective From a medical standpoint, cannabis is not just about recreational enjoyment; it has significant health implications. Many health professionals have praised Collins’ efforts to regulate the industry, which have made it possible for patients to have access to safe, tested, and reliable cannabis products for therapeutic use. Under Collins’ leadership, the Commission has ensured the strict regulation of product quality, offering a degree of certainty that was previously lacking. For conditions such as chronic pain, epilepsy, and multiple sclerosis, cannabis has shown considerable promise. Thus, having a well-regulated supply chain has been crucial in patient care. However, not all feedback from the medical community has been positive. Some health professionals argue that the commission’s focus on commercial and recreational use might overshadow the importance of medical cannabis, pushing patients’ needs to the backburner. Section 2: The Customer’s Lens For the average customer, the rise of the cannabis industry under Collins’ watch has been a welcome change. The most obvious benefit has been the availability of a wider range of products. Consumers now have access to a variety of cannabis strains and related products, from edibles and tinctures to topicals and concentrates. Furthermore, rigorous quality checks mean that customers can trust the products they buy. Another important aspect from the customer’s perspective is the economic impact. The cannabis industry has generated significant revenue and created numerous jobs. Many customers appreciate that their purchases are contributing to local economic growth and job creation. Section 3: The View from the Sidelines Not everyone is a fan or user of cannabis, and for these people, the growing prominence of the industry can be a source of indifference or even resentment. Some fear that easy access to cannabis might lead to increased misuse, particularly among younger users. However, many recognize that regulation is preferable to prohibition. Having clear laws and regulations in place is seen as a way to control misuse while allowing adults who wish to use cannabis responsibly to do so. In this context, Collins’ work is acknowledged as necessary, even by those who might not personally support cannabis use. Conclusion Shawn Collins’ impact on the Massachusetts cannabis industry is undeniably substantial. His efforts have helped create a well-regulated, economically vibrant sector that caters to both medical patients and recreational consumers. While some criticism and challenges are inevitable, the industry’s growth is a testament to Collins’ dedication and the comprehensive framework the Commission has put in place. It remains to be seen how the industry will evolve in the coming years, but for now, Massachusetts seems to be on the right track. [...] Read more...
July 25, 2023The recent fluctuations in the market have sent ripples across industries, and one sector that has especially caught our attention is the cannabis industry. The intriguing part? Unlike the majority of stocks that are riding the upward wave, cannabis stocks are demonstrating a distinct trend, diving when others are soaring. This unexpected behavior, as perplexing as it is, offers us an opportunity to delve deeper into the complex world of the cannabis industry and its stock market performance. Why Cannabis Stocks Are Falling When discussing stock market trends, it’s important to understand that these trends are reflections of a multitude of factors, both tangible and intangible. In the case of cannabis stocks, these factors are as diverse as the products the industry produces. Firstly, let’s discuss the elephants in the room – regulatory barriers. Cannabis, despite its increasing acceptance, still finds itself tangled in a web of legal constraints. The varying laws from state to state and the federal illegality of cannabis in the US pose serious challenges for the industry. These uncertainties can make investors uneasy and lead to volatility in cannabis stocks. Secondly, the cannabis industry is still in its infancy, with companies still exploring the best ways to operate profitably. Many cannabis companies are focusing heavily on scaling their operations, often prioritizing growth over profitability. This can result in inflated valuations that are not backed by strong financials, making the stocks more susceptible to market downturns. Tilray: A Case Study Take Tilray, for example, a cannabis company that also has stakes in pharmaceutical distribution and alcohol businesses. Despite its diversified portfolio, Tilray has not been immune to the current downturn in cannabis stocks. Its stock has seen a significant dip in 2023, a worrying indication ahead of their Q4 report. This illustrates that the industry’s challenges can impact even the biggest players, regardless of their diversification strategies. Looking Ahead: What Could Potentially Turn Things Around? Despite the current downturn, there are reasons to remain optimistic about the future of cannabis stocks. One such reason is the potential for regulatory reform. As societal attitudes towards cannabis continue to evolve, there’s hope for a more progressive legislative framework that could alleviate some of the current regulatory pressures. Moreover, as the industry matures, we can expect to see companies beginning to focus more on profitability rather than just growth. This shift could lead to more robust financials, thereby making cannabis stocks more attractive to investors. Ultimately, the future of cannabis stocks remains uncertain. Investors and stakeholders must stay informed, adaptable, and open to new perspectives. With a thorough understanding of the industry’s fundamentals and a close eye on market trends, it’s possible to navigate through this uncertain terrain and make informed investment decisions. [...] Read more...
July 19, 2023I’m absolutely thrilled to share with you the upcoming launch of my very own “Doctor-Approved Cannabis Handbook”. This has been a labour of love, the fruit of years of intense research, and a quest to bring forth the multifaceted benefits of this incredible plant – cannabis. Yes, you heard that right. My mission is not just to shed light on the often misunderstood world of cannabis, but to challenge our prevailing perceptions, and spark an informed conversation about its potential. Click to check out the amazing endorsements and to order: https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana-ebook/dp/B0BSKRN1M7 Can you believe that over the last decade, cannabis has undergone such a remarkable transformation? It’s moved from being a largely taboo topic to becoming a potential game-changing therapeutic tool within our medical community. This transition is undoubtedly encouraging, yet it has been clouded by widespread misinformation and a whole lot of uncertainty. To address this, I’ve written an all-inclusive guide that seeks to demystify the medical applications of cannabis. My handbook is designed to empower you, whether you’re a healthcare professional, a patient, a caregiver, or just someone curious about the subject. In Part 1 of the book, I take you through a guided tour around the cannabis plant, explaining its intricacies, and discussing the various products you can buy off the market. But that’s not all. I even delve into how you can DIY cannabis edibles and topicals, opening up an exciting world of homemade therapeutic treatments. As we move into Part 2 of the book, we dive deeper into the clinical uses of cannabis. Every single claim made is backed by an indexed, evidence-based, peer-reviewed reference. Together, we explore the potential of cannabis in addressing a range of conditions: mental health issues, sleep disturbances, headaches, neurodegenerative diseases, seizures, and even end-of-life care. But the journey doesn’t end there. My book also unravels how cannabis can be a potent ally in managing physical pain, skin conditions, gastrointestinal issues, enhancing sexual health, and even mitigating symptoms associated with cancer treatments. You see, the “Doctor-Approved Cannabis Handbook” is not just another medical guide on the shelf. It’s a testament to the REAL opportunity that holistic, patient-centered healthcare presents. In a world that’s largely dominated by pharmaceutical models, I’m hoping (and trying my best!) to bring alternative approaches to the forefront. Can you imagine what it would mean if a cannabis-positive book made it to a best-seller list? It would not only command attention but also bring much-needed respect to an industry that has often been run over. More importantly, it could bring hope to millions of people who have suffered unnecessarily because of a lack of access to this information! As we embark on this path, we do recognize the challenges we face. Societal prejudices, regulatory complexities, and even the frustrating “algorithm” which often auto-cancels cannabis. But with informed knowledge and a shared understanding, we can overcome these hurdles together. After all, every paradigm shift begins with a single, daring step. So join me in this journey to redefine wellness. Pre-order your copy of the “Doctor-Approved Cannabis Handbook” today, and together, let’s command attention, respect, and inspire a change that could potentially save lives for the better. [...] Read more...
July 13, 2023The use of cannabis for self-medication is a growing trend, particularly among neurodivergent individuals. A recent poll found that 1.8 million people in the UK are using cannabis to manage symptoms and improve their quality of life, a 29% increase from 2019. This trend highlights the unique intersection of physical and psychological phenomena that cannabis research is uncovering. The Medical Perspective From a medical standpoint, the use of cannabis for self-medication among neurodivergent individuals is a complex issue. On one hand, cannabis has been shown to help improve attention, emotion regulation, concentration, and executive functioning, while also reducing anxiety and sleep problems. These are common symptoms among neurodiverse individuals, making cannabis an attractive option for self-medication. However, the medical community also recognizes the potential risks associated with self-medication, particularly when it comes to unregulated substances. Without proper regulation and oversight, individuals may be at risk of consuming cannabis with high levels of THC, which could induce paranoia, anxiety, or psychosis. The Viewpoint of Someone Against Medical Cannabis Those against the use of medical cannabis often cite the potential for abuse and the lack of comprehensive research as reasons for their opposition. They argue that while cannabis may provide temporary relief for some symptoms, it does not address the underlying causes of these symptoms. Additionally, they express concern about the potential for dependency and the long-term effects of cannabis use. The Perspective of Someone New to Cannabis For someone new to cannabis, the idea of using it for self-medication can be both intriguing and intimidating. The stigma associated with cannabis use can be a significant barrier, as can the legal implications. However, the potential benefits of cannabis for managing symptoms of neurodivergence can also be very appealing. The Perspective of Someone Experienced with Cannabis Consumption for Medical Purposes Those who have experience with using cannabis for medical purposes often have a more nuanced perspective. They understand the potential benefits of cannabis, but also recognize the importance of using it responsibly and under the guidance of a healthcare professional. They may also have firsthand experience with the challenges of obtaining cannabis for medical use, particularly in regions where it is not yet legal. In conclusion, the rise of self-medication with cannabis among neurodivergent individuals is a complex issue with many different perspectives. As our understanding of both neurodivergence and the potential therapeutic uses of cannabis continues to evolve, it is crucial to continue the conversation and explore all angles of this important topic. [...] Read more...
July 11, 2023In the dynamic world of cannabis, THC-O-acetate has recently emerged as the new player on the field, largely due to bold claims of it providing a ‘psychedelic’ experience. But what does the science actually say? A new study led by UB has delved into these claims and found that the effects of THC-O-acetate are more aligned with inducing relaxation, euphoria, and pain relief rather than a psychedelic experience. This contradicts the current narrative floating around the cannabis community. Moreover, the study raises an important point of concern. The cannabis market, as it currently stands, is largely unregulated. This can result in product contamination, potentially causing unexpected and undesirable effects. Hence, it emphasizes the importance of being cautious in this seemingly Wild West market. As consumers, it’s crucial to be vigilant and rely more on scientific evidence rather than simply accepting manufacturer claims. In the rapidly expanding world of cannabinoids, safety should always be paramount. Dive deeper into the study here: https://bit.ly/46KsuEv [...] Read more...
March 14, 2023Whether you have tried other forms of treatment and failed to find relief, or you just prefer a holistic alternative, you may be wondering if medical cannabis is right for you. As a whole, over the last several decades we have learned so much about the benefits of cannabis and how this plant can help you find relief. However, we’re learning each day that the plant is complex in how it works with our bodies. No matter your symptoms or type of relief you’re seeking, it’s important to learn how to know if medical cannabis is right for you. History of Medical Cannabis Patients have touted the benefits of medical cannabis for not only years, and decades, but also through the centuries. Evidence suggests that cannabis was used extensively in what is now Romania, more than 5,000 years ago. And before that, archeological evidence has found cannabis in human culture as far back as 12,000 years ago.  In the U.S., cannabis was widely utilized as a patent medicine during the 19th and early 20th centuries, described in the United States Pharmacopoeia for the first time in 1850. In the grand scheme of things, cannabis prohibition only existed for a handful of recent years, as opposed to centuries of acceptance. Over the last several decades, many states, including Massachusetts have recognized the need and legalized cannabis in some capacity. Massachusetts now allows both recreational and medical cannabis use, but there are still a number of benefits to obtaining a medical marijuana card in Massachusetts. How Does Cannabis Work? Every creature with vertebrae has an endocannabinoid system. A series of receptors exists throughout the body and serves the purpose of restoring and maintaining balance (homeostasis), as well as other multiple forms of neurological communication. Cannabinoids (cannabis molecules) interact with these receptors in different ways depending on their molecular structure. Some major cannabinoids include THC and CBD. Others you may have heard of include CBN, CBG, CBC many more (over 100 more, actually). There are a plethora of cannabis strains to choose from. Just like there are countless varieties and hybrids of roses, the same can be said for cannabis strains. Like any other plant, they can be cultivated to have specific properties like a higher ratio of CBD, or other plant compounds like terpenes, fatty acids, and proteins. Different combinations of cannabinoids and plant compounds may affect the body in slightly different ways. For example, the terpene linalool is also found in lavender and is known to have a calming effect, so strains with more linalool may be encouraged for those who are anxious or stressed. What Are The Benefits of Medical Cannabis? There are countless benefits of consuming medical cannabis, though it is important to note that your experience may not be exactly the same as someone else’s. In general, some of the primary ways medical cannabis can help you find relief is through:        • pain relief,        • decreased stress, anxiety, or worry        • better sleep habits and sleep patterns        • along with other more specific benefits depending on your specific need Qualified Conditions For a Massachusetts Medical Card In answering the question, “how do you know if medical cannabis is right for you,” it’s important to note how the condition you are seeking treatment for is certainly relevant. In order to obtain a medical cannabis certification, the state requires that you have a qualifying condition. Patients 18 and older with a Massachusetts medical cannabis card can buy larger quantities of cannabis than those who purchase recreational cannabis. Some of these qualifying conditions in a medical cannabis evaluation include:        • Amyotrophic Lateral Sclerosis (ALS)        • Cancer        • Crohn’s disease        • Glaucoma        • HIV/AIDS        • Hepatitis C        • Multiple Sclerosis        • Parkinson’s disease These conditions are governed by the Massachusetts Cannabis Control Commission for medical marijuana doctors and patients and are continually updated as additional conditions are evaluated. The diagnosis of any of these qualifying conditions must be verified by a medical doctor, and the patient must go through an application process. If your exact condition is not listed above, do not let that be a deterrent. Dr Caplan has the ability to determine what conditions may benefit from medical cannabis and has the authority to issue cards for any condition where it is medically appropriate. How Do You Know If Medical Cannabis Is Right For You? Many people, with and without a medical condition can benefit from cannabis use. CED champions a holistic approach to healthcare and wellness that includes medicinal cannabis. Meet with our team of marijuana doctors in Massachusetts to discuss your medical marijuana card needs – through a cannabis evaluation, we’ll review your medical history, answer all your questions, address your symptoms and discuss how cannabis could better your health. If you think getting a Massachusetts medical marijuana card could be right for you, request an appointment online at your preferred time or call us to schedule one at (617) 500-3595 and we will be more than happy to guide you through the process. [...] Read more...
March 7, 2023Medical cannabis use was approved in 2006 for Rhode Island residents with a qualifying condition. The Rhode Island Department of Health’s Medical Marijuana Program administers all aspects of the state Medical Marijuana Act and all regulations for patients and certifying practitioners. This includes who is eligible to receive a Rhode Island medical marijuana card, based on their qualifying health or medical condition. Medical Cannabis Use in the United States Over the past few decades, the benefits of medical cannabis have become increasingly accepted. One survey showed that 86 percent of respondents believe in the positive benefits of cannabis for medical conditions. There are nearly 20,000 medical marijuana cardholders in Rhode Island. Because marijuana is not federally-regulated, each state that has a legal medical marijuana program has its own set of laws. Medical marijuana is available in Rhode Island for a variety of conditions. First, a patient must obtain a formal diagnosis in a medical cannabis evaluation to apply for their Rhode Island medical marijuana card. Qualifying Conditions toApply for Medical Marijuana in Rhode Island In the state of Rhode Island, there are two categories of qualifying conditions required to get a medical marijuana card. The first category lists specific health diseases or illnesses. Cannabis is also authorized to help with symptoms derived from the treatment of these conditions. • Cancer • Glaucoma • Positive status for Human Immunodeficiency Virus (HIV) • Acquired immune deficiency syndrome (AIDS) • Hepatitis C The second category of qualifying conditions can relate to a chronic or debilitating disease,medical condition, or its treatment that produces one or more of the following: • Cachexia or wasting syndrome • Severe, debilitating, chronic pain • Severe nausea • Seizures, including but not limited to those characteristic of epilepsy • Severe and persistent muscle spasms, including but not limited to those characteristic of multiple sclerosis or Crohn’s disease • Agitation related to Alzheimer’s Disease Determining the Diagnosis of Your Qualifying Condition CED Clinic provides medical cannabis services for those seeking treatment for Rhode Island’s qualifying conditions. At CED Clinic, our cannabis doctors and physicians focus on individual patient care for specific needs. Our clinicians will review your health history in a medical cannabis evaluation to better assess the benefits for your medical concerns. During this cannabis clinic visit, it is important to talk to your doctor about all of the symptoms you are experiencing. Some chronic symptoms that do not respond to general medical treatment may qualify you for Rhode Island’s medical marijuana program – even if they are not in one of the two explicit categories. Mental health conditions like depression, anxiety, and post-traumatic stress disorder (PTSD) are not on the list of qualifying conditions but may be considered for a medical marijuana prescription. Applying for a Rhode Island Medical Marijuana Card The first step in the medical cannabis application process is to be formally diagnosed. CED Clinic offers telehealth options across multiple states, including Rhode Island. You can expedite the process by scheduling your appointment and filling out the intake form. Our cannabis clinicians will evaluate your health history and Rhode Island qualifying conditions for a cannabis medical card. We are here to walk you through the medical marijuana card application process and look forward to helping you feel empowered and educated about your cannabis choices. [...] Read more...
February 28, 2023The disappearance of Plant Medicine from mainstream American Medicine was a complex phenomenon that involved various factors, including the rise of modern medical care, the growth of a modern pharmaceutical industry, and changing attitudes towards natural remedies. One of the key events that contributed to the disappearance of plant medicine was the passage of the Pure Food and Drug Act of 1906. This legislation required manufacturers to accurately label their products and disclose any harmful or addictive ingredients. While this was a step forward for consumer protection, it also created an environment in which synthetic drugs could plant a foothold in the consumer market, as medicines/formulations could be patented and sold exclusively by their manufacturers, at great financial benefit. At the same time, the medical profession was undergoing a transformation, with doctors increasingly turning to scientific research and laboratory testing to guide their practice. This shift away from traditional remedies was fueled by the belief that science could provide more effective treatments for disease than natural remedies, which were more challenging to study. The Flexner Report, published in 1910, played a significant role in this transformation, as it called for medical schools to adopt a more scientific and rigorous approach to education and research. The rise of the pharmaceutical industry also played a crucial role in the disappearance of plant medicine. Pharmaceutical companies were able to invest heavily in research and development – and political lobbying efforts – and they could patent and market their products directly to doctors and patients. As a result, synthetic drugs began to replace natural remedies, which were often difficult to standardize and lacked the financial incentives of patented drugs. At the same time as the pharmaceutical industry blossomed and a more sterile system of ingredients and methods of study evolved, changing attitudes towards natural remedies also contributed to the disappearance of plant medicine. As modern medicine became more dominant, natural remedies were often seen as outdated and unscientific. This attitude was reinforced by the media, which often portrayed natural remedies as ineffective or even dangerous, relative to the more machined alternatives. The disappearance of plant medicine from mainstream American medicine was a complex phenomenon that involved a wide variety of interconnected factors, including the rise of the modern medical approach, birth and growth of the pharmaceutical industry, and evolving attitudes towards natural remedies by experts and professionals. While plant medicine is still used today by some healthcare providers, its disappearance from mainstream medical care was largely due to the emergence of synthetic drugs and the transformation of the medical profession towards a more scientific approach to treatment. [...] Read more...
February 8, 2023Once you have your medical marijuana card, it’s easy to feel like you’re on your own. Unfortunately, there is a trend among cannabis clinics of providing exceptional service until clients have their medical marijuana certifications, and then rushing them out the door. That’s not the case at CED Clinic. Current cannabis cardholders — not just those hoping to become patients — are welcome to make telemedicine appointments at any time with their medical cannabis doctor. Our Massachusetts cannabis doctors are here to provide holistic, cannabis-centered care throughout the duration of your treatment. These are just some of the reasons you might schedule a follow-up. 1. Your medical needs have changed. Life is dynamic. Whether you obtained your medical cannabis card last week or two years ago, your overall wellness may have changed since. The following are some examples of updates you may want to communicate to your cannabis doctor: New diagnosis Upcoming medical procedures Changing or worsening symptoms Dramatically improved symptoms Your cannabis doctor can answer questions, provide professional insight, and recommend any necessary adjustments to your medical marijuana prescription. 2. Your cannabis prescription isn’t working out the way you’d hoped. Perhaps you’re not seeing the results you wanted from cannabis use. This could mean you’re not feeling relief from your symptoms or the effect is minimal. Perhaps cannabis use is helping, but with other undesired effects. It’s important to remember that these issues occur with prescription medications, and you can consider a follow-up at our cannabis clinic the same way you would with your primary care provider. The truth is, there are myriad reasons why cannabis might not be delivering the desired benefits: it could be related to your dosage, the products you’re using, the method of consumption, or even other aspects of your routine or treatment regimen. By raising your concerns, you allow your canna-doctor to identify potential causes and make informed recommendations. 3. Your treatment used to work, and is now no longer effective. Sometimes cannabis loses its effectiveness — even when you’ve been using the same strain from the same company for an extended period of time. Trust us, you’re not crazy. There are several potential causes: Lack of consistency in medical cannabis products (which is a well-known problem in the industry) You’re building up a tolerance Changes in your medications, routine, or diet During your appointment, your cannabis doctor can shed some light on the issue, and offer suggestions on how to combat it. 4. There are updates to share with your cannabis doctor about your journey. When you have a traditional check-up, it helps your PCP stay informed of your wellbeing, monitor your progress with various treatments, and learn of any changes in your health. Our goal is for you to think of your care at CED Clinic the same way. Consider this: you want a medical professional to keep tabs on your overall well being, your prescriptions and whether they’re helping your symptoms; why wouldn’t you want the same as a medical marijuana patient? 5. You need a medical liaison to represent your cannabis treatment. Whether you have a regular doctor’s appointment approaching, are seeing a new specialist or have an upcoming medical procedure, your cannabis use may be relevant information. These are all opportunities for your cannabis doctor to offer support. Dr. Caplan can communicate directly with the providers involved, acting as a go-between or liaison for your medical needs. Further, receiving updated medical details allows him to make recommendations for your cannabis care routine if necessary — for example, increasing your dosage after a procedure, or altering usage to prevent adverse reactions with new medications. 6. You’re curious about new developments in the medical cannabis industry. Maybe you’ve heard about new cannabis products or formulations, or while conducting your own research, stumbled across new potential use cases, studies or data. As a result, you wonder, “How does this affect me, and what does it mean for my cannabis treatment? Should I alter my approach?” Luckily, you’re in the right place for this conversation. Dr. Caplan is not only the founder of other cannabis businesses (such as EO Care, Inc, a new digital therapeutics company that is changing the future of cannabis care), but shares access to the CED Clinic Library, (which is the world’s largest digital library of free medical cannabis research). By sharing free research with his medical cannabis patients, there are no barriers to learning cannabis health for all. You’re welcome to make an appointment to gain his professional insight and to discuss this research or other cannabis-related developments. 7. You want to learn how cannabis interacts with your medications, diet and more. If you’ve been experiencing altered effects in your cannabis use, have you noticed they correlated with changes in your health and wellness routine? If so, you could be onto something. The way that cannabis affects your body — specifically, how cannabinoids interact with your endocannabinoid system — is directly connected with things like food, exercise habits, sleep patterns and much more. If you’re seeking information about the potential interactions of cannabis and related effects (especially if you’re starting a new medication), Dr. Caplan would be happy to address this with you. Remember: cannabis knowledge is power over your own health. Ready to schedule your appointment Just visit our website and request an appointment online for a medical cannabis evaluation. If you have questions, please feel free to contact us. We look forward to hearing from you! [...] Read more...
January 31, 2023The endocannabinoid system (ECS) has long been associated with how we process emotions, including stress and fear. Anandamide, the very first discovered, and likely most well-understood endogenous cannabinoid, functions as a neurotransmitter that actively combats the feelings of stress and fear. In the body, Anandamide is degraded by the Fatty Acid Amide Hydrolase (FAAH), so blocking FAAH activity can effectively increase anandamide in our bodies, much like how preventing a faucet from closing will set up for a flood of extra water. Fear extinction is one of the core known functions of the anandamide molecule. When a stimulus is un-coupled from a fear response in the body, this is a process governed by anandamide. For example, mice can be trained to associate a certain noise with a shock (fear training) and then dissociate the noise from the shock when they are presented with the noise by itself (fear extinction training). Research about the endocannabinoid system and fear In astudy published in Molecular Psychiatry, administration of an FAAH inhibitor in mice decreased fear when it was paired with a fear extinction training. Interestingly, however, the FAAH inhibitor did not impact fear if no extinction training occurred. Of particular interest, anandamide levels in the amygdala, another memory organ in the body, were increased, after fear extinction training, an effect that was increased further in the presence of a FAAH inhibitor. Considering these findings, the researchers speculate that variations in the FAAH gene, and therefore one’s expected level of anandamide breakdown, may be a relevant chemistry dynamic that underlies differences in one person’s ability to detect fear or cope with stress, from another’s. Consider, for example, a young boy who is afraid of a spider. When he notices the spider, consciously or not, his body immediately responds with a flight or fight response. This process happens in a synchronized way across multiple organs, including the amygdala, the adrenal glands, and traversing blood vessels throughout the body and brain. What does this mean for me? Toward a goal of minimizing the impact of fear, the natural response can be subdued in the presence of anandamide, perhaps aided and amplified by the actions or inactions of FAAH. Should someone have a gene which builds for them a very weak FAAH system, it is likely that they will have a much easier time recovering from fearful stimuli, because there will be less breakdown of anandamide. On the other hand, someone who has a very strong FAAH system would degrade their natural levels of anandamide and may have more persistent fear responses. In a world flush with fear, anxiety, and aggression, it is easy to imagine the relevance of a body system that helps to quell these negative emotions. Or, the contrary, it becomes simple to see the opportunity presented by a system of introducing molecular copy-cat molecules to some of the substances. To learn more about the endocannabinoid system and existing research about cannabinoids, explore the CED blog for our insights.   [...] Read more...
January 30, 2023Why is industrial hemp growth coming from the Cannabis Sativa L. strain of cannabis is restricted in many countries? Because it’s often confused with marijuana. But this lower THC strain has very little psychoactive properties, and is more often used for textile purposes. Also, essential oils from this low THC cannabis strain may have hidden benefits: antimicrobial activity. Can Hemp Oil Fight Bacteria? This essential oils of industrial hemp study looked at the antimicrobial properties of hemp oils against different types of bacteria. They looked at three different hemp oils (Carmagnola, Fibranova, and Futura) and found the oils might be most effective at fighting off gram positive bacteria (i.e. strep or staph infections). Futura Oil Fought Best Out of three different varieties of industrial hemp, oils from the Futura plant were the best at fighting a broader range of bacteria including food-born pathogens. Futura oils were virtually identical in composition to the other two essential oils, with the exception of a twofold increase in terpinolene compared to Carmagnola and Fibranova. The Key is Terpinolene Concentration Therefore, the higher terpinolene concentration is likely the cause of the increased antimicrobial activity. This effect is particularly applicable in the context of rising antibiotic resistance, where diseases such as MRSA become resistant to our current antibiotics. Topical hemp oils with antimicrobial effects could provide an alternative method of fighting off bacteria. Curious About Hemp and Cannabis as an Alternative to Antibiotics? To learn how the essential oils of hemp and cannabis could be used to help fight against antibiotic-resistant bacteria, book an appointment with our medical cannabis doctors through our virtual booking link or by giving us a call (617-500-3595). Dr. Caplan and his team at The CED Clinic in Chestnut Hill, MA are available to guide and support you! Social Media Post This study finds yet another use for industrial Hemp – antimicrobial activity. The researchers here tested essential oils from three different types of industrial hemp plant (Carmagnola, Fibranova, and Futura) against bacteria. They found that Futura oils had the broadest and most pronounced antimicrobial activities compared to the other two hemp varieties. Futura oils had a higher concentration of the compound terpinolene compared to Carmagnola and Fibranova oils, which likely explains their higher antimicrobial activity. Hemp oils might be a beneficial alternative to fight bacteria, particularly in the context of increasing antibiotic resistance. Tweet Hemp oils have antimicrobial properties and could be used to help fight against antibiotic resistant bacteria. Infographic/Question Would you trust hemp oils over other antibiotic treatments such as neosporin? [...] Read more...
Cannabis News
March 28, 2024Cannabis News​ Regulated sales of marijuana in Arizona topped $1.4 billion last year, according to state data, marking the third year in a row that licensed weed sales have exceeded $1 billion in the Grand Canyon State. Sales of recreational marijuana totaled more than $1 billion in 2023, while sales of medical cannabis brought in nearly $350 million, the Arizona Mirror reported on Tuesday. Arizona’s continued strong weed sales were welcome news for the state’s licensed cannabis businesses. Luke Flood, senior vice president and West regional leader for multistate operator Curaleaf, said, “Arizona has been a strong success story for us, and has become one of the top markets in the country for Curaleaf.”  “Since the launch of adult use, we have seen a lot of consolidation in the market on the retail side, along with a multitude of new third-party brands and products coming into the market, resulting in a wider selection for consumers at an affordable price,” Flood wrote in an emailed statement. “Uniquely, Arizona offers one of the lowest prices per gram at the retail level in the country.” Adult-use cannabis sales came to $1.1 billion in 2023, according to data from the Arizona Department of Revenue (ADOR), or about 72% of the year’s total sales. The year before, recreational marijuana sales contributed 70% of the yearly total. In 2021, the year adult-use cannabis sales began in Arizona, recreational weed made up only 45% of the state’s total cannabis market. “Reaching $1.4 billion in sales is a huge milestone for the state and I think it speaks to the wider efforts of de-stigmatization surrounding the plant,” Josh Hirschey, president of Arizona-based concentrate manufacturer Timeless, said in a statement. “The consumer demand for high-quality cannabis is there and Arizona brands are strategic in navigating natural limitations to normalize the plant,” he added. Monthly sales of recreational marijuana have totaled between about $80 million and $93.5 million since July 2022, peaking in March 2023 at $100 million. In January, adult-use sales dropped to $76.8 million, the first time in 18 months the figure was below $80 million. Medical cannabis sales totaled $348 million last year as the market for medicinal weed in Arizona continues to decline. Medical sales hit a monthly sales record of $73.4 million in April 2021 and have steadily decreased nearly every month since then. The decline in medicinal cannabis sales has coincided with a drop in the number of registered patients in Arizona’s medical marijuana program. Last month, the total number of medical marijuana cardholders was 111,168, down from the peak of 299,054. Arizona levies a 16% excise tax on adult-use cannabis sales in addition to the usual sales tax. Medical patients pay the sales tax of about 6%, depending on the area. Additionally, local jurisdictions add a tax of about 2% to all weed sales.  Last year, cannabis excise taxes totaled $172.8 million. Since recreational marijuana sales began in January 2021, the marijuana excise tax has generated $451 million in revenue for the state. Approximately one-third of Arizona’s marijuana tax revenue is earmarked for community college and provisional community college districts and 31% is dedicated to fire departments, fire districts, law enforcement and other first responders. One-fourth of state cannabis taxes are reserved for the Arizona Highway User Revenue Fund, while 10% is dedicated to the justice reinvestment fund supporting public health services, counseling, job training and other social services for communities that have been disproportionately affected by the War on Drugs. Although Arizona’s cannabis market has begun to stabilize, many of the state’s weed retailers are still optimistic about this year. Eivan Shahara, CEO of Mint Cannabis, said the business is “anticipating an even busier 2024, as we prepare to employ more people to serve more customers at our additional dispensary locations.” “The marijuana industry is blossoming into a significant job creator,” Shahara wrote in an email to High Times. “It’s estimated that the cannabis industry employs about 500,000 full-time equivalent positions in the U.S., with about 280 new jobs being added daily. This showcases a promising trend, as more than 100,000 new jobs were established in the previous year, making the cannabis industry one of America’s fastest-growing job sectors.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 28, 2024Cannabis News​ The Los Angeles Times reported that “Costa Mesa police and city employees trucked more than 100 pounds of cannabis flower, boxes of oil cartridges and vaporizers along with documents, devices and security equipment held in police storage” to the owners of Se7enleaf, Michael Moussalli and Matteo Tabib, reached a settlement agreement with the city of Costa Mesa, California. According to the Times, Costa Mesa attorneys “had been mounting an offense against what they believed was illegal commerce taking place at the site.” “They didn’t like that they had to return the stuff,” Tabib told the Los Angeles Times. “They didn’t like that they were wrong, and they didn’t like that they were embarrassed and that nobody was charged. They gave no consideration that me and Michael and our employees’ lives are not in a good place right now.” As the newspaper noted, officials in the city are currently “undergoing a review of the city’s retail cannabis ordinance, considering amendments that would establish a buffer between dispensaries and residential properties and cut back on costly employee badge requirements.” Earlier this month, the Costa Mesa city council held an hours-long meeting where they considered possible changes to local laws regarding retail cannabis dispensaries.  As the Voice of OC reported at the time, the council is “looking to limit the number of retail cannabis shops to 35 after city officials began questioning just how many should operate within the city,” in addition to considering “how close the shops should sit next to homes, youth centers and other cannabis storefronts.” The Los Angeles Times reported that the members of the Costa Mesa city council “generally supported establishing a separation requirement of 250 feet between any new cannabis dispensaries and residentially zoned properties and 1,000 feet between storefronts and youth centers where children recreate.” “If passed, such a rule would make any already-approved shops inside that red zone ‘legal, nonconforming’ businesses. Although they may continue to operate in violation of the new rules, it’s not clear whether that status could hamper a property or business in the future,” the Times reported earlier this month. “The panel also agreed to process up to 35 cannabis business permits, to allow would-be operators who’ve already passed a pre-application stage to continue the process. After that, through attrition, a new citywide cap of 10 dispensaries could be instituted upon final approval. But because a cannabis business permit runs with an individual operator and may not be transferred if a dispensary is sold, it is unclear whether another owner would be able to apply for a new permit or be shut out by the cap.” Costa Mesa voters have twice passed ballot measures that have re-shaped the legal cannabis market in the city. Per Costa Mesa’s official website: “In 2016, Costa Mesa voters approved Measure X, known as the City of Costa Mesa Medical Marijuana Measure, which allows certain non-retail cannabis-uses (i.e. manufacturing, distribution, processing, transportation, research and development laboratories, and testing laboratories) in one industrial area of the City, commonly known as the “Green Zone.” In 2020, Costa Mesa voters approved Measure Q, the Costa Mesa Retail Cannabis Tax and Regulation Measure. This measure allows the City to adopt rules permitting retail cannabis uses within the City, including storefronts (dispensaries) and non-storefront uses (delivery only).” Those two measures figured prominently in the dispute between the city and Moussalli and Tabib, who are majority owners of High Seas Cannabis, a boutique dispensary in Costa Mesa. “Store owners had been waiting for a cannabis business permit, a final step delayed as city prosecutors and police processed the aftermath of the raid and an earlier inspection that discovered High Seas-branded product at a local cannabis delivery that had been co-packaged by Se7enleaf,” the Los Angeles Times explained last week. “Moussalli maintains the company was testing the marketplace ahead of the dispensary’s opening and not doing anything illegal. Since it opened in Costa Mesa after voters approved Measure X in 2016, Se7enleaf has engaged with the city’s chamber of commerce and even helped inform the 2020 retail cannabis ballot initiative Measure Q.” Moussalli told the newspaper that he and his partner are “still treated as the stepchildren of businesses in the city.”  “We just want the same basic opportunities and rights as businesses that are regulated in the same ways as ours, like liquor stores,” he said. “I’m concerned they’re going to impose more regulations on us that they don’t understand the consequences of,” he continued. “I just implore them to engage in more conversations with the industry, so we can avoid situations like the Se7enleaf/High Seas fiasco.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 28, 2024Cannabis News​ Should restaurant patrons who smell like weed be denied service at a restaurant? That’s the question South Africans are asking after one of the country’s top rappers was denied service along with two friends.  South African rapper Emtee was denied service, along with two fellow rappers, from a branch of Mike’s Kitchen in Johannesburg, South Africa earlier this month after the restaurant complained that they smelled like weed. (Personal cannabis use at home is decriminalized and medical use is legal in South Africa.) The incident is prompting a national debate about the odor of cannabis in public spaces, and many people think the rappers were profiled as well. Emtee, who has millions of followers on Instagram, along with rappers Uncle Vinny and Yungseruno, said they were refused entry from Mike’s Kitchen in Parktown because they were “smelling of weed and had too many tattoos.” The restaurant chain is known for South African heritage-based dishes. TimesLIVE, South Africa’s second-biggest news website, reports that Emtee’s lawyers demanded an apology from Mike’s Heritage House in the upscale Parktown neighborhood of Johannesburg or he will take legal action against the restaurant. “We decided to go have lunch at Mikes Kitchen, Parktown,” Emtee said. “We were dropped off. We walked in and as we were being ushered to our table, a white man comes and tells us to leave because we ‘smell of weed and we had too many tattoos’. Mind you, our transport has left. This ho ass nigga kicked out the yard,” Emtee said. While apartheid ended decades ago, a severe case of race inequality remains rampant in Johannesburg, with nearly 40% of Black South Africans unemployed, a much higher ratio than their white counterparts. South African leaders, however, are currently taking measures to promote equity. On April 12, 2023, South African President Cyril Ramaphosa signed into law the Employment Equity Amendment Bill of 2020, which enacts “equity targets” to promote equity in the business sector. Emtee sounded fed up after being denied entry from the restaurant, suggesting racism was at play as well. “Fuck Mikes Kitchen in Parktown!” Emtee said. “You are about to get served. The fuck!? Fuck y’all food! At this, you are all fucking with me and my guys for nothing. Talking about ‘I’m gonna call the police’, call them! Scary ass bitch. Say never go to Mikes Kitchen Parktown. The son of biches is racist! Yeah I said! You all gone have to kill me. Mikes kitchen in Park Town is going down!” Emtee’s legal representatives have demanded that Mike’s Kitchen issue a public apology on Wednesday to the star or they will proceed with legal action. Mike’s Kitchen publicist Melinda Shore told TimesLIVE, “We are handling this privately. It’s not a matter they want to handle in the media. It’s being handled and taken seriously.” Emtee responded by posting a video on Instagram of himself buying a bottle of cologne, probably referring to the Mike’s Kitchen incident. “They say I’m this, they say I’m that,” Emtee posted on Instagram. “They forgot to tell you I smell best. When you see, embrace me.” “My life isn’t easy but I woke up feeling blessed,” Emtee sings on his latest single. “Smokin’ on that zaza, tryna balance out the stress…” In the U.S. the E-Bar restaurant in Dallas, Texas also discriminates against and denies service to patrons if they smell like weed. Last November, the South African National Assembly approved a bill that would decrminalize the personal use of cannabis. The Cannabis for Private Purposes Bill has been in the works since the country decriminalized private cannabis use in 2018 and now heads to the National Council of Provinces for concurrence. While it’s legal at home, it’s still illegal to smoke outside of one’s private dwelling, and it’s also illegal to buy or sell cannabis. Medical cannabis may also be prescribed. Democratic Alliance Member of Parliament Janho Engelbrecht spoke about the bill in the National Assembly, highlighting adults will only be allowed to use cannabis privately in their homes and sales will still be strictly prohibited should the measure pass. “People should bear in mind what this bill is about. It is about cannabis for private use by adults. You are not allowed to buy or sell cannabis, because this still remains a criminal activity with severe consequences. If you want to smoke it, you have to grow it, don’t buy it,” Engelbrecht said. Despite decriminalization and medical cannabis in the country, South Africa still is in need of change.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 27, 2024Cannabis News​ At a conference last week, Andrés Manuel López Obrador, Mexico’s president since 2018, said, “We are not going to act as policemen for any foreign government,” as quoted by the Associated Press. “Mexico First. Our home comes first.” As the Associated Press noted, López Obrador has, in previous years, “laid out various justifications for his ‘hugs, not bullets’ policy of avoiding clashes with the cartels.”  “In the past he has said ‘you cannot fight violence with violence,’ and on other occasions he has argued the government has to address ‘the causes’ of drug cartel violence, ascribing them to poverty or a lack of opportunities,” the AP reported, adding that “López Obrador’s view — like many of his policies — harkens back to the 1970s, a period when many officials believed that Mexican cartels selling drugs to gringos was a U.S. issue, not a Mexican one.” On Friday, the president “basically argued that drugs were a U.S. problem, not a Mexican one,” and he “offered to help limit the flow of drugs into the United States, but only, he said, on humanitarian grounds,” according to the Associated Press. “Of course we are going to cooperate in fighting drugs, above all because it has become a very sensitive, very sad humanitarian issue, because a lot of young people are dying in the United States because of fentanyl,” the president said. Over 70,000 Americans die annually because of synthetic opioids like fentanyl, which are mainly made in Mexico from precursor chemicals smuggled in from China,” López Obrador said. In February, The New York Times reported that United States “law enforcement officials spent years looking into allegations that allies of” López Obrador “met with and took millions of dollars from drug cartels after he took office.” The Times, citing U.S. records and three people familiar with the matter, said that the previously unreported inquiry “uncovered information pointing to potential links between powerful cartel operatives and Mexican advisers and officials close to the president while he governed the country.” “But the United States never opened a formal investigation into Mr. López Obrador, and the officials involved ultimately shelved the inquiry. They concluded that the U.S. government had little appetite to pursue allegations against the leader of one of America’s top allies, said the three people familiar with the case, who were not authorized to speak publicly,” the Times reported at the time. More from the Times’ report at the time: “Much of the information collected by U.S. officials came from informants whose accounts can be difficult to corroborate and sometimes end up being incorrect. The investigators obtained the information while looking into the activities of drug cartels, and it was not clear how much of what the informants told them was independently confirmed. For example, records show that the investigators were told by an informant that one of Mr. López Obrador’s closest confidants met with Ismael Zambada García, a top leader of the Sinaloa drug cartel, before his victory in the 2018 presidential election. A different source told them that after the president was elected, a founder of the notoriously violent Zetas cartel paid $4 million to two of Mr. López Obrador’s allies in the hope of being released from prison. Investigators obtained information from a third source suggesting that drug cartels were in possession of videos of the president’s sons picking up drug money, records show.” López Obrador, responding to The New York Times’ reporting, vehemently denied the allegations and called on the United States to clear up the matter. “It’s all completely false,” López Obrador said in February. “The U.S. government is going to have to address this.” He even suggested that the report could damage Mexico’s relationship with the U.S. “Does this diminish the trust the Mexican government has in the United States?” Mr. López Obrador said, as quoted by the Times. “Time will tell.” A spokesperson for the U.S. Department of Justice said there was no investigation into the Mexican president at the time. The Associated Press, in its report on Lopez Obrador’s latest comments, has a rundown on his relatively lax view toward the cartels: “López Obrador has argued before against ‘demonizing’ the drug cartels, and has encouraged leaders of the Catholic church to try to negotiate peace pacts between warring gangs. Explaining why he has ordered the army not to attack cartel gunmen, López Obrador said in 2022 ‘we also take care of the lives of the gang members, they are human beings.’ He has also sometimes appeared not to take the violence issue seriously. In June 2023, he said of one drug gang that had abducted 14 police officers: ‘I’m going to tell on you to your fathers and grandfathers,’ suggesting they should get a good spanking. Asked about those comments at the time, residents of one town in the western Mexico state of Michoacan who have lived under drug cartel control for years reacted with disgust and disbelief.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 27, 2024Cannabis News​ Medical marijuana patients would be permitted to grow up to 16 cannabis plants at home under a bill now pending in the state legislature. If approved, patients and caregivers would be able to grow twice the number of plants allowed under the state’s recreational marijuana legalization law, which went into effect on August 1 of last year. Minnesota legalized medical marijuana in 2014 with a law that allows patients diagnosed with certain qualifying conditions to use cannabis medicinally with a doctor’s recommendation. The law also allows the state’s approximately 41,000 registered patients to designate a caregiver to pick up medical marijuana from a licensed medical dispensary on their behalf. The law did not authorize home cultivation by patients or caregivers, however. The recreational marijuana legalization bill passed last year allows adults to grow up to eight cannabis plants at home, including up to four mature plants. Under a bill (HF 3766) introduced by Democratic Representative Jessica Hanson earlier this month, registered medical cannabis patients would be permitted to grow 16 plants. The bill also allows registered caregivers to grow marijuana on a patient’s behalf. At a hearing on the legislation on Monday, Hanson said the bill would allow more medical marijuana patients to benefit from homegrown cannabis. She noted that because of their medical conditions, many patients have limited incomes that do not allow them to buy medical marijuana at dispensary prices. Additionally, patients who are disabled or face other limitations often are not able to grow cannabis themselves. “As it stands, people with disabilities and conditions that qualify them to be on the medical program can only grow their own if they know how to, if they can afford to, if their condition or living situation allows them to or if they know someone who will gift them homegrown products,” Hanson said, according to a report from CBS News. Hanson told her colleagues that approving the bill would allow more patients to take advantage of the state’s medical cannabis program. “We do not think that people with qualifying medical conditions on our medical cannabis program ought to be left out of the ability to benefit from homegrown cannabis simply because they are unable to grow it by themselves,” Hanson said in a news report of the hearing published by the Minnesota House of Representatives. Republican state Representative Anne Neu Brindley questioned the need for Hanson’s bill, noting that the recreational marijuana legalization law allows all adults to grow cannabis at home. She also noted that cannabis grown under Hanson’s bill would not face the same safety testing requirements faced by commercial cannabis growers. “I would question whether or not caregivers are the best place to do that. They’re not trained in this and we’re treating this as medicine in this situation particularly,” she said. “And so I would question whether or not this is the most appropriate way to move forward on that.” Hanson replied that the cannabis lab testing infrastructure in Minnesota would not be able to accommodate the demand that would be created by requiring all homegrown medical cannabis to be tested. She also noted that the law does not require testing of home-cultivated recreational marijuana. “It’s my opinion that setting a different or a higher bar for people with disabilities who simply need help growing their own cannabis at home is not inclusive,” Hanson said. Leili Fatehi, a cannabis advocate and partner and principal of Minneapolis-based consultancy firm Blunt Strategies, said that the “legislation takes a thoughtful approach to the complex issues faced by patients with debilitating conditions, aiming to reduce the financial burden associated with accessing effective treatment.” “The efforts of Rep. Jessica Hanson and local advocates highlight a commitment to compassionate, patient-centered healthcare, reflecting the best in both legislative and community leadership,” Fatehi wrote in a statement to High Times. “Moreover, recognizing that many in our registry program are either physically incapable of cultivating cannabis due to health conditions or are hindered by their living situations, this bill addresses the critical need for accessible alternatives to forcing patients to choose between high dispensary prices or the unpredictability of receiving cannabis through legal gifting.” Hanson’s bill has been referred to the House Commerce Finance and Policy Committee for consideration.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 27, 2024Cannabis News​ The New York State Cannabis Control Board (CCB) recently voted to waive cannabis cultivator licensing fees for the next two years. Gov. Kathy Hochul celebrated this recent progress to help struggling cultivators. “Farmers are the backbone of our State, and we’re making sure the family farms across New York that are building our cannabis industry have a real chance to succeed,” Hochul said. “I have made it clear that New York State needs to issue more dispensary licenses and kickstart cannabis sales in New York, and this two-year promise to Adult-Use Conditional Cultivators will make sure these farmers can reap the benefits of this growing industry.” On the same day, the CCB also approved 114 new cannabis business licenses (45 for retail dispensaries and 31 microbusinesses) which allows the grantees to grow, process, and sell cannabis. The state currently has 89 licensed dispensaries currently operating, and hundreds more licenses that have been granted, with 223 approved in 2024. Additionally, the CCB approved 38 non-conditional adult-use licenses as well.  Until 2026, cultivators will no longer have to pay for the fee that is applied when they transition to a non-conditional license, such as cultivation or microbusiness licenses. Conditional license fees range anywhere between $4,500 to $40,000, and the price is based on their license tier size and canopy size, according to a press release published by Hochul’s office. Chris Alexander, executive director of the New York Office of Cannabis Managementalso provided a statement regarding the new licenses. “New York State’s cannabis market is moving in the right direction, and by waiving licensing fees for two years, we’re making sure conditional cultivators have a chance to reap the rewards of this growing industry,” Alexander said. “As we mark three years of legalized adult-use cannabis in New York state, we look forward to this next chapter of our cannabis story.” The 114 applicants who were granted licenses on March 22 submitted their applications prior to Nov. 17, 2023, and also already own a physical location for their business. Those who applied after Nov. 17 but before Dec. 18 will likely be approved within the next few months “on a rolling basis.” At the March meeting, the CCB also renewed permits for 17 testing labs. “Since the last Cannabis Control Board meeting in February, 16 new adult-use cannabis dispensaries have opened their doors across New York State,” the CCB wrote in a press release. “This is a continuation of the swift rate of store openings since the December lifting of an injunction preventing New York’s retail cannabis licensees from opening their doors.” There are an estimated 2,000 illegal cannabis business operators in New York, according to The New York Times. In comparison to the 89 legal businesses (10 which are delivery-only), that is approximately 24 illegal businesses for every one legal business. The original legal framework for New York’s adult-use cannabis program was signed by former Gov. Andrew Cuomo in March 2021, and Hochul replaced him and took office later that year in August. Last month Hochul spoke about the initial framework. “You have to go back to the very beginning,” Hochul said. “Prior to my time , the legislation was crafted in a way that was not poised for success.” As a result though, legal cannabis businesses have been struggling. “We’ve got farmers who are just losing money. We’ve got these people who took out loans and are excited about their opportunities, ready to start,” Hochul said. “And meanwhile, no money is flowing back to the state. We have all this, and the illicit market is flourishing.” Earlier this month, the New York Senate discussed a budget proposal that would earmark $128 million to support cannabis businesses. This includes $60 million to go toward farmers’ loans, $40 million for Cannabis Farmer Relief Fund grants, and $28 million for cannabis farmers who lost money due to the state’s slow ramp-up for its legal industry. A few weeks ago on the Senate floor, Sen. George Borrello spoke about the importance of the bill. “We are now three years into where we have passed the legalization of recreational marijuana in New York state—three years now this month,” said Borrello, according to The Post-Journal. “We are now proposing a bailout for pot farmers of $128 million. We all, I think, would agree this has been an abject failure. It’s been said on both sides of the aisle. Somehow New York state has managed to screw up pot. I don’t know how that happens, but we did.” Sen. Michelle Hinchey proposed a bill last year that was ultimately vetoed by Hochul but would have opened up opportunities for cannabis farmers earlier. “I don’t right now have any numbers on the broader spectrum of cannabis across the state, but I think it’s incredibly important to recognize and acknowledge that these are growers who we asked to grow the product for the market and so the $128 million here is to cover the losses they would have seen since the rollout was delayed and making sure they have the funds to be able to stay in business until the next growing cycle,” Hinchey explained.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 27, 2024Cannabis News​ A majority of cannabis flower products purchased at licensed retail pot shops in Colorado contained less THC than indicated on the label, according to a study performed by a researcher at the University of Colorado Boulder. The study showed that THC levels indicated on the label of approximately 70% of products tested were at least 15% higher than those reported by a third-party lab after purchase. The research was conducted by Anna Schwabe, an associate lecture professor of modern cannabis science at the University of Colorado Boulder. To complete the study, Scwabe collected 23 cannabis flower samples from 10 licensed dispensaries located across the northern Colorado Front Range, which includes the cities of Denver, Fort Collins and Garden City.  The samples represented 12 different cannabis strains including sativas, indicas and hybrids, with different THC potency levels reported on the product packaging. Some THC potency levels were reported as a range from 12.8%-19.3% on the lower end and 28.07%-31.28% on the higher limit, while others were reported as a single value such as 16.4% or 17.4%. After the samples were collected, they were sent to an independent laboratory for analysis using high-performance liquid chromatography (HPLC), which separates, identifies and quantifies the different chemical compounds contained in a mixture. HPLC is the most commonly used method in cannabis testing to determine cannabis potency and detect contaminants, making it an important tool to ensure consumers that products have been tested for safety, purity and potency. A comparison of lab testing results revealed that approximately 70% of the samples had reported THC levels that were at least 15% higher than the levels determined by the independent laboratory. “Among the 23 flower samples analyzed, 18 displayed lower THC levels than reported – with 16 falling below 15% of the stated value, 13 falling below 30% of the reported THC and three samples falling below half of the reported THC,” Schwabe wrote in a report about the research published by nonprofit news source The Conversation Four of the samples were within the range indicated on the label, while only one product contained more THC than the potency level reported on the packaging.  Schwabe noted that the lower THC values determined through independent lab testing were not due to degradation, adding that THC can degrade to the cannabinoid CBN (cannabinol) over time. However, CBN was not detected in measurable amounts in the samples, and additional testing showed that THC levels were stable over time. The research also revealed a significant increase in cannabis potency over the last 15 years, a period that includes the 2014 legalization of recreational cannabis in Colorado. “THC levels averaged 9.75% back in 2009, based on testing of DEA-seized cannabis flower. Today, levels reportedly surpass 35%, though they’re not as common as consumers have been led to believe,” Schwabe wrote in her report. “DEA-seized cannabis flower averaged 13.88% in 2019, which is closer to my observed mean of 14.98% than the reported mean of my samples, which was 20.27%-24.10%.” The research did not determine who is responsible for the misinformation found in reported cannabis potency levels. Cannabis cultivators or dispensaries could be selecting the best flowers to submit for laboratory testing. Although regulations require tests to be performed on a random sample of a batch of cannabis flowers, oversight to enforce the guidelines is lacking. The inaccuracy in cannabis potency labeling could also be the result of fraud. Cannabis testing labs could be manipulating the testing process or doctoring the numbers indicated on certificates of analysis to ensure repeat business or gain new clients, the author of the study noted. Schwabe noted that accurate lab testing of cannabis potency is important for medical marijuana patients who may want to carefully control their dose of THC. Proper potency testing is also significant for consumers who purchase recreational weed because companies can charge higher prices for cannabis with high levels of THC. Schwabe, who is also a board member for the nonprofit Agricultural Genomics Foundation, said that the cannabis industry should focus on educating “consumers on how to make more informed choices by looking beyond mere THC percentages.”  “People generally do not shop for wine or beer based on alcohol content,” the researcher wrote. “Instead of focusing on THC content, a novice cannabis consumer might consider brands that are reputable or strains that have an aroma or flavor profile they enjoy. Eventually, they may move on to find a favorite breeder or grower, or a trusted dispensary that employs a knowledgeable budtender.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 26, 2024Cannabis News​ Monday was not a good day for billionaire Sean “Diddy” Combs—once one of the most highly respected producers in hip-hop and one of the most successful Black entrepreneurs to enter the game—as feds from multiple agencies raided two of his homes in Los Angeles and Miami.  Two of Diddy’s homes were raided as part of a federal investigation led by the Southern District of New York into alleged human trafficking. Homeland Security officers from at least three locations took part in the raid, as well as other law enforcement members. “Earlier today, Homeland Security Investigations (HSI) New York executed law enforcement actions as part of an ongoing investigation, with assistance from HSI Los Angeles, HSI Miami, and our local law enforcement partners,” the spokesperson said. “We will provide further information as it becomes available.” Diddy’s lavish $40 million dollar home in Holmby Hills in Los Angeles was raided. Aerial footage from KTLA in Los Angeles showed multiple SWAT vehicles descending on his house. It boasts 17,000 square feet and has a 3,000 square-foot guesthouse, and Los Angeles Times reported that it has a theater, a gym, a wine room, and an underwater swimming tunnel connecting to an underground grotto. His other home—Emilio and Gloria Estefan’s former home on Star Island in Miami Beach, Florida, worth $35 million—was also raided. Combs, 54, was in the Miami area when the raids were taking place, according to law enforcement agents who obtained a warrant for his arrest Investigators seized the phones of Combs, as he was scheduled to depart for a vacay to the Bahamas.  In December 2023, a lawsuit was filed against Combs by a Canadian woman identified only as Jane Doe, who says she was sex-trafficked and gang raped in 2003 when she was 17 and in the 11th grade. She says two of her associates were also victims, and she is accusing him of running a “sex trafficking scheme.”  The lawsuit names Combs, former Bad Boy Entertainment president Harve Pierre and an unnamed third defendant, claiming Pierre and the third unnamed defendant approached the girl at a lounge in Detroit, Michigan, where Pierre allegedly told her he was “best friends” with Combs and dialed him up. With photographic evidence, the lawsuit alleges Pierre and the unnamed defendant convinced the girl to take a private jet to Combs’s studio in New York City, where she alleges she was drugged up, and gang raped by all three defendants. Jane Doe is the fourth person to file a lawsuit accusing Combs of sexual assault. An earlier complaint, for instance was made on Nov. 16, 2023, when the producer’s former girlfriend, Cassandra “Cassie” Ventura, filed a lawsuit against Combs, accusing him of sex trafficking and sexual assault. Since the allegations, Diddy has stepped down as chairman of Revolt, a music-oriented digital cable television network founded by the rapper and producer, which he founded about 10 years ago. Combs took to social media on Dec. 6, 2023, to denounce the allegations against him and defend himself, writing in a post on IG and Twitter, “Enough is enough.” “Sickening allegations have been made against me by individuals looking for a quick payday,” he said. “Let me be absolutely clear: I did not do any of the awful things being alleged. I will fight for my name, my family and for the truth.” Diddy’s downfall is epic, given his prior successes. As founder of Bad Boy Records, which peaked at $100 million in value, Combs is best known for discovering and transforming The Notorious B.I.G., Usher, Mary J. Blige, rapper-turned-preacher Ma$e, and many other prolific artists. He won three of 13 Grammy Award nominations. He moved into fashion in 1998, and was brand ambassador for Cîroc vodka up until last year when his legal troubles caught up with him. Changing his name numerous times, including Puff Daddy, P. Diddy, and other names, Combs had multiple no. 1 albums and singles as an artist or featured artist. His ode to Notorious B.I.G. sampling Sting, “I’ll Be Missing You,” spent 11 weeks atop the Billboard Hot 100. In 2022, Combs planned to launch what was billed as the world’s largest Black-owned cannabis brand with the $185 million purchase of existing licensed cannabis operations in three states, but the deal collapsed in 2023. Diddy’s allegations come amid the fanfare of Quiet on Set on Max, a documentary exposing the dark underside of Nickelodeon, with allegations of multiple sex crimes involving the cast of All That and other shows on the network.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 26, 2024Cannabis News​ European countries are gradually turning their attention toward cannabis reform as medical and adult-use cannabis steadily become the new status quo in states around the U.S. While Germany gears up to launch its adult-use program next month, Switzerland has embraced an alternative approach in the form of an adult-use cannabis pilot program. Earlier in March, Swiss officials published the first data from its pilot study in Zürich, offering initial insights on the demand for legal cannabis in the country along with some emerging consumer trends. The results of the study will be used to determine what, if any, public health implications adult-use cannabis availability might inflict on Switzerland as well as the rest of Europe. Switzerland is currently running trials in the cities of Lausanne, Zürich, Liestal, Allschwil, Bern, Bienne, and Lucerne, along with the cantons of Basel-Stadt and Geneva. Regarding the recently shared data on the “ZüriCan” study, a total of 2,100 people are able to take part with 1,928 currently included and eligible to purchase cannabis as part of the study.  Significantly more men (80.7%) than women (18%) or nonbinary people (1.2%) are taking part. This disparity was predicted, with researchers referencing a country-wide online survey from 2016 that similarly showed the majority of Swiss cannabis consumers were men. The 28-32 age group is also the most frequently represented in the study, with a mean age of 35 years. The data also takes a closer look at the consumption habits of study participants, with the majority consuming cannabis four or more times a week. “Participation in the study seems to be particularly attractive for people who consume frequently,” researchers state via translation. “However, people who only use cannabis a few times a month also take part in the study. This will allow us to compare people with different consumption habits in our study.” Researchers also note that approximately a fourth of participants had evidence of a cannabis use disorder before they had access to the products in the study — confirmed via a screening questionnaire, the Cannabis Use Disorder Identification Test (CUDIT). Researchers note that this trend mirrors other similar studies. Acknowledging and honing focus on this variable could also prove to be valuable from a research perspective: “Regulated distribution of cannabis can create a framework that promotes lower-risk cannabis consumption. In particular, cannabis users who have problematic consumption have easier access to advice and treatment services,” authors note. “… The sales staff at the reference points have been specially trained to provide advice and prevention so that individual, targeted advice is possible. Since study participants always buy their study cannabis from the same source, a closer relationship of trust can develop over time, in which problematic developments can also be identified and discussed.” The program originally offered five options, but in December 2023, it expanded to include nine different cannabis products — five flower and four hash products — with varying levels of THC and CBD. Researchers note that study participants have requested “all products,” with a total of approximately 16,500 sales so far and a total of around 140 kg (around 309 lbs) of cannabis products sold in five-gram packs. The data did not include any further breakdowns surrounding consumer behavior or the popularity of specific products, however. The European cannabis company Cannavigia is working with the Swiss Federal Office of Public Health on the study, namely to track cannabis sales and provide data on consumption trends through its Cannabis Dispensary System.  According to Cannavigia Head of Marketing Tobias Viegener, these initial findings are already providing some major insights. “The initial data from the ‘ZüriCan’ pilot, published this month, reveals promising insights into the regulated cannabis market’s functionality and its acceptance among participants,” he told Forbes. “This level of engagement indicates a positive reception and an effective distribution system, setting a solid foundation for informing future cannabis policy and regulation.” On March 18, officials also shared an announcement of the country’s latest study, which will run for five years and could see as many as 7,500 participants — Switzerland’s largest trial to date.  The study will also include a comparison group, with consumers continuing to source cannabis through the illicit market, while the other groups located in Winterthur, Schlieren and Horgen will have access to regulated products through participating pharmacies and retail locations. Cannavigia software will also be used in the recently announced Canton Zürich pilot study.  According to the Federal Office of Public Health, “The aim of the pilot trial in the canton of Zürich is to investigate the social and economic consequences of legalising recreational cannabis use in Switzerland. In addition, the effects of a self-regulation programme for the prevention of excessive cannabis use are to be studied. This involves a randomised controlled trial (RCT).”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 26, 2024Cannabis News​ A recent property tax relief bill in Nebraska is seeking to create new income opportunities for the state, including a variety of sales tax exemptions. This includes adding sales taxes for products like candy and soda, as well as services such as pet care and grooming, but most importantly, adding a 100% tax to CBD and hemp products. Legislative Bill 388 was recently passed by the Nebraska Legislature’s Revenue Committee on March 21 in a seven to 10 vote. The bill was initially introduced by Sen. Lou Ann Linehan in January, who is also the chair of the Revenue Committee. “Sales tax exemptions will be removed on pop and candy, on pet services, on advertising revenue over $1 billion dollars, increased taxes on games of skill to 20%, and lottery tickets,” Linehan wrote in an outline. “Taxes on cigarettes will increase from 63 cents to one dollar and on vaping by 20%. We are going to tax hemp and CBD at 100%. This will result in new revenue of $182 million dollars.” Overall, Linehan estimated that this would allow approximately $560 million in property tax credit funds that would be granted to schools, providing $3,000 per student in foundational aid. It would also create $650 million in property tax relief. The outline also describes “essentials” such as electricity, natural gas, or propane, as things that should not be taxed. “We are in a time of great revenue growth,” the outline concluded. “We have the revenues to pay for this now and for the foreseeable future.” These proposals have created a rift among Nebraskan legislators. Gov. Jim Pillen approved the committee’s work on approving the bill so it can proceed to the floor for debate. “I want to congratulate the members of the Revenue Committee on advancing historic and transformational property tax relief and reform out of committee on a 7-0 vote,” Pillen said in a statement. “Thank you for delivering once in a lifetime transformational property tax relief plan to all Nebraskans.” Many others, such as Sen. Julie Slama, expressed shock regarding the CBD and hemp tax increase. “I’m 100% opposed to LB-388, which is the largest tax increase in Nebraska history,” Slama said. John Gage, state director of Americans for Prosperity, criticized the bill. “There’s nothing innovative about raising taxes on Nebraskans. This bill does not solve our property tax problem and will result in a higher tax bill for hardworking families,” Gage said, according to KETV. “This is the kind of big government nonsense you expect in California, not Nebraska. Legislators will be held accountable if they choose to vote for the largest tax increase in state history.” Platte Institute CEO Jim Vokal called LB-388 a bad tax policy. “In recent years, the legislature has repeatedly succeeded and shown the best path to lowering taxes is to constrain all sources of revenue and spending growth,” said Vokal. “Such constraints need to be imposed upon local governments. We believe that constraining state and local revenue and spending growth is the best path forward rather than raising new sales tax revenues to lower property tax revenues.” Cannabis is illegal in Nebraska, although sales of hemp-derived cannabinoid products continue to thrive. In January, Legislature Bill 199 was introduced by Sen. Teresa Ibach which, if passed, would ban the sale, possession, and consumption of such products. “While a product could be advertised as delta-8 or delta-10, these products could—and most likely do—contain chemicals, compounds and other impurities that are not listed on the label,” Ibach explained. Meanwhile, advocates with Nebraskans for Medical Marijuana (NMM) are hard at work collecting signatures to qualify their medical cannabis initiative for the 2024 ballot later this year. The group needs to collect signatures from 7% of voters in the state and 5% of voters in 38 of the state’s 98 counties (with approximately 125,000 raw signatures in total) by July 3. As of March 15, NMM said on social media that it has collected more than 72,000 signatures from voters in nearly all Nebraska counties (with the exception of Grant, Keya Paha, McPherson, Sheridan, and Wheeler). NMM has attempted to get medical cannabis legalized since 2020. Back then, they only collected 14,212 signatures in three qualified counties, followed by 16,328 signatures in four counties in 2022.  Recent polling conducted by the Neilan Strategy Group in February revealed that 70% of participants want to see medical cannabis legalization. “Nebraskans are clearly ready to legalize medical marijuana,” the Neilan Strategy Group stated. NMM held its own poll in 2022 and found that 80% of participants said they approved of medical cannabis legalization. “Nebraskans are obviously ready to legalize medicinal cannabis,” said NMM campaign manager Crista Eggers, who explained how excited advocates are to be making so much progress this year. “We’re very excited about where we’re at. This time, we’re going to get it done or it is not going to happen,” Eggers said.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 26, 2024Cannabis News​ Regulated marijuana sales in the United States are expected to exceed $31 billion this year, according to a recent economic forecast from a firm specializing in cannabis and hemp business consulting, data, and economic research.  The projection from Portland, Oregon-based Whitney Economics estimates that legal sales of medical marijuana and adult-use cannabis will total $31.4 in 2024. The forecasted amount is an increase of $2.6 billion from 2023, representing a growth rate of 9.14% year over year. The projection notes that legal sales of cannabis have been suppressed since the end of the COVID-19 pandemic, citing changes in consumer purchasing power, higher interest rates and delayed implementation of regulations in new markets as challenges facing the industry. Despite these factors, overall cannabis growth has remained positive. Legal cannabis sales declined in 10 states, however, an indication that new markets are needed for the industry to continue to grow. Beau Whitney, chief economist at Whitney Economics, said that the new projection builds on a similar market analysis completed by the company last year. “We are quite proud of our predictive analytics that resulted in last year’s forecast versus actuals being 98.3% accurate,” Whitney said in a statement about the new projection. “Although there are uncertainties in the near-term outlook, demand for legal cannabis in the U.S. will remain strong throughout the decade, with growth coming from newer markets.” The forecast projecting continued growth of regulated cannabis sales was welcomed by executives in the cannabis industry. Some noted, however, that the industry’s continued growth will depend on regulatory changes that permit cannabis businesses to operate like those in any other sector, including engaging in interstate commerce and access to banking services. David Craig, chief marketing officer of Missouri licensed cannabis producer Illicit Gardens, said “It should be clear by now that cannabis isn’t going anywhere.” “If the federal government is going to drag its feet on descheduling, then it’s up for the states to take the lead in removing regulatory hurdles to operators, especially multi-state ones,” Craig wrote in an email. “What most outside the industry don’t realize is the extreme burden operating without uniform standards across legal states.” “It’s time for a coalition of states to come together and standardize the basics: packaging and labeling requirements, compliance fundamentals, marketing, and other restrictions,” he added. “Operating even in two contiguous states right now is practically the same as operating in two different countries. Resolving those disparities is an easy win for business and government alike.” Sarah Carter, communications director at Symple Seeds, said that it is “fantastic to see the continued growth of the legal cannabis industry.”  “This significant increase of $2.6 billion from the previous year underscores the momentum and potential within the market.” Carter wrote in an email to High Times. “However, amidst this success, it’s crucial to acknowledge the persistent challenge of limited access to banking for cannabis businesses. This obstacle not only hinders the industry’s ability to operate efficiently but also poses risks in terms of safety and transparency.” Legislation that would allow businesses in the regulated cannabis industry to access traditional banking services has been passed in the U.S. House of Representatives more than half a dozen times in recent years. An updated version of the bill, known as the Secure and Fair Enforcement Regulation Act is pending before the U.S. Senate. In a statement last fall, Majority Leader Chuck Schumer of New York said that he intends “to bring the SAFER Banking Act to the Senate floor with all due speed.” “Addressing this banking issue is paramount for unlocking the full potential of the cannabis sector,” said Carter. “With proper access to banking services, businesses can streamline operations, improve financial transparency, and foster greater investor confidence. Moreover, it would facilitate responsible business practices and compliance with regulatory requirements.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 25, 2024Cannabis News​ Former Medford, New Jersey mayor and former New Jersey General Assemblyman Scott Rudder is opening a dispensary in Riverside in his home state. Riverside, a suburb in the greater Philadelphia-Camden area, is a prime location for growth in the cannabis sector. Rudder, who is Republican, founded the New Jersey CannaBusiness Association in 2016, a leading cannabis trade industry association. He’s also a veteran and helped organize and was a top consultant to statewide campaigns to legalize adult-use cannabis in New Jersey in 2020, and also that year, NJ.com named Rudder the “Mayor of Cannabis.”  Township Green will hold its grand opening today with local officials and dignitaries, including State Senator Troy Singleton, who will take part in the ribbon-cutting ceremony for the state’s most recent cannabis dispensary to open.  “Township Green exemplifies what we hoped to achieve by legalizing cannabis in New Jersey,” said Rudder. “We’re focused not just on providing a great product but on building a sense of community and bringing commerce to downtown Riverside. Please join us on March 25 as we start this new and exciting chapter for the community.” The reasoning behind the opening of this retail location is to help revitalize and bring more foot traffic to Riverside’s downtown business district. It will also provide about 20 jobs, with the majority of them being given to local residents, some of whom can walk to work.  Last year, Rudder spoke to Insider NJ and said that about 70% of New Jersey towns have opted out of allowing cannabis businesses in their communities. However, he added, “that makes those remaining 30% very competitive.” He pushed to expand the state’s cannabis sector forward. “Although more and more people are picking up cannabis and putting down alcohol,” Rudder continued, “a lot of people still feel very closeted about it, which surprises me. … Some towns are a little slow getting to the mark. But some towns are also looking to opt back in , due to the tax benefits and job creation. I’m a former mayor, father of three. I understand those concerns.” With his new dispensary, he hopes to continue to take part in the growth of the state’s cannabis sector. It involves people who are respected in the community. Township Green’s Chief of Security, for instance, is the retired Riverside Chief of Police and several of the security personnel for the dispensary are local firefighters. Township Green’s grand opening will take place today, March 25 at 10:30 a.m. at 15 Scott Street, Riverside, New Jersey. Meanwhile, the state is making strides in cannabis reform, such as ironing out the rules for consumption lounges. The New Jersey Cannabis Regulatory Commission (CRC), responsible for the rules and regulations of cannabis in the state, met on Jan. 17 and unanimously approved regulations for consumption lounges in the state. According to a CRC press release, the rules need to be approved by the New Jersey Office of Administrative Law, but after that occurs, dispensary operators need to seek municipal approval in order to be endorsed by the CRC to have a consumption lounge. Endorsements last for one year and must be renewed every year. CRC Executive Director Jeff Brown said in a statement that consumption lounges would contribute to the success of New Jersey’s cannabis industry. “New Jersey’s cannabis industry is well on its way to being a billion-dollar industry, and consumption areas will likely bolster that—fostering a communal experience for those 21 and older around cannabis in a regulated and secure space,” Brown said. The primary rules state that a consumption area can’t be a standalone business, but that it must be attached to a retail store. If a dispensary owns multiple dispensaries, they are only permitted to have one consumption space. In addition, as medical sales and enrollment gradually decline amid adult-use sales, the CRC is introducing digital medical cannabis cards with no registration and renewal fees shortly after reducing fees for its physical medical cards. According to the commission, the new digital cards will begin rolling out in a few weeks and were introduced to prioritize patient accessibility and convenience. The digital cards can be presented on a mobile device, eliminating the risk of losing or damaging a physical card while also enhancing accessibility, the commission said. Those who would still like a physical medical card are still in for a bargain, as the CRC also recently reduced its physical registration fees to $10—they will not be required to pay again until renewal two years later, which is also a $10 fee. The opening of Township Green add to New Jersey’s growing industry, with plans to prioritize local community members.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 25, 2024Cannabis News​ In the midst of blossoming cannabis and CBD reform throughout the West, hemp-derived cannabinoid products are increasingly taking center stage as legislators continue to raise red flags surrounding the lack of regulation and intoxicating potential of these products. Just in the past several months, a number of states have moved to introduce new policies to limit or ban the sale of psychoactive hemp-derived cannabinoid products, like delta-8 THC. Similarly, many are calling out some of the issues surrounding the regulatory gaps surrounding hemp-derived products in the market. Among them is CBD Oracle, a consumer research company aiming to improve safety and transparency surrounding cannabis products.  Most recently, it turned its attention to CBD gummies and other hemp products available for purchase on Amazon.com. While the company notes that Amazon will “tell you confidently” that they do not allow CBD gummies on the platform, CBD Oracle’s new independent analysis on such products begs to differ. While Amazon doesn’t technically allow CBD products, CBD Oracle suggests that sellers on the site largely get around this obstacle by avoiding the term “CBD” and instead using “hemp” on packaging and in product descriptions.  Neurogan CEO Jan Brandup said that Amazon’s “hemp products” are not related to actual hemp and rather use the term as a sales tactic. “It’s alarming how easily consumers are deceived into trusting these products, just because they are sold on a reputable platform like Amazon,” Brandup said. “The best case is they may drain your wallet.” Sunday Scaries CEO Mike Sill agreed, adding that many of the products on Amazon automatically lack credibility and ultimately quality due to the nature of the platform’s regulations. “When you search for ‘CBD gummies’ on the platform, no reputable brands populate in your search results,” Sill said. “The reason for this is that credible brands like Sunday Scaries, Charlotte’s Web and cbdMD are not allowed to sell on Amazon without being banned.” Rather, Sill said these companies engage in “brand burning,” meaning that once they are banned from Amazon, they essentially rebrand with a new name and packaging only to reupload the same products to the site and continue sales. “Their business model doesn’t include a focus on building a reputable brand and providing the highest quality and safest products to consumers; they are just looking for a quick sale and will do whatever is necessary to stay ‘live’ on Amazon,” Sill said. So what exactly do Amazon “hemp” products contain? In an effort to analyze the specific contents of CBD products on Amazon, the company purchased 56 of the most popular hemp products on the site and tested them through InfiniteCAL Labs. Most of the products (80%) were gummies, with eight tinctures, two topical creams and one pack of mints. A majority (89%) also made specific numerical claims regarding dosage. Around 30% (17 of 56) of the products tested contained CBD, averaging 547 mg per package. However, there was a large variance in CBD quantity between products, with a minimum of 28 mg of CBD and a maximum of 1,582 mg. While CBD Oracle notes that this at least shows Amazon isn’t being totally dishonest about some of these products containing hemp and hemp compounds, it still violates Amazon’s policies and may not be legally compliant. THC is also banned from Amazon sales, though six (11%) of the tested products contained the cannabinoid with the three containing the most comprised primarily of delta-8 THC. While all of the products were under the THC threshold set by the 2018 Farm Bill, the three delta-8 products “had very high quantities of THC” with 641, 2,507 and 3,028 mg per pack. The product with the highest amount of THC had 76 mg per gummy. The majority of tested products (35 of 56 products, or 62.5%) contained no cannabinoids at all with more than a third (24 of 56 products, or 43%) containing no hemp. InfiniteCAL Lab Manager Dr. Erik Paulson explains that hemp is typically infused into consumable products through hemp seeds, which contain no cannabinoids, or through extractable material pulled out of leaves, stems or buds — generally to create cannabinoid-infused products. “Simply put, if you buy ‘hemp’ from Amazon it is likely that you will actually be buying an expensive jar of gummy bears. Gelatin and sugar, priced at a premium,” CBD Oracle notes in the report. The report also confirmed that a whopping 96% of tested products did not advertise an accurate dosage. “If we assume the dosage listing refers to cannabinoids (and not just the total mass of hempseed oil), just two products were confirmed by lab testing to have a dosage within 10% of that listed on their labels,” the report states. “They contained an average of just 25% of the advertised dosage. In most cases, this was less than advertised, but one product primarily containing delta-8 THC had twice the promised dosage.” In addition, 52% of the products appeared to make an unapproved medical claim, and almost 95% of products did not provide Certificates of Analysis (COA), typically considered an essential for reputable companies selling hemp products. While the report focused on Amazon products, CBD Oracle notes the prevalence of this trend, as other companies like eBay, Walmart and Alibaba carry similar products — sometimes the exact same options. Authors note the potential ramifications of selling these products, beyond safety and health concerns, in that it could undermine the broader hemp and cannabis industries and the reform progress so many are actively pushing for. “Amazon has demonstrated that they don’t understand the difference between hemp seed oil and hemp extract that contains cannabinoids,” said Forge Hemp’s Kelly Lombard. “As long as sellers are vague about a product’s contents, Amazon doesn’t seem to care. This is problematic because U.S. consumers need more information about hemp and CBD, not less. Amazon’s convenience and return policy may entice more consumers to try hemp products, but if their experience is negative, that hurts the industry.” CBD Oracle also lists some potential solutions to remedy these issues, though they largely fall on Amazon to either adhere to more strict verification and COA guidelines, if not completely remove any products making false claims. They note that customers tend to have limited impact and that individual efforts to combat or report these products may ultimately result in frustration and wasted time.  Authors also cite that the current model, a blanket ban on CBD encouraging companies to be dishonest and actively work around it, may not be the answer. “Even establishing a bare minimum requirement for hemp sellers — showing an up-to-date lab report — would be enough to send the snake oil sellers running for the hills,” the report concludes. “Will you be able to pretend that CBD isn’t available on your platform? No. But customers who are buying CBD on your platform — who already exist, like it or not — would be much, much more likely to get safe products that offer what they say on the label.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 25, 2024Cannabis News​ The German government last week adopted a bill to end the prohibition of cannabis for adults that will make possession and home cultivation of weed legal in Europe’s most populous nation as of April 1. The legislation, which also allows for the establishment of cannabis clubs, was given final approval on Friday in the Bundesrat, Germany’s legislative chamber representing the country’s 16 federal states. The bill has already been approved by the second chamber of parliament known as the Bundestag, which voted to pass the legislation late last month. Under the limited legalization bill known as CanG, adults aged 18 and up will be permitted to possess up to 25 grams of marijuana and store up to 50 grams of weed at home beginning on April 1. The measure also permits adults to grow as many as three cannabis plants at their residences.  On July 1, Germany’s weed legalization plan will begin permitting non-commercial cannabis clubs, where members will have access to legally cultivated marijuana. Each cannabis club will be limited to no more than 500 members. The legislation does not include provisions that allow for-profit recreational marijuana producers or retailers. “The fight was worth it,” Health Minister Karl Lauterbach wrote on X, the social media platform formerly known as Twitter, according to a translation from Politico. “Please use the new option responsibly.” “Hopefully this is the beginning of the end for the black market today,” he added. Before Friday’s vote, the leaders of several federal states called for a mediation committee to be convened to resolve disputes over the legislation with the Bundestag. Had the mediation committee been called, enactment of the cannabis legalization plan would have been delayed, likely by about six months. The states raised concerns about an amnesty provision in the law that requires judicial review of tens of thousands of past cannabis cases, fearing the process would overwhelm the courts. Some also criticized the maximum cannabis possession amount as too high and called for weed prohibition zones near schools and kindergartens. A motion to convene a mediation committee was offered but did not gain the number of votes needed for approval. The Bundesrat then voted to approve the plan to legalize cannabis in Germany, which will join Malta and Switzerland in the small group of European nations that have approved limited cannabis legalization plans. Niklas Kouparanis, the CEO and co-founder of Frankfurt-based medical cannabis company Bloomwell Group, says that the legalization of adult-use cannabis in Germany will also have a significant impact on the nation’s existing medical marijuana industry. While there are now an estimated 200,000 to 300,000 medical cannabis patients in Germany, Kouparanis says that number is likely to increase by as much as 10 times when reclassification goes into effect. “While it will probably take some time before the first licensed clubs – permitted under the new law – produce significant amounts of recreational cannabis, the CanG is the best news for the German medical cannabis industry since the ‘Cannabis as Medicine’ law passed in March 2017,” Kouparanis wrote in a statement to High Times. “Starting April 1st, medical cannabis will no longer be classified as a narcotic, and can now be prescribed by physicians as a completely ‘normal’ Rx, such as antibiotics or high-dose ibuprofen,” he added. “This reclassification significantly reduces costs and other administrative burdens to access–from cultivation to further processing and distribution, to storage to dispensing in the pharmacy.” The limited cannabis legalization bill adopted on Friday is considered the “first pillar” of Germany’s cannabis policy reforms, Politico reports. The “second pillar” is expected after the decriminalization plan is in effect, and will consist of five-year municipal pilot programs for state-regulated cannabis to be sold at licensed retailers.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 22, 2024Cannabis News​ In an “hours-long discussion,” the officials on a Costa Mesa panel considered various ways of amending the city’s laws governing legal cannabis shops. Those laws “have engendered complaints from neighbors and proprietors alike,” according to the Los Angeles Times, which said that Tuesday’s meeting “ended with a flurry of motions from City Council members that, if approved, could have sweeping local impacts on the industry.” The Times reported that the council “considered a slate of recommendations submitted by the Planning Commission in three earlier public hearings and cataloged in a draft revision of the original 2021 ordinance.” “But where commissioners went in with scalpel-like precision, carefully weighing potential edits against real-world consequences before posing eight specific suggestions, the City Council adopted a somewhat scattershot approach,” the Times said. The publication Voice of OC reported that the Costa Mesa City Council is “looking to limit the number of retail cannabis shops to 35 after city officials began questioning just how many should operate within the city,” while also “eying how close the shops should sit next to homes, youth centers and other cannabis storefronts.” “Part of my intent today is to not only figure out the new buffers and also the cap, but also to address issues raised by the industry,” Manuel Chavez, a member of the Costa Mesa City Council, said at Tuesday’s meeting, as quoted by Voice of OC. “I think we’re doing a piece by piece approach which is fine but I do want to make sure we’re reforming some of the comments we hear from the industry.” According to the Los Angeles Times, the council “generally supported establishing a separation requirement of 250 feet between any new cannabis dispensaries and residentially zoned properties and 1,000 feet between storefronts and youth centers where children recreate.” More from the Times on the measures considered by the council: “If passed, such a rule would make any already-approved shops inside that red zone ‘legal, nonconforming’ businesses. Although they may continue to operate in violation of the new rules, it’s not clear whether that status could hamper a property or business in the future. The panel also agreed to process up to 35 cannabis business permits, to allow would-be operators who’ve already passed a pre-application stage to continue the process. After that, through attrition, a new citywide cap of 10 dispensaries could be instituted upon final approval. But because a cannabis business permit runs with an individual operator and may not be transferred if a dispensary is sold, it is unclear whether another owner would be able to apply for a new permit or be shut out by the cap.” Voters in Costa Mesa, a city in Orange County of around 17,000 people, approved a ballot proposal in 2020 called Measure Q, also known as the Costa Mesa Retail Cannabis Tax and Regulation Measure, which “allows the City to adopt rules permitting retail cannabis uses within the City, including storefronts (dispensaries) and non-storefront uses (delivery only),” according to the city’s official website. Measure Q also established “buffers between some properties and storefronts to limit the distance between them,” which the Costa Mesa City Council began considering last fall. In October, the council “voted unanimously for staff to take another look at the buffers,” directing the “planning commission first consider any changes and make recommendations to the council within the next two months,” according to Voice of OC. “The current ordinance does not include buffer zones between storefronts and residential areas. Some residents have expressed concerns about the distance of cannabis storefronts from residential areas and schools and the overconcentration of the businesses, especially at Broadway and Newport Boulevard…Local officials are also concerned for the well-being of students as they pass many cannabis stores on their commute to school,” the outlet reported in the fall. “My kids are eight, and they ask me all the time, ‘What’s Nectar? What’s Mr. Nice Guys?’ It’s hard to explain to them what’s going on in the community,” Erik Weigand, a Newport Beach councilmember, said at the meeting in October. Alex Frank, an attorney representing home and business owners in Costa Mesa, said that if “four cannabis businesses are put at that corner, it will effectively turn that corner into Costa Mesa’s cannabis row, and it will do so less than 25 yards from homes and many families in our community,” according to Voice of OC. “My firm has been retained to encourage the city to reverse course on this before pot shops dominate that corner and damage my clients’ businesses and their homes. And if the city will not do that, my clients intend to proceed with litigation to seek damages for the resulting injuries,” Frank said at the meeting, as quoted by the outlet.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 22, 2024Cannabis News​ Nearly two dozen attorneys general from across the country wrote a letter to congressional leaders this week, urging them to enact legislation to federally regulate intoxicating hemp products. In the letter, the top law enforcement official from 21 states wrote that the legalization of hemp with the 2018 Farm Bill has resulted in “the proliferation of intoxicating hemp products across the nation and challenges to the ability for states and localities to respond to the resulting health and safety crisis.” The letter, dated March 20, was addressed to the committee chair and ranking minority members of the Senate Committee on Agriculture, Nutrition, & Forestry and the House Committee on Agriculture. The correspondence was led by Indiana Attorney General Todd Rokita and Arkansas Attorney General Tim Griffin, both Republicans, and co-signed by the attorneys general of 19 additional states, including Democrats and Republicans. In their letter, the state officials call on the leaders in Congress “to address the glaring vagueness created in the 2018 Farm Bill.” The legislation has led to the proliferation of products containing psychoactive novel and minor cannabinoids that can be derived from hemp, including delta 8 THC, THCA, HHC and others. “The reality is that this law has unleashed on our states a flood of products that are nothing less than a more potent form of cannabis, often in candy form that is made attractive to youth and children — with staggering levels of potency, no regulation, no oversight, and a limited capability for our offices to rein them in,” reads the letter. To address the issue, regulators and lawmakers in many states across the country are seeking ways to stem the tide of unregulated intoxicating hemp products, arguing that they pose a health risk, particularly to young people. Advocates for tighter controls on intoxicating hemp products in states with legal weed note they pose a competitive threat to licensed marijuana businesses, which face the high costs and taxes often associated with the regulated pot industry. Regulating intoxicating hemp products has been resisted by some businesses and industry advocates. Some companies marketing intoxicating hemp products have filed lawsuits to block new regulations, arguing that the 2018 Farm Bill specifically legalizes hemp-derived cannabinoids other than delta-9 THC. These legal actions have produced mixed results. In Arkansas, a federal judge issued a preliminary injunction in September that bars the implementation of a law to ban intoxicating hemp products.  “These inconsistent court rulings are part of the reason I have urged Congress to step in and create consistency across the nation to protect our children from these dangerous drugs,” Griffin said in an email to Politico. California Attorney General Bonta, one of the attorneys general who signed the letter to congressional leaders, said that intoxicating hemp products constitute a health risk for young people. “Our children deserve better,” Bonta said in a statement. “The 2018 Farm Bill, however well-intentioned, created a loophole that has led to the proliferation of products, often containing synthesized cannabinoids, that are more intoxicating than legal and regulated cannabis products. These products often take the form of candy and are designed to appeal to young people and children. California prohibits intoxicating cannabinoids in hemp products, whether naturally derived or synthetic. The California Department of Justice will continue to protect the legitimate businesses who are operating responsibly in this space.” The letter calls on the leaders of the congressional agricultural committees to take action to regulate intoxicating hemp products by redefining hemp in the next farm bill, which is currently being debated in Congress. The legislation, which guides policy on a wide range of issues related to agriculture, is updated every five years, although progress on last year’s anticipated renewal of the legislation was delayed to this year. “The reason Congress needs to act is that its definition of industrial hemp is the original source of the problem and the confusion that has sprung up around what is allowed and what’s not allowed under state and federal law,” Indiana Solicitor General James Barta said in an interview with Politico.  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 22, 2024Cannabis News​ The median reported potency of regulated weed in California has been steadily dropping over the past six months, according to a report from Bay Area news source SFGate. The drop in potency, which includes a decline of 7% in just the past three months, coincides with the recent implementation of new state regulations governing how the potency of cannabis flower is determined by testing labs in the state. According to information from cannabis market data analytics firm Headset shared with SFGate, the median potency of cannabis flower tested in California was 30.7% in December. The data, which is based on more than 90,000 potency test results from the state, also shows that the median potency for cannabis flower had declined to about 28.5% by March 1, a decrease of about 7% in just three months. Reported cannabis potency has long been a point of contention in California’s cannabis industry. Cannabis flower that shows higher levels of THC in lab testing results is more desirable to many consumers and thus more valuable. As a result, reported median cannabis potency levels have steadily risen in California, with some retail offerings listing THC potency exceeding 30% or even higher in some cases. The drop in the median potency of California came as new regulations for a standardized cannabinoids test method and standardized operating procedures for the testing of dried cannabis flower and non-infused pre-rolls were implemented in the state in January. The rules were adopted by the California Department of Cannabis Control (DCC) in 2022 after legislation mandating the regulations was passed by state lawmakers the year before. DCC officials noted that the legislature passed the law for the new testing regulations over concerns of cannabis potency inflation and reports of “lab shopping” by businesses in the industry attempting to show test results higher than what is actually contained in the cannabis flower or product. “One of the challenges we face in regulating an industry that is not federally recognized, is the lack of standardized, and validated methods for testing,” DCC Director Nicole Elliott said at the time in a statement from the regulatory agency. “Individual, licensed laboratories use different methods which may produce inconsistent results and inaccurate data on cannabis cannabinoid content. DCC is working to change that so there is greater integrity in the market, accurate information for consumers, and confidence among stakeholders.” When the new rules for testing cannabis flower potency went into effect at the beginning of the year, the DCC reported that only 18 labs had taken the steps to be compliant with the new regulations, leading to a shutdown of flower testing at the remaining labs. Since then, the number has increased by nearly half, with 26 labs now demonstrating compliance, according to the latest data from the department. Zach Eisenberg, a vice president at San Francisco licensed testing lab Anresco Laboratories, said that the drop in the median reported potency of cannabis flower in California appears to be a sign that the new rules are beginning to have an effect. “We certainly heard from customers and potential customers that they’re seeing potency values dropping at other laboratories,” Eisenberg told SFGate. “Some labs were even proactively saying, ‘Be prepared for our results to be lower after this change.’” Eisenberg added that the drop in median potency is likely not caused by any change in the products. Instead, he believes that test results are now a more accurate indication of the reality of cannabis potency in California. “I highly doubt anything has changed in terms of the actual composition of the cannabis products,” Eisenberg said. Andrea Golan, an attorney at the Los Angeles office of cannabis law practice Vicente LLP and a member of the firm’s Regulatory Compliance and Hemp and Cannabinoids Departments, agrees, saying that it is “unlikely California cannabis is ‘suddenly getting weaker’ as the SFGate headline implies.” “For years, the efficacy of cannabis lab test results has been widely discussed across the California cannabis industry due to inflated potency test results and inconsistencies in results due to labs using different methodologies for testing cannabis,” Golan writes in an email to High Times about the regulations that went into effect on January 1.  “The change in law ends the practice of shopping for labs with less strict testing methods in order to inflate THC content,” Golan added. “Therefore, rather than cannabis getting weaker, recent changes may now provide a more accurate reflection of true potency.”  Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 22, 2024Cannabis News​ Bliss + Lex is a Black woman-owned cannabis dispensary in Manhattan and its team says it’s the first dispensary of its kind to do so in a March 20 announcement. Licensed adult-use cannabis businesses are beginning to appear in New York City as they compete with unlicensed businesses.  “This is a once-in-a-lifetime opportunity to pull up our own seat at the table in the cannabis industry. As entrepreneurs, we have a chance to create a legacy, change the trajectory of our family’s future and give back to the community in new ways,” said Nicole Lucien, co-Founder and CEO of Bliss + Lex, who is opening the dispensary with her husband, Christopher Lucien. “As a former New York City public school educator, my life has been dedicated to family and community, our careers in service, and now we are proud to share our passion for the plant.” It is Manhattan’s first Black woman-owned dispensary and a Conditional Adult-Use Retail Dispensary (CAURD) licensee. Bliss + Lex is the second retailer to open in collaboration with the Housing Works CAURD Community Initiative, which provides critical support for New York social-equity cannabis entrepreneurs. The New York Cannabis Control Board (CCB) met on Feb. 16 and voted on a few new cannabis draft rules, including cultivation and research, and also announced the first round of adult-use licenses. The CCB approved a total of 109 licenses for the state, with 38 licenses that are retail-specific, and 26 that are microbusiness licenses.  Currently, the only cannabis business license holders in the state were approved under the CAURD program, which were granted specifically to social equity applicants. While those business owners hold conditional licenses, the CCB’s most recent round of licenses are the first non-conditional licenses to be granted, meaning that they did not qualify as social equity applicants. They benefited from a New York state program that prioritizes giving people with criminal histories the first retail licenses to sell cannabis in the state, as Nicole’s husband has a prior conviction. “Never in my wildest dreams did I think a cannabis conviction, that until now has created a barrier to jobs, housing, and acceptance, would be the key to this door of opportunity for myself and my family,” said Christopher Lucien, co-founder and COO. “I’ve always been driven to support the underdog in my work in nonprofits serving the homeless, and becoming a business owner is an invigorating way to help my community.” “Housing Works is honored to work alongside and support the opening of Manhattan’s first Black woman-owned dispensary, Bliss + Lex, through our CAURD Community initiative,” said Sasha Nutgent, Director of Retail at Housing Works Cannabis Co. “This opening marks a big step forward in our efforts to build an equitable market here in New York. Nicole and Christopher represent exactly what NY’s adult-use market needs more of–mission-focused and dedicated to educating and building a fostering community–and we look forward to seeing and aiding the team’s success however they need.” Nicole is the first Black woman in Manhattan to be awarded a coveted license to open a cannabis dispensary. Her husband, also on the license, has a prior drug conviction. They benefited from a New York state program that prioritizes giving those with criminal histories the first retail licenses to sell marijuana. Christopher Lucien, owner, said, “I have tried to start several businesses like my wife was saying home improvement construction, and because of my criminal background I was denied, even after 20 some odd years of a clean record there was never a chance where I had a second chance this was always been held against me.” CCB chair Tremaine Wright spoke at a recent meeting, expressing his relief that the time has come to move forward with New York’s cannabis industry, beginning with social equity applicants. “This moment has been a long time in the making,” said Wright. “We assure you it only represents the beginning. The office has been diligently working to prepare as many applications as possible for consideration, and the board will continue to approve additional licenses at future board meetings.” He added that the CCB’s goal is to “tackle a number of the matters that we hope will help propel our industry forward.” The 2,603 square-foot retail store aims to provide highly-individualized consumer experiences including, on-the-go ordering to inclusive, step-by-step walk-through education. Bliss + Lex will carry a range of cannabis products from brands such as Off Hours, 1906, TYSON 2.0, and more. You can visit the retail store located at 128 East 86th St. with close subway access, and it is open seven days a week.    Read More The Latest Marijuana News Today | HighTimes Magazine  [...] Read more...
March 22, 2024Cannabis News​ The Daily Hit is a recap of the top financial news stories for March 21, 2024. On the Site Subversive Capital ETF shutting down Subversive Capital ETF (CBOE: LGLZ) joins the list of cannabis ETFs that have closed. According to an SEC filing on March 20, Tidal Investments LLC, the fund’s investment adviser, and Subversive Capital Advisor LLC, the fund’s investment subadviser, recommended that the board of trustees of Tidal ETF Trust close and liquidate the fund. Read more here. Boost expected for Illinois cannabis sales this year Illinois marijuana sales are expected to grow at a faster rate this year after slow growth in 2023. Cannabis research firm Whitney Economics is forecasting combined recreational and medical cannabis sales of $2.2 billion this year, up from $1.96 billion in 2023. Recreational products account for 83% of the Illinois market. Read more here. Hempacco expanding footprint with partial acquisition of Covalent CBD San Diego-based nutraceutical company Hempacco Co. Inc. (NASDAQ: HPCO) plans to expand its production and distribution capacity with the acquisition of some of the assets owned by competitor Covalent CBD. Read more here. Earnings: • Charlotte’s Web continues to suffer revenue declines • SNDL delivers rising revenue for 2023 as it lowers losses In Other News Maryland Legislation aimed at preventing counties from enacting overly burdensome zoning rules cleared a key hurdle in the Maryland General Assembly on Thursday, moving it closer to becoming law just as the state hands out the first round of new cannabis licenses. Read more here. HYTN Innovations HYTN Innovations Inc. (CSE: HYTN) has been awarded Good Manufacturing Practice certification by Australia’s Therapeutic Goods Administration for its Kelowna production facility. Read more here.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ The state reported slower sales in 2023. This story was republished with permission from Crain’s Chicago and written by John Pletz.  Illinois marijuana sales are expected to grow at a faster rate this year after slow growth in 2023. Cannabis research firm Whitney Economics is forecasting combined recreational and medical cannabis sales of $2.2 billion this year, up from $1.96 billion in 2023. Recreational products account for 83% of the Illinois market. Overall sales in the state should grow 11.5% this year, compared with 2.8% in 2023, the firm says. Nationally, cannabis sales are expected to rise 9.1% to $31.4 billion. If the forecast pans out, it will mean more tax dollars for Illinois, which takes in about a half-billion dollars from marijuana sales. The number of retail outlets in Illinois increased by more than half last year to 177 locations, but many opened later in the year. Wholesale and retail prices also dropped in the state, as they did elsewhere. More stores are likely to open this year as the winners of new retail licenses race to meet a July deadline to find locations for dispensaries and build them out. “There was kind of anemic growth in 2023,” says Beau Whitney, founder of the research firm based in Portland, Oregon. “But when you have greater access, you get greater participation (purchases).”  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​U.S. Treasury Secretary Janet Yellen said on Thursday she would welcome legislation that would rectify the conflict between federal and state laws on the sale and use of marijuana that… The post Yellen would welcome US legislation to aid cannabis banking access appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​Voters overwhelmingly approved a ballot measure in 2022 to allow recreational cannabis sales, but a March poll shows mixed feelings Maryland voters resoundingly approved legalizing recreational marijuana but are divided over the… The post After voting to legalize weed, Marylanders are mixed on impact, poll finds appeared first on Cannabis Business Executive – Cannabis and Marijuana industry news. Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Charlotte’s Web (OTC: CWBHF) has been caught in a protracted sales downturn, but management is optimistic that it can still turn the tides for the once stand out CBD maker. The MLB-partnered company reported a 14.8% slide in net revenue in 2023, down to $63.2 million from 2022. Lower sales in both e-commerce and business-to-business (B2B) sectors drove the decline. While the company has been taking “multiple actions to maintain gross profit margins, reduce cash burn, and safeguard our financial position,” according to CFO Jessica Saxton, she emphasized in a call with investors that’s not the only strategy. “I think it’s important for us to note that we are not in purely cost-cutting mode,” Saxton said. “There are ways that we can deploy our cash better and increase our return on investment.” True North Part of the turnaround strategy, according to CEO Bill Morachnick, is the “True North” strategy being undertaken, which he said targets operational efficiency, data-driven decision-making, and market growth. It’s sort of a branded extension of the savings strategies the company has already been pursuing. “We are in the process of doing deep dives on our ROI associated with pretty much all of our discretionary spend,” he said. “We have made a big focus right now in our marketing, starting with paid media because it’s a big chunk of the dollars that we spend.” Apparently it’s paid dividends on the balance sheet. The company’s net loss improved in the fourth quarter, falling from $35.2 million in the fourth quarter of 2022 to $8.5 million for the period ended Dec. 31, 2023. E-commerce Direct-to-consumer sales continue to play a significant role for Charlotte’s Web, but the dynamics of playing in that space are changing. Morachnick noted the importance of updating the company’s IT infrastructure, saying it’s needed before it can enhance marketing efforts. He said the firm’s made progress by setting up a new customer relationship management system. “The next big unlock is the Shopify platform,” he said. “So, a new e-commerce platform that we will deploy in (the second quarter), and with that comes a whole set of tools that allows us to do things that we are not able to do today.” Management hopes the e-commerce platform upgrades will improve the customer experience and drive revenue growth. Saxon said the company’s been test piloting with businesses to work out kinks. “What I can say is the initial reaction is really positive. We have seen an uptick in terms of volume … it’s probably too soon to give any more than that. We are closely monitoring it,” she said. Other strategic moves The company also slashed prices on its tinctures by about 25% to try and boost revenue. “It was completed to position us competitively, drive value and really maintain quality as well,” Saxon said. The actual amount of the price drop varied, from $2 to $75, depending on the product’s strength and size, she noted. In addition, the company extended its partnership with Major League Baseball, an agreement that enhances brand visibility and distributes sponsorship costs over a longer period. But that partnership will likely see other changes as well. “By extending that out by a couple of years our existing agreement … it flattens out the cost structure associated with it, but it also gives us time to work together to come up with the type of activation that’s in both parties’ interest,” Morachnick said.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Plaintiffs in a federal lawsuit over the Second Amendment rights of medical marijuana cardholders—including a local prosecutor in Pennsylvania who is himself a cannabis patient—filed a fresh brief in their case on Tuesday, arguing that the “deprivation of Second Amendment rights for merely using a medicinal substance has no basis in this nation’s history or tradition and is unconstitutional, full stop.” The underlying suit was filed in January by Pennsylvania’s Warren County District Attorney Robert Greene, along with advocacy group the Second Amendment Foundation and a U.S. military veteran who was recommended medical marijuana but has not registered as a patient because it would deny him the right to possess a firearm. The latest filing, in support of a motion for a preliminary injunction that would prevent the government from enforcing the federal gun ban while the overall case is considered, comes as U.S. Supreme Court weighs whether to take up a separate case over the constitutionality of the law. “Simply put, throughout this nation’s history, there was no tradition of limiting an individual’s Second Amendment rights by virtue of their use of marijuana—let alone their use of alcohol, an intoxicant widely known and used by the American populace,” says the new brief, filed in U.S. District Court for the Western District of Pennsylvania. Plaintiffs are asking the court to prevent the government from enforcing legal restrictions around cannabis and guns, including those “which prohibit firearms purchases and possession by persons who use marijuana or other controlled substances,” according to the Bellevue, Washington-based Second Amendment Foundation (SAF). “Individuals are placed in the untenable situation of having to choose whether to use a medicine recommended to them by a doctor to treat their symptoms at the expense of their Second Amendment rights or exercise their rights at the detriment of their health,” Adam Kraut, the group’s executive director, said in a press release. “Having to make such a choice is simply wrong and we look forward to vindicating the rights of those affected.” “It is long past the time for this restriction to be challenged,” added the SAF’s founder and executive vice president, Alan M. Gottlieb. “Our lawsuit raises very legitimate issues for a growing number of law-abiding citizens whose Second Amendment rights are unquestionably and arbitrarily infringed upon. The restriction lacks any direct or analogous historical support, as required by the Supreme Court’s 2022 Bruen ruling.” In addition to the 2022 case (NY State Rifle and Pistol Assn. v. Bruen), which invalidated a New York state law requiring applicants for concealed carry permits to demonstrate proper cause, lawyers for the plaintiffs also point to Supreme Court rulings such as D.C. v. Heller, which held in 2008 that the Second Amendment entails an individual right to possess firearms, and 2010’s McDonald v. Chicago. In the mid-1800s, some states—including Kansas, Missouri and Wisconsin—did prohibit people from carrying firearms while intoxicated, the brief says. But plaintiffs in the case “are not challenging potential prohibitions on carrying firearms while intoxicated, but the total bar on their ability to even possess firearms and ammunition for merely using a ‘controlled substance’ at some point in time that is not necessarily contemporaneous with their physical possession of a firearm.” The new filing quotes a federal appeals court ruling that opined, “Throughout American history, laws have regulated the combination of guns and intoxicating substances. But at no point in the 18th or 19th century did the government disarm individuals who uses drugs or alcohol at one time from possessing guns at another.” The lawsuit names U.S. Attorney General Merrick Garland, as well as the heads of the FBI and Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), as defendants. The suit represents what the lead attorney for the plaintiffs believes to be the first civil, rather than criminal, challenge to the federal statute barring gun ownership by cannabis users. Participation by Greene, who has been a district attorney since 2013, is especially notable. The complaint states that the local prosecutor “intends to lawfully purchase, possess, and utilize firearms and ammunition so that he may exercise his constitutional right to keep and bear arms for self-defense and all other lawful purposes.” But he’s barred from doing so under federal statute because of his status as a state-certified medical cannabis patient. The prosecutor announced late last year that he will not be seeking re-election and will be turning his focus to advocacy on medical cannabis patient rights issues. Unlike the various previous court cases challenging the constitutionality of the gun ban for plaintiffs who have been criminally prosecuted, with a civil suit like this, “you’re looking at a challenge on behalf of people that are just asserting that this prohibition is unconstitutional, either on its face or as applied,” Adam Kraut, lead attorney for the plaintiff and executive director of SAF, told Marijuana Moment when the suit was filed. “What I’m hoping is not only to win in our lawsuit, but that it sparks the federal Congress to do something and solve this problem because you have millions of Americans who are disenfranchised from their Second Amendment rights, being forced to choose either between treating their symptoms with medical marijuana or exercising their constitutionally guaranteed right,” he said. “That’s not acceptable.” A Republican state senator in Pennsylvania, meanwhile, recently previewed a bill that he said would remove the state’s own barriers to letting medical marijuana patients carry firearms. Sen. Dan Laughlin circulated a co-sponsorship memo about the forthcoming bill last month, noting that while the state’s 2016 medical marijuana law allows patients to “LEGALLY treat specific medical conditions with marijuana,” other state mechanisms—including the issuance of licenses to carry firearms—still treat cannabis as unlawful. “A valid medical marijuana cardholder should NOT be considered an unlawful user and denied their rights,” Laughlin’s memo said. More recently, Second Amendment rights advocates criticized a pair of developments that they say further underscore the need for reform. Last month during a routine audit of a gun dealer, a federal Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) investigator reportedly ordered the store to stop the sale of a pistol because the investigator claimed the would-be buyer smelled of marijuana. Meanwhile in a federal appeals court case this month, the Department of Justice argued that marijuana users “are more likely than ordinary citizens to misuse firearms,” likening them to “the mentally ill” as well as “infants, idiots, lunatics, and felons.” “Because they are not ‘responsible citizens,’” DOJ lawyers wrote, “unlawful drug users and addicts do not have a Second Amendment right to possess firearms.” The case is the Biden administration’s appeal of a federal court decision out of North Carolina that found the government’s prohibition of firearm possession by a person who “is an unlawful user of or addicted to any controlled substance” is unconstitutional on its face. The Firearms Policy Coalition noted that the filing came just hours before President Joe Biden said during his State of the Union address that no one should be in jail for using or possessing marijuana. The issue has been raised in multiple state legislatures and federal courts in recent years, as marijuana and gun rights advocates challenge the constitutionality of the federal ban that currently prevents cannabis consumers from owning firearms. Just this month, Maryland lawmakers took testimony about a measure that would protect the gun rights of medical marijuana patients under state law, while organizers in Colorado are preparing to gather signatures to qualify a ballot initiative that would remove state barriers prohibiting gun owners from obtaining concealed handgun permits for lawful use of medical marijuana. The federal Justice Department has insisted on the necessity of the banning cannabis consumers for possessing guns in numerous federal courts, arguing at points that people who use marijuana pose a unique danger. Supreme Court justices are expected to decide soon whether they will hear a federal government appeal of a circuit court ruling that found the firearm restriction violates the Second Amendment. That ruling came from the U.S. Court of Appeals for the Fifth Circuit, which examined the federal statute known as Section 922(g)(3) that prevents someone who is an “unlawful user” of an illegal drug from buying or possessing firearms. The circuit court found the policy unconstitutional as applied to a man who faced a conviction after admitting to having used cannabis while in possession of a gun. While people who use cannabis are barred from owning firearms under the statute, a little-notice FBI memo from 2019 that recently surfaced shows that the federal government generally does not consider it a violation of the law for medical cannabis caregivers and growers to have guns. Republican congressional lawmakers have filed two bills in the first half of this current two-year session that focus on gun and marijuana policy. Rep. Brian Mast (R-FL), co-chair of the Congressional Cannabis Caucus, filed legislation last year to protect the Second Amendment rights of people who use marijuana in legal states, allowing them to purchase and possess firearms that they’re currently prohibited from having under federal law. Senate Majority Leader Chuck Schumer (D-NY) has committed to attaching that legislation to a bipartisan marijuana banking bill that advanced out of committee in September. Meanwhile, Mast is also cosponsoring a separate bill from Rep. Alex Mooney (R-WV) this session that would more narrowly allow medical cannabis patients to purchase and possess firearms. Congressman Demands Answers From Biden Admin On Marijuana Rescheduling Legal Opinion Request For DOJ Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ A new federally funded study examining the possible risks of organ donation by marijuana users found no indication that recent cannabis use increases the likelihood of significant side effects in the year immediately after a transplant—even as many healthcare providers continue to restrict transplants to cannabis consumers. Findings of the research, which looked at rates of infections, transplant failures and deaths among recipients, “suggest that organs from donors with a history of recent marijuana use do not pose significant infectious risks in the early posttransplant period.” “Despite concern that donor exposure to marijuana increases the risk of fungal infection in recipients, our study found that a donor history of marijuana use did not increase (1) the likelihood of donor culture positivity (including respiratory cultures), or (2) the risk of early recipient bacterial or fungal infection, graft failure, or death posttransplant,” authors wrote. “Even when evaluating only lung recipients, there remained no association between donor marijuana use and the risk of posttransplant infection.” As more states have legalized marijuana, reported rates of use among adults have also risen, notes the new study, published late last month in the American Journal of Transplantation. “It is likely that a growing proportion of deceased organ donors have a history of marijuana use, as well,” it says, “though this metric has not been specifically reported.” “Our data suggest that organs from donors with a history of recent marijuana use do not pose significant infectious risks in the early posttransplant period.” Infections are a main concern, it continues, pointing to past findings that marijuana leaves themselves can be contaminated with potentially dangerous bacteria and fungi. Inhaled marijuana has been associated with certain infections among transplant recipients, while bacterial outbreaks have also been linked to marijuana use among the non-transplant population. What has been less clear is whether organs from marijuana users could pose risks to transplant recipients. “Whether a deceased organ donor with a history of marijuana use posses risk to the SOT recipient has not been clearly evaluated,” the paper says, and “no studies have determined the impact of SOT donor marijuana use on donor culture results and risk for donor-derived infection (DDI) among recipients.” “The goal of our study,” authors wrote, “is to better characterize the infection risks that marijuana use among deceased organ donors may pose to SOT recipients.” Conducted by researchers at the University of Pennsylvania, University of California San Francisco, Temple University and the Gift of Life Donor Program, the study looked at data from three transplant centers in Philadelphia. It included transplants between January 1, 2015 and June 30, 2016 involving organs procured by the Gift of Life program. The research was funded by the National Institutes of Health, Centers for Disease Control and Prevention and Transplant Foundation’s Innovative Research Grant Program. Transplants were defined as coming from a recent marijuana user either if a toxicology screening showed the presence of THC or if next-of-kin or a donor informant reported the donor had a history of cannabis use within the past 12 months. Analyzing data from hundreds of organ transplants, researchers assessed three primary outcomes: whether cultures from donors themselves tested positive for bacterial or fungal infection, whether organ recipients developed new bacterial or invasive fungal infections and whether the transplant resulted in either graft failure or the recipient’s death. For each outcome, they found no significant increase in risk involving donors with a history of recent cannabis use. “Among donors with a history of recent marijuana use, 79 (89%) had at least 1 positive culture, compared to 264 (87%) among those with no history of marijuana use,” it says, for example. “On donor respiratory cultures, 76 (85%) donors with a history of recent marijuana use and 250 (82%) donors with no history of recent marijuana use had bacterial or fungal growth on respiratory cultures. On both unadjusted analyses and multivariable analyses, there was no association between recent donor marijuana use and donor culture positivity.” Notably, the study did not account for the amount or duration of marijuana use by donors. It also had a smaller cohort of lung transplant recipients than past studies, which authors note “have shown mixed results.” The report acknowledges that relying on interviews with next-of-kin or donor informants was “an imperfect measure” of a donor’s actual cannabis use, though they added that “when we limited the exposed group to those with a positive toxicology screen for THC, there remained no association with donor culture results or recipient outcomes.” “In conclusion,” they wrote, “our study demonstrates that donors with a history of recent marijuana use are not more likely to have positive donor cultures, and their recipients are not more likely to develop a bacterial or fungal infection, graft failure, or death in the early posttransplant period (in the context of current management). These results suggest that organs from donors with a history of recent marijuana use do not pose significant novel infectious risks to recipients in the early posttransplant period.” Current guidance around cannabis use and organ donation is inconsistent, as noted in a recent review by a student fellow at the Petrie-Flom Center at Harvard Law School. The U.S. Organ Procurement and Network defers decisions on transplant eligibility to each transplant center, it says, though in practice many marijuana users are deemed ineligible. “Many transplant centers prevent cannabis users from receiving solid organ transplantation due to concerns regarding interactions between cannabis and immunosuppressant drugs used for transplants, treatment non-adherence, fungal infections, and neuropsychiatric effects,” the review says. But the latest study is among a growing body of work pushing back against that policy. “Although larger-scale studies are needed to validate these findings, these studies suggest that medical cannabis use should not be an absolute contraindication to solid organ transplantation,” the Harvard post says. “Research has also suggested that THC, a component of cannabis, might actually help to prevent transplant rejection.” As for actually identifying recent cannabis use, at least two recent developments are expected to allow researchers to test subjects with more precision. Researchers behind a federally funded study recently said they’ve developed new procedures to enhance the selectivity of a popular forensic testing method, allowing better detection of delta-9 THC and its metabolites in blood. The federal government also funded separate recently published research identifying a promising new method to test for recent marijuana use. That study, funded in part by the National Institute on Drug Abuse (NIDA), determined that more accurate method of testing than currently used is by analyzing the molar metabolite ratio of THC to THC-COOH in the blood. The research is part of a growing call for more precise and reliable ways to measure recent marijuana use and impairment—often around driving—as more jurisdictions legalize the drug. Federally Funded Study Enhances Marijuana Screening Procedure To Detect THC In Blood Photo courtesy of Mike Latimer. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Congressional leaders have unveiled a second package of spending legislation to keep the government funded, with provisions included that would continue to block Washington, D.C. from legalizing marijuana sales, fund psychedelics-related clinical trials and more. House and Senate appropriations leaders released the bill on Wednesday after reaching an agreement on the remaining Fiscal Year 2024 spending that wasn’t included in separate legislation enacted earlier this month. The plan is to pass the package ahead of a Friday deadline when the current continuing resolution is set to expire. Despite repeated calls from advocates and lawmakers to remove a controversial rider that’s barred the District of Columbia from using its local tax dollars to implement a system of legal cannabis sales since 2014, that component was left intact in the bipartisan and bicameral deal. It was also recently included in President Joe Biden’s 2025 budget request for the fourth year in a row. The language, championed by prohibitionist Rep. Andy Harris (R-MD), is again being proposed in the Financial Services and General Government (FSGG) appropriations legislation even though D.C. voters approved legalization at the ballot a decade ago. Lawmakers in the District have enacted certain workarounds, including allowing people to self-certify as medical marijuana patients, but the congressional blockade has been a consistent source of frustration. “SEC. 809. (a) None of the Federal funds contained in this Act may be used to enact or carry out any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative. (b) No funds available for obligation or expenditure by the District of Columbia government under any authority may be used to enact any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act (21 U.S.C. 801 et seq.) or any tetrahydrocannabinols derivative for recreational purposes.” Another section of a bill covering the Departments of Labor, Health and Human Services and Education broadly prohibits the use of funds “for any activity that promotes the legalization of any drug or other substance” in Schedule I, including cannabis and various psychedelics. “SEC. 509. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications.” Rep. Alexandria Ocasio-Cortez (D-NY) has previously sought to strip that component with an amendment, aiming to promote psychedelics research, but it was shot down in floor votes. There are some new drug policy-related provisions in this year’s package, as well. That includes two funding allocations for psychedelics clinical trials under the measure covering the Department of Defense (DOD). The report attached to the legislation specifies that $10 million to be appropriated to DOD for department-wide “psychedelic medical clinical trials.” This seems to be the funding mechanism for a component of the 2024 National Defense Authorization Act (NDAA) that Biden signed in December that instructs DOD to carry out trials involving psilocybin, MDMA, ibogaine and 5-MeO-DMT for active duty service members with post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI). Under a section for “base operations and communications,” another $200,000 that’s designated as “undistributed” is earmarked for “psychedelic treatment for TBI report,” specifying funds focused on the role of psychedelics in treating traumatic brain injuries. Another new cannabis component was including the report covering funding for the Department of Homeland Security (DHS). The section, introduced by Congressional Cannabis Caucus co-chair Rep. Dave Joyce (R-OH), calls on the department’s Homeland Security Investigations (HSI) division to report to Congress on issues related to illicit grow operations in legal marijuana states that are run by “transnational criminal organizations, including but not limited to those based in the People’s Republic of China.” “Illegal Grow Operations.-Within 60 days of the date of enactment of this Act, HSI shall provide a briefing to the Committees on ongoing investigative efforts regarding illicit grow operations of marijuana in States with legal production and sales frameworks that are run by transnational criminal organizations, including but not limited to those based in the People’s Republic of China. The briefing shall include HSI’s coordination with the DOJ and details of investigations of ancillary crimes, such as human trafficking and forced labor, that are potentially tied to illegal grow operations.” In a statement on Thursday, Joyce said he was “proud to have successfully included this critical language in this year’s Homeland Security Appropriations bill.” “This directive will help identify and combat the illicit actors who are abusing state legal cannabis markets and harming public safety for nefarious purposes,” he said. This is the second and final round of appropriations legislation for the current fiscal year. A separate package that Biden signed earlier this month also includes provisions preserving protections for state medical cannabis programs as well as report language that calls for the federal government to study state legalization laws and expand scientists’ access to commercially available cannabis for research. The House has also previously attempted to use the FSGG bill to secure limited protections for banks that work with state-legal marijuana businesses, but leadership did not seek to enact that reform through appropriations this round. However, once this latest funding legislation is passed, Senate Majority Leader Chuck Schumer (D-NY) has signaled he will be prioritizing a standalone bipartisan cannabis banking bill that cleared committee last year and is pending floor action. Congressman Demands Answers From Biden Admin On Marijuana Rescheduling Legal Opinion Request For DOJ Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Washington Gov. Jay Inslee (D) has signed legislation into law to exempt registered medical marijuana patients from the state’s 37 percent cannabis excise tax, which is currently one of the highest in the country. The exemption will only apply, however, to products that have been certified to higher testing standards than typical state-legal products. HB 1453, which lawmakers sent to the governor earlier this month, would allow registered patients and caregivers to avoid the tax when purchasing products that are compliant with Department of Health (DOH) testing standards. Medical marijuana cardholders already are eligible for exemptions from sales and use taxes on cannabis, but they are not currently exempt from the state excise tax. The tax exemption would apply only to products that are DOH-compliant, meaning the products have been tested more rigorously for safety. While manufacturers in the state are required to submit all medical and adult-use products to labs for testing, producers can voluntarily have additional testing done—to screen for heavy metals, for example—that isn’t otherwise required. Marijuana that passes the additional testing can be labeled with a DOH-developed logo. “This bill will lead to a wider variety of DOH-compliant cannabis products on the market available to qualifying patients and designated providers, will improve program participation, and will help ease suffering,” a legislative staff summary of public testimony in support of the legislation says. Provisions of the new law, sponsored by Rep. Sharon Wylie (D) and two other Democrats, are set to expire on June 30, 2029. A report by the Joint Legislative Audit and Review Committee on the tax impacts of the change would be due in 2028. One of the bill’s co-sponsors, Rep. Shelley Kloba (D) also sponsored a cannabis homegrow bill this session—the latest in a series of such measures introduced over the past several years—but the proposal ultimately died in committee. If passed, HB 2194 would have allowed adults 21 and older to grow up to four plants per person, with no more than 10 allowed per household. Home cultivation of marijuana without a medical marijuana card remains a felony in the state. Kloba told Marijuana Moment last month that she’s committed to continued advocacy for the policy change and plans to introduce yet another homegrow measure next year. “I am committed to this issue, and plan to run a bill again next session,” she said. “Every session has its own character and constraints, which so far have meant that the bill has not advanced to the Senate. But I am not giving up.” Washington voters legalized marijuana for adult use through a ballot measure in 2012. —Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— Separately, lawmakers this session also sent the governor a measure from Rep. Lauren Davis (D) that originally would have limited THC potency in retail marijuana products. That provision was removed, however, and as passed by the legislature, it instead would require cannabis retailers to warn of the possible health risks of high-THC products. It would become null and void if not funded by lawmakers in separate legislation. Another cannabis bill introduced in Washington this session would have rolled back recently enacted protections for job applicants who use marijuana, undoing the anti-discrimination protections for people seeking to work in the drug treatment industry. It did not receive committee consideration in time to advance, however. Lawmakers also introduced legislation to create a legal system to allow veterans and first responders to access psychedelic-assisted therapy. The measure would build on a limited pilot program signed into law last year, but it also did not advanced after being filed. Late last year, the state Department of Commerce issued recommendations regarding how $200 million should be spent to address racial, economic and social disparities created by the war on drugs. The state has also approved $10 million in refunds for vacated drug convictions. Congressional Leaders Again Seek To Block D.C. Marijuana Sales, While Funding Psychedelic Studies, In New Spending Bill Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ A congressional committee met on Thursday to take up a series of bills, including two GOP-led veterans-focused measures concerning medical marijuana and psychedelics. The U.S. Department of Veterans Affairs (VA) is supporting the cannabis legislation if it undergoes “extensive amendments,” and it opposes the psychedelics measure, describing it as “unnecessary.” The House Veterans’ Affairs Health Subcommittee—which made history last November by holding a first-ever congressional hearing focused on psychedelics-assisted therapy for veterans—also heard from a number of veterans service organizations (VSOs) that are advocating for the reforms. One of the bills that was on the agenda, sponsored by the subcommittee chair Rep. Mariannette Miller-Meeks (R-IA), is titled the Veterans Cannabis Analysis, Research, and Effectiveness (CARE) Act. It would require the U.S. Department of Veterans Affairs (VA) to “conduct and support research relating to the efficacy and safety of forms of cannabis” for chronic pain, post-traumatic stress disorder (PTSD) and “other conditions the Secretary determines appropriate.” “For years we’ve heard anecdotal firsthand accounts from veterans who have experienced decreased PTSD symptoms and pain through medical cannabis,” Miller-Meeks said at the hearing. “It’s important not to let stigmas interfere with the health care treatment veterans are receiving if it therapy is proven to be safe, effective and improves veterans quality of life.” “I’m proud to introduce this bill so that we can gain insight into new therapies that could help those who need it most,” the congresswoman said. The legislation specifies that the VA studies must involve plants and extracts, at least three varieties of cannabis with different concentrations of THC and CBD and “varying methods of cannabis delivery, including topical application, combustable and non-combustable inhalation, and ingestion.” VA would first have to submit a research plan to House and Senate Veterans’ Affairs Committees and make any requests to support the studies. Over the course of five years after the bill is enacted, VA would need to send annual reports on its progress to the panels. VA’s Ajit Pai told the committee that the department supports the bill ” if amended, and subject to the availability of appropriations,” laying out a number of concerns that they wants lawmakers to address. That includes concerns that, “as drafted, the bill is too prescriptive in its design,” specifically as it relates to the required study of whole-plant cannabis products with THC concentrations that have “undetermined therapeutic benefit or harmful effects.” “VA generally supports efforts to study the effects of cannabis products on the health outcomes of users of such products to determine whether the use of such products can benefit Veterans who have been diagnosed with PTSD and who are experiencing chronic pain or other conditions as deemed appropriate by VA. We recommend extensive amendments to this bill, though, to ensure that its requirements would yield scientifically and clinically valid results.” The department offered a series of recommendations to revise the measure, including inter-agency coordination to develop a plan for the studies, a required feasibility analysis for proposed patient registries, authorization to conduct additional clinical trials and more. “VA would be happy to provide specific amendments to the bill text and to discuss our recommendations further with the Committee,” Pai said. Miller-Meeks pressed another VA official, Wendy Tenhula, about the department’s suggestion that her legislation is overly prescriptive, pointing out that it was specifically crafted to ensure flexibility. She asked for clarification on VA’s recommendation for inter-agency coordination. Tenhula said VA is “interested in working with other federal agencies in developing a plan for an observational study that would allow us to understand cannabis use among not only veterans, but a broader population and not only veterans that seek care in the VA Health Care System.” “So allowing us to work with other federal agencies on those efforts would allow for more unbiased data collection and would provide data that could influence clinical trials that you mentioned and advise us in what direction to go with those trials,” she said. The VSOs Disabled American Veterans (DAV), Wounded Warrior Project (WWP) and Paralyzed Veterans of America (PVA) submitted testimony in support of the proposal. “Many veterans are currently using cannabis, and it is important for medical research to continue exploring the safety and efficacy of cannabis usage for medical purposes,” DAV said. “It is crucial for clinicians to be able to offer veterans with PTSD and chronic pain appropriate guidance on the potential impacts, harms, and benefits of cannabis use to provide comprehensive support.” WWP said it “believes that choosing an alternative treatment is a personal decision that should be made between a warrior, his or her family, and his or her medical team.” “We also support warriors having access to evidence-based and evidence-informed therapies, as well as complementary and alternative therapies, that have proven to be effective in rehabilitation and recovery,” the group said. “As several early studies have shown promising results for veterans using cannabis to treat conditions like chronic pain, WWP supports continued research in this field and the passage of the Veterans CARE Act.” PVA said that there’s a “growing body of evidence that cannabinoids are effective for treating conditions like chronic pain, chemotherapy induced nausea and vomiting, sleep disturbances related to obstructive sleep apnea, multiple sclerosis spasticity symptoms, and fibromyalgia.” “PVA supports evidence-based alternative treatments, including research into the efficacy of medical cannabis,” it said. “A series of clinical trials on the use of medicinal cannabis may help determine if it could provide any medical benefits for veterans.” The measure as drafted is identical to an earlier measure Miller-Meeks sponsored last Congress. On the Senate side, a committee approved a separate bill last February to promote research into the therapeutic effects of marijuana for military veterans with certain conditions. However, Senate Republicans blocked a procedural motion to advance it to the floor. The other bill that was taken up in the House subcommittee hearing on Thursday, sponsored by Rep. Derrick Van Orden (R-WI), would instruct VA to notify Congress if any psychedelics are added to its formulary of covered prescription drugs. At the hearing, Van Orden discussed the suicide epidemic among veterans and stressed that “we have to try something different—we simply do.” “I’ll tell you what, honestly, I’m not 100 percent sold on this. I am not,” he said, referencing psychedelics treatment. “But you know what? It works for some of our veterans. It does. Some of our veterans on this committee actually have done psychedelic treatment to prevent or to help them deal with PTSD, and it worked for them.” “I’m asking you all to vote for this, understanding that it’s not a do-all, fix-all for everybody,” Van Orden said. “But it’s gonna help at least save one veteran’s life so that I don’t have to go to their funeral and get on my knees one more time and speak to these fatherless children and look at their widow and try to explain to them why we didn’t do everything we possibly can to prevent their husband from committing suicide.” The bill states that VA must report to Congress on the addition of any psychedelic medicines to its formulary within 180 days of their federal approval by Food and Drug Administration (FDA). The report would need to include “the determination of the Secretary whether to include such drug in the formulary of the Department,” as well as “the justification of the Secretary for such determination,” the bill text says. Rep. Greg Murphy (R-NC) also voiced support for the legislation, echoing Van Orden’s comments about the urgency of exploring novel solutions to the veterans suicide epidemic. “We’re gonna get back to where this is literally the end of the road for individuals,” he said. “I was very skeptical of psychedelics. I read the literature and I’m very much a proponent of this.” “I am not a fan of marijuana in a general sense,” he added, referencing the other legislation being considered at the hearing. “But if it’s going to help our veterans and it’s very restricted,” he said he’s in favor. The congressman also pointed out that veterans “may have to travel” out of the country for psychedelics treatment. “Well, if the option is traveling to a cemetery or traveling to a VA to go get this, by God, we ought to be knocking down the doors of hell to do it. It’s critical.” Currently, there are no psychedelic drugs that are federally approved to prescribe as medicine. But that could soon change, as FDA recently agreed to review a new drug application for MDMA-assisted therapy on an expedited basis. The agency has also designated psilocybin, and more recently an LSD-like compound, as “breakthrough therapies.” In January, VA separately issued a request for applications to conduct in-depth research on the use of psychedelics to treat PTSD and depression. In testimony, VA said that it opposes the proposal because the department views it as “unnecessary.” “VA already has processes in place where formulary decisions regarding inclusion or exclusion of a drug are released publicly,” it said. “In this context, the bill would include additional administrative burden without any increase in transparency or accountability.” “We are also concerned about the precedent this could set; further reporting would only delay actions that would improve Veterans’ access to new drugs and treatments,” it said. “VA makes decisions regarding which drugs to include in the formulary in consideration of the best clinical outcomes of Veterans; if the FDA approves any psychedelic drugs, VA will review these drugs using the same process as any other drug or medication.” “These concerns are hypothetical at this point, though, as no psychedelic drugs have been approved by FDA yet. VA is developing plans to respond in the event such drugs are approved. All drugs that are approved by the FDA are available to Veterans with clinical need, regardless of whether the drug is available on the formulary.” DAV, meanwhile, testified in favor of the legislation, saying it supports “research to develop new, safe, and effective treatments and therapies for veterans, particularly when seeking relief from hard-to-treat injuries and illnesses.” “Our nation’s veterans deserve access to the most effective treatments and therapies available, including alternative options available under the law,” it said. “It is important that Congress and VA support safe and effective innovations in delivering evidence-based treatments to improve veterans’ health and quality of life.” Van Orden, who filed the psychedelics bill, is also a co-sponsor of a bipartisan measure to provide funding to the Department of Defense (DOD) to conduct clinical trials into the therapeutic potential of certain psychedelics for active duty military members. That reform was signed into law by President Joe Biden under an amendment attached to the 2024 National Defense Authorization Act (NDAA). On Wednesday, congressional appropriations leaders also unveiled a spending package that contains language providing $10 million to facilitate the psychedelics studies. Meanwhile, in a floor speech last year, the Miller-Meeks, the subcommittee chair, talked about the need to support “novel forms of research” to unlock the potential of psychedelics and cannabis for the treatment of conditions like PTSD that commonly afflict veterans. She also touted first-ever FDA guidance on psychedelics research that she separately requested in a bill filed last year alongside Reps. Dan Crenshaw (R-TX) and Ro Khanna (D-CA). —Marijuana Moment is tracking more than 1,400 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— During joint U.S. House and Senate committee meetings earlier this month, VSOs also pressed members of Congress to more urgently pursue the potential benefits of psychedelic-assisted therapy and medical marijuana. The requests from groups like the Iraq and Afghanistan Veterans of America, Veterans of Foreign Wars of the United States, Disabled American Veterans and the Wounded Warrior Project came on the heels of organizations at last year’s set of annual VSO hearings criticizing VA for “dragging their feet” on medical marijuana research. In October, VA separately launched a new podcast about the future of veteran health care, and the first episode of the series focuses on the healing potential of psychedelics. FDA officials also recently joined scientists at a public meeting on next steps for conducting research to develop psychedelic medicines. Congressional Leaders Again Seek To Block D.C. Marijuana Sales, While Funding Psychedelic Studies, In New Spending Bill Image element courtesy of Kristie Gianopulos. Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Some lawmakers who backed the ban in principle feared it “could have unintended consequences.” By Kyle Pfannenstiel, Idaho Capital Sun A bill to criminalize advertising illegal services or products—like marijuana—in Idaho failed to pass the Idaho Senate on Wednesday. Marijuana is illegal in Idaho and in federal law. But states surrounding Idaho, like Washington, Montana, Nevada and Oregon, have legalized marijuana for recreational use in recent years. House Bill 613 would have allowed misdemeanor charges for ​​”any person who willfully publishes any notice or advertisement, in any medium, within the state of Idaho for a product or service that is illegal under the laws of the jurisdiction where the product or service is offered, including federal, state, or local laws.” Rep. Judy Boyle, R-Midvale, who sponsored the bill, has pitched the bill as a way to reign in advertisements for marijuana. The Idaho Senate rejected the bill on an 18-16 vote on Wednesday. The House passed the bill on a 47-22 vote. Some Idaho senators critiquing the bill in floor debate on Wednesday worried about the bill’s application of federal law. Sen. Brian Lenney, R-Nampa, said he supported the bill’s intent, but he said the bill “could have unintended consequences” and should be “narrowed down in scope.” “I’m thinking about things like pistol braces or bump stocks or suppressors… Because we know there’s always arguments around these things,” said Lenney, who voted against the bill. Sen. Tammy Nichols, R-Middleton, said she would have loved to support the bill, but she said she had issues with its legality and constitutionality. “The federal government at any time can make something illegal. Let’s take vitamins or raw milk or something like that, for instance. Now all of a sudden that can’t be advertised, according to what I’m reading in this legislation,” Nichols said. If passed, the bill would have taken effect July 1, 2024. This story was first published by Idaho Capital Sun. Delaware Senators Approve House-Passed Bill To Expand Medical Marijuana Access By Letting Patients 65+ Self-Certify Without Doctors Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
March 22, 2024Cannabis News​ Ongoing federal marijuana prohibition has created a “real problem” for banks amid the growing state legalization movement, a top Biden administration official says, adding that it would be “desirable” for Congress to pass reform legislation to address the issue. At a House Appropriations Financial Services And General Government Subcommittee hearing on Thursday, Rep. Dave Joyce (R-OH) asked Treasury Secretary Janet Yellen to weigh in on regulatory complications resulting from the “conflict” between federal and state marijuana policies. “Can you tell me what is presently this administration’s position on” the Secure and Fair Enforcement Regulation (SAFER) Banking Act, Joyce, co-chair of the Congressional Cannabis Caucus, asked. Yellen began by saying that her department would “potentially welcome legislation in this area that would clarify for banks what their responsibilities are” with respect to the cannabis industry. She added that “the fact that marijuana is outlawed by the federal government creates an impediment to willingness to provide banking services to cannabis firms, and it creates all the problems that you’re familiar with.” “I think legislation may be necessary to raise the comfort level that banks have with doing this business.” Rep. Steny Hoyer (D-MD) also told the secretary that he agrees “100 percent” with Joyce that the issue needs to be resolved. He said that while he’s not personally a cannabis consumer, “it is a shame that the Senate has not passed legislation that we passed in the House” to fix the banking problem. The Senate Banking Committee approved the SAFER Banking Act last September, but it’s currently pending floor action. To Hoyer’s point, the House has passed earlier versions of the legislation at least seven times in some form over recent sessions. “We’re putting people in a very vulnerable position where they have large amounts of cash. We’re encouraging criminals to break into businesses that deal in cannabis,” Hoyer said. “I am neither a user nor suggester of using, but the fact of the matter is every state that’s voted on it has made it legal, and I appreciate your work and whatever I can do to help you on there.” Notably, this is the second time that the former House majority leader proactively voiced his support for cannabis banking reform this week. He also went out of his way to criticize the “contradictory and confusing” status quo during a separate Appropriations subcommittee hearing on Wednesday. Joyce concluded by asking Yellen whether she’d agree with her Trump administration predecessor, former Treasury Secretary Steven Mnuchin, that the current situation is “untenable.” “I think it’s a real problem,” she replied. “And it would be desirable to have legislation that alleviated this problem.” —Marijuana Moment is tracking more than 1,400 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.— Yellen has long expressed frustration about ongoing barriers to traditional financial services for the marijuana industry under federal prohibition, saying last year that it is “unfortunately” the case that banks remain reluctant to work with state-licensed cannabis businesses, and it’s something regulators “have been looking for solutions to.” In 2022, she said that it’s “extremely frustrating” that Congress has so far been unable to pass marijuana banking reform legislation and that Treasury is “supportive” of the proposal. Yellen has also made headlines recently for lighter news, including her joking during a late night show that smoking marijuana “always helps” when you “get stuck” on a difficult level of the mobile game Candy Crush. (In reality, she said she hasn’t used cannabis since the summer before attending Yale University.) The secretary also ventured to China last year where she inadvertently ate a “delicious” meal featuring a mushroom with hallucinogenic properties. On marijuana banking legislation, Senate Majority Leader Chuck Schumer (D-NY) recently recommitted to prioritizing the SAFER Banking Act, telling Marijuana Moment that there have been “very productive” bicameral talks to reach a final agreement. The chair of the Senate Banking Committee also said recently that passing marijuana banking legislation remains a priority for the chamber, despite political complications in the House. And a top Republican congressman reaffirmed his support for the bipartisan cannabis measure, despite not being “a marijuana guy.” VA Asks Congress To Amend Medical Marijuana Bill For Veterans While Opposing Psychedelics Measure At Hearing Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.  Read More Feedzy  [...] Read more...
Cannabis Recipes
August 3, 2023Ingredients 4 quarts popped popcorn 1 cup brown sugar 1/2 cup corn syrup light 1/2 cup cannabis butter 1/2 tsp salt 1/2 tsp pepper 1 tsp vanilla extract 1/2 tsp baking soda Instructions Preheat your oven to 250 degrees Fahrenheit. Spray a large shallow roasting pan with cooking spray and add popcorn. In a separate bowl mix brown sugar, corn syrup, cannabis butter, and salt in a heavy saucepan. Stirring constantly, bring to a boil over medium heat. Boil 5 minutes without stirring. Remove from heat. Stir in baking soda and vanilla; mix well. Pour syrup over warm popcorn, stirring to coat evenly. Bake for 45 minutes, stirring occasionally. ​ Enjoy! Keep refrigerated for extended shelf life. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
August 3, 2023Ingredients 6 cups fresh or frozen blueberries (you may substitute some pitted cherries too!) 1 Tbsp lemon juice 1/4 cup all-purpose flour 1/2 cup white sugar (you may add canna-sugar for increased potency) 1/4 tsp cinnamon 2 Tbsp canna-butter, cut into small pieces (you may substitute canna-coconut oil) 2x pie crust recipe or store bought Directions Preheat oven to 350°F/175°C. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12–15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023This recipe may be used with heavy cream or whole milk. Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients ​6 grams cannabis flower 2 cups whole milk or heavy cream ​ Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the milk or heavy cream, in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Cannabis infused sugar offers a simple way to enhance your baked goods or beverages. Materials Mason Jar ​Cheesecloth Baking Sheet 9in x 13in Baking Pan Ingredients -3 grams of cannabis flower -1/2 cup of high-proof alcohol, such as Everclear -1/2 cup granulated sugar Directions 1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Transfer the cannabis to a jar and cover with the alcohol. Screw the lid on tight and shake every 5 minutes for 20 minutes. 3. Strain through a cheesecloth set over a bowl, discarding solids. Mix the strained alcohol with the sugar and spread into an even layer in a glass 9-by-13-inch baking dish. ​ 4. Bake at 200°F, stirring occasionally, until the alcohol has evaporated and the sugar is lightly golden. This recipe is available for download HERE The original recipe is from Vice.com [...] Read more...
August 3, 2023Servings: 12 Ingredients 1 cup soybean oil ½ ounce ganja shake 2 large egg yolks 1 teaspoon fresh lemon juice Pinch of salt 1 teaspoon white vinegar ½ teaspoon Dijon mustard ​Directions In a double boiler, combine the oil and ganja. Heat over low until the ganja smell is pronounced but not nutty or burnt. (The oil should have an earthy green tint to it.) Let cool. Remove and strain the herb, squeezing the weed in a metal strainer against the mesh with the back of a spoon to wring out every drop of oil. Make sure that all your ingredients have been brought to room temperature — this is crucial! ​In a small metal bowl, use an immersion blender or whisk to thoroughly blend the egg yolks, lemon juice, salt, vinegar, and mustard. This can also be done in a food processor or blender. ​Using a ½ teaspoon measure, very slowly add the infused oil to the small metal bowl, a few drops at a time, while constantly blending on low or whisking until the mayo is thick and starting to form ribbons. (If it’s too thick, you can add room-temperature water in tiny increments.) If your mixture “breaks,” it can be repaired by whisking some more room-temperature egg yolks in a separate bowl, then slowly whisking those yolks into the “broken” mayo mixture. If that doesn’t do it, add a few drops of hot water. ​Cover and chill; it’ll keep in the refrigerator for 4 to 5 days. Original recipe from: Boudreaux, Ashley. The Official High Times Cannabis Cookbook. Red Eyed Deviled Eggs. https://saltonverde.com/wp-content/uploads/2017/09/10-High_Times_Cannabis_Cookbook.pdf [...] Read more...
August 3, 2023Ingredients 2/3 cup Cannabis oil (coconut or olive oil will work) 4 large potatoes peeled 3 tbsp salt Instructions Preheat your oven to 400 degrees Fahrenheit and line a large baking sheet with parchment paper. Cut your peeled potatoes into strips (cut them into fries!) and spread them evenly on the baking sheet. Drizzle the cannabis-infused oil over them and season with salt. Try to coat each fry relatively evenly with the oil so that there is a consistent potency. Cook the fries until they are golden brown. Around 15–20 minutes. Allow the fires to cool down, around 5 minutes. Divide the fries into equal proportions and serve. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
August 3, 2023Ingredients Cupcakes: 2 cups flour 1 cup sugar 1 Tbsp baking powder 1/4 Tsp salt 1 cup milk 2 eggs 1/4 cup canna-oil (vegetable is best) 1/4 vegetable oil 2 Tsp vanilla extract 1/3 cup rainbow sprinkles Frosting: 1 cup sugar 1 cup egg whites 1lb butter, salted, room temperature 1 Tsp vanilla extract ​ Directions ​Cupcakes: Preheat oven to 350°F. Line a cupcake pan with cupcake liners. Mix all of the dry ingredients together in a medium bowl. Whisk all of the liquid ingredients together until blended. Add the liquid ingredients to the dry ingredients & mix until there are no large lumps. Do not overmix. Gently stir in the rainbow sprinkles until just blended. ​ Use a 2-ounce portion scoop & fill each cupcake liner with one scoop. Bake for 15–18 minutes or until a toothpick inserted in the middle comes out clean. Remove from the oven & allow to cool a bit before removing them from the pan. Frosting: Put 2 inches of water into a medium-size pot, & bring to a boil. Place the sugar & egg whites into a small stainless bowl that will sit on top of the pot of boiling water, or use a double boiler system. DO NOT allow the bowl with the egg white mixture to directly touch the boiling water or the egg whites will cook very quickly. Whisk constantly until temperature reaches 140°F/60°C or until the sugar has completely dissolved & the egg whites are hot to the touch. DO NOT leave unattended or you will have a sweet egg white scramble! Use a hand mixer or pour the egg white mixture into a bowl that is fitted for a stand mixer. Using the whisk attachment, begin to whip until the meringue is thick & glossy, about 10 minutes on medium-high. Place the mixer on low speed, add the cubes of butter, a couple at a time, until incorporated. Continue beating until it has reached a silky smooth texture. If the buttercream curdles simply keep mixing & it will become smooth. If the buttercream is too runny, refrigerate for about 15 minutes before continuing mixing. Add the vanilla & continue to beat on low speed until well combined. Once the cupcakes have completely cooled, place a large star tip into a piping bag & fill with the buttercream. Pipe a rosette onto each cupcake & add the sprinkles on top. Serve immediately, the same day or keep in an airtight container in the fridge for up to 4 days. They can also be frozen for up to 3 months. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -1 pound unsalted butter Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the butter in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023Ingredients 2 slices of bread Cheese Canna-Butter Optional fillings: tomato, green onion, chicken, tuna Directions 1. Use a knife to coat both pieces of bread with canna-butter Be sure to coat both sides of the bread 2. Bring skillet to medium heat and add a small scoop of canna-butter ​ 3. One the butter has melted, place one slice of bread on the skillet 4. Add as much cheese and fillings as you like, then place the second slice of bread on top 5. Flip the sandwich when the bottom is golden brown, add more butter if needed for the new side 6. When the sandwich looks adequately fried and the cheese is melted to your liking, take it off of the skillet, slice in half, and enjoy! Original recipe from Satori MJ [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 1 ½ cups of mozzarella cheese, shredded 1/2 cup cheddar cheese, shredded 6 eggs 1 cup of milk (canna-milk may be used for a more potent dish) 1 pie-crust, unbaked Filling: 1/2 cup of canna-butter 1 onion, diced 1 cup broccoli, chopped 1 head of garlic ​ Instructions 1. Melt canna-butter in a pan over medium heat ​ 2. Add vegetables to butter and cook on medium heat for about 5–8 minutes (or until veggies are cooked) Do not let the butter or vegetables burn, to maintain potency of the butter 3. Scoop cooked vegetables into empty pie crust and cover with shredded cheeses 4. Beat eggs and milk together and pour into the pie crust 5. Bake for 35–40 minutes at 360°F Allow quiche to cool 10 minutes before serving This recipe is available for download HERE Original recipe from cannabis.wiki [...] Read more...
August 3, 2023Ingredients 4 Pork chops Salt and pepper 1 Tbsp minced rosemary 2 Cloves minced garlic 1/2 Cup canna-butter 1 Tbps canna-oil Instructions 1. Preheat oven to 375°F. Season pork chops with salt and pepper 2. In a small bowl, combine canna-butter with rosemary and garlic. Set aside 3. In an oven-safe skillet over medium heat, heat canna-oil and add pork chops. Sear until golden, about 4 minutes, flip and cook for another 4 minutes. 4. Brush pork-chops generously with the garlic canna-butter mixture and place skillet in the oven to bake for 10–12 minutes. Serve with more garlic butter. ​If you do not have an oven-safe skillet, you may use a regular one and transfer to a baking dish. Be sure to collect all the oil from the pan when transferring. This recipe is available for download HERE Original recipe from Eat Your Cannabis.com [...] Read more...
August 3, 2023Ingredients 1 cup breadcrumbs 1/2 cup canna-milk 1 lb ground beef 1/2 lb ground pork 1/2 lb Italian sausage, casing removed 1 small onion, finely diced 3 cloves garlic, minced 1 cup grated parmesean cheese 1/4 cup chopped parsley 2 large eggs, beaten 2 Tbsp canna-oil 1 (32oz) jar marinara sauce Instructions 1. In a small bowl, stir bread crumbs with canna-milk until evenly combined. Let sit 15 minutes, or while you prep other ingredients. 2. In a large bowl, use your hands to combine beef, pork, sausage, onion, and garlic. Season with salt and pepper, then gently stir in breadcrumb mixture, eggs, Parmesan, and parsley until just combined. Form mixture into 1” balls. 3. In a large high-sided skillet over medium heat, heat oil. Working in batches, sear meatballs on all sides to develop a crust. Set meatballs aside, reduce heat to medium-low, and add sauce to skillet. Bring sauce to a simmer then immediately add meatballs back to skillet. Cover and simmer until cooked through, about 8 minutes more original recipe from eatyourcannabis.com [...] Read more...
August 3, 2023Ingredients 2 lbs of potatoes 4 tablespoons cannabutter 4 tablespoons sour cream or plain cream cheese Salt and pepper ¼ to ½ cup of milk or cannamilk for increased potency 2 cloves of garlic minced or 1 tsp of garlic powder Instructions Cut the potatoes in half or quarters to make medium-sized pieces. Place the potatoes in a saucepan filled with water and bring to a boil. Cook until fork-tender, between 20–30 minutes. Drain the potatoes and remove their skins. Add the cannabutter, garlic and sour cream to the bowl along with a splash of milk (don’t add it all at once.) Mash the contents, adding just a splash of milk each time until you’ve reached the desired consistency. ​ Stir in salt and pepper to taste. This recipe is available for download HERE original recipe from satorimj.com [...] Read more...
August 3, 2023Ingredients 2 cups shredded green cabbage 1 Tbsp lime juice 1/2 Tsp salt 3 Tbsp cilantro 1/4 cup canna-oil 1 tomato, diced 1/2 cup salsa 1/2 onion, diced 1 jalapeno, diced 1 avocado, sliced Meat of choice (fish or a ground meat like beef or turkey) 4 corn tortillas Directions 1. Cook choice of meat with fajita seasoning in frying pan, set aside 2. In a large bowl, mix shredded cabbage, line juice, salt and cilantro 3. In a separate bowl, mix canna-oil with tomato, onion, jalapeno and salsa 4. Wrap the tortillas in paper towels and heat in the microwave for 30 seconds, or until warm 5. Fill each tortilla with meat, cabbage mixture, cannabis salsa mixture and diced avocado ​Serve with lime wedge The recipe is available for download HERE Original recipe from Eat Your Cannabis [...] Read more...
August 3, 2023Ingredients 3 Tbsp mayonnaise 2 Tsp Dijon mustard 1/2 Tsp salt 1/2 Tsp pepper 2 Eggs, lightly beaten 1lb Lump crab meat 2 Tbps finely chopped parsley 3 Tbsp canna-butter Instructions 1. Whisk together mayonnaise, mustard, salt, pepper and eggs. Then gently stir in crab meat, panko and parsley. 2. Shape mixture in to 12 (3-inch) patties, pressing gently to flatten. Cover with plastic wrap and refrigerate for 1hr. 3. Melt half the canna-butter in large, nonstick skillet over medium heat. Add 6 patties to the pan and cook for 2 minutes on each side, or until golden brown. Repeat with the remaining half of canna-butter and remaining 6 patties. The recipe is available for download HERE original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Ingredients blender ¼ cup tahini ¼ cup lemon juice, freshly squeezed w/o seeds 15 ounce can of chickpeas, drained and rinsed 2 garlic cloves ¼ cup CannaOil ½ cup ground cumin 2 tablespoons water salt and pepper to taste Instructions Combine lemon juice and tahini in a blender. Blend for 30 seconds. Add chickpeas, garlic, Canna Oil, cumin and water. Blend for 1 minute until smooth. Add more water if needed to reach desired consistency. Pour hummus in a serving bowl, or store in the refrigerator for later. This recipe is available for download HERE Original recipe from eatyourcannabis.com [...] Read more...
August 3, 2023This soup can be enhanced with any of your favorite vegetables. Materials Soup Pot Frying Pan Hand-Blender or Regular blender (optional) Ingredients ​3 cups vegetable stock 1 cup chopped broccoli 1/2 red onion, chopped 2 stalks of celery, chopped 1 and 1/2 cup heavy cream (canna-cream may be substituted or blended with regular cream for increased potency) 2 TBSP olive oil Fresh cilantro (optional) Salt and Pepper to taste ​Canna-Oil (dose-dependent) Directions 1. Heat vegetable stock and broccoli in a large pot Boil for around 6 minutes 2. On another burner, saute garlic, onion and celery in olive oil until soft — about 4 minutes ​​ 3. Take the pan off the heat and add desired dose of canna-oil to vegetables Stir thoroughly and then pour mixture in to the big soup pot Be sure to scrape all material to get the maximum amount of canna-oil 4. Heat for another 6–8 minutes then reduce heat to low and add heavy cream, add salt and pepper to taste ​ 5. Let simmer for 5 minutes, serve hot  ​Garnish with cilantro if desired This recipe is available for download HERE The original recipe is from Royal Queen Seeds [...] Read more...
August 3, 2023Ingredients 1 can whole peeled tomatoes 28 oz. 1 jar roasted red peppers 12 oz. 4 large eggs ½ cup plain Greek yogurt ¼ cup CannaOil plus more for drizzling 1 teaspoon coriander seeds 1 teaspoon cumin seeds 6 garlic cloves divided 2 medium shallots divided Kosher salt Freshly ground black pepper Mint leaves and crusty bread for serving Crush coriander and cumin seeds, pressing down firmly with even pressure. Transfer seeds to a small heatproof bowl. Slice 2 garlic cloves as thinly and evenly as you can; add to bowl with seeds. Finely chop the remaining 4 garlic cloves. Cut half of 1 shallot into thin rounds and then add to the same bowl with seeds and garlic. Chop remaining shallots. Open a jar of red peppers and pour off any liquid. Remove peppers and coarsely chop. Combine ¼ cup oil and seed/garlic/shallot mix in the skillet you used for crushing seeds. Heat over medium and cook, stirring constantly with a wooden spoon, until seeds are sizzling and fragrant and garlic and shallots are crisp and golden, about 3 minutes. Place a strainer over the same heatproof bowl and pour in the contents of the skillet, making sure to scrape in seeds and other solids. Do this quickly before garlic or shallots start to burn. Reserve oil. Spread out seed mixture across paper towels to cool. Season with salt and pepper. Return strained CannaOil to skillet and heat over medium. Add remaining chopped garlic and shallot and cook, stirring often, until shallot is translucent and starting to turn brown around the edges, about 5 minutes. Season with salt and lots of pepper. Add chopped peppers to the skillet and stir to incorporate. Using your hands, lift whole peeled tomatoes out of the can, leaving behind tomato liquid, and crush up with your hands as you add to the skillet. Discard leftover liquid. Season with more salt and pepper. Cook shakshuka, stirring often, until thickened and no longer runs together when a spoon is dragged through, 10–12 minutes. Reduce heat to low. Using the back of a wooden spoon, create four 2″-wide nests in tomato sauce. Working one at a time, carefully crack an egg into each nest. Cover skillet and cook, simmering very gently and reducing heat if necessary, until whites of eggs are set while yolks are still jammy, 7–10 minutes. Uncover skillet and remove from heat. Season tops of eggs with salt and pepper. Top shakshuka with dollops of yogurt, sprinkle with seed mixture, then drizzle with more olive oil. Finish by scattering mint leaves over top. ​ Serve pita or crusty bread alongside. This recipe is available for download HERE Original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Ingredients 1 package of Instant Ramen Vegetable or Beef broth (use the amount listed on the package for water) Frozen vegetable medley One egg or tofu Dried seaweed (to garnish) Sesame Seeds (to garnish) Cannabis Tincture Directions 1. Follow the instructions on the ramen package, but swap the water out for broth 2. Add the frozen veggies when broth gets hot 3. Crack an egg in the hot broth and stir for a few minutes You can also use a hard-boiled egg or chopped tofu ​ 4. Add as much cannabis tincture that you want. If you are unsure, start with 1–2 drops 5. Top soup with dried seaweed and sesame seeds Original recipe from Satori MJ [...] Read more...
August 3, 2023Ingredients ¼ cup cannabuter, room temperature ½ cup regular butter, room temperature 1 cup brown sugar ½ cup white sugar 2 eggs, room temperature 1 tsp vanilla extract 2 ½ cups all-purpose flour 1 tsp cinnamon ½ tsp baking soda ½ tsp sea salt 1 cup mini chocolate chips 1 cup mini marshmallows 18 graham crackers Coating chocolate, melted Directions Preheat oven to 350°F/175°C. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12–15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Ingredients 4 eggs 1 cup white sugar ½ cup brown sugar, packed 1 ¼ cups grapeseed oil ¼ cup canna-oil 2 tsp vanilla extract 1 ¾ cups pure pumpkin puree 3 cups all-purpose flour 1 tbsp ground cinnamon 1 tbsp pumpkin spice 2 tsp baking powder 2 tsp baking soda 1 tbsp orange zest, optional Directions Preheat the oven to 350°F/175°C. Line a jumbo muffin tin with liners. Place the eggs, white sugar, brown sugar, grapeseed oil & canna-oil into a bowl fitted for a stand mixer or use a whisk to thoroughly beat ingredients together. Blend in the pumpkin & vanilla extract. In a small bowl mix the dry ingredients together. Add to the wet ingredients & mix until just blended. Stir in the orange zest (optional). Divide the batter evenly between 12 muffin cups using a muffin scoop, about 3 ounces each. Sprinkle with pumpkin seeds. Bake for 22–25 minutes or until a toothpick inserted into the middle comes out clean. ​ Allow to cool, remove from the tins & sprinkle with cinnamon. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Ingredients 2 cups all-purpose flour 4 Tbsp sugar (canna-sugar may be substituted to increase potency) 1 Tbsp baking powder ½ Tsp salt 2 large eggs 1 ½ cups whole milk (canna-milk may be substituted to increase potency) ¾ cup canna-butter, melted ​1 teaspoon vanilla extract Instructions 1. In a bowl, combine dry ingredients: flour, sugar, salt, baking powder 2. In another bowl, combine wet ingredients: beat the eggs with the milk, then add the vanilla extract 3. Stir the wet ingredients into the dry ingredients until just combined ​Do not over-mix, batter will be thick and slightly lumpy 4. Bake in a preheated waffle-iron according to manufacturer’s directions until golden brown This recipe is available for download HERE! Original recipe from allrecipes.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -​Thermometer -Mesh-sieve or cheesecloth Ingredients -​6 grams cannabis flower -2 cups oil (olive, coconut, canola or vegetable oil) Directions ​ ​1. Decarboxylate the cannabis Heat the oven to 225°F. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. ​Take care not to let the temperature go over 225°F and burn (if this happens, you can lose potency). Bake for about 35–40 minutes, then remove from the oven and cool before grinding into a coarse powder. ​ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the oil in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200°F for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible ​The oil will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 4 large eggs salt and pepper (to tasste) 1 tbsp butter (canna-butter may be used to increase potency) 1/2 cup canna-milk Filling: 2 tbsp diced green pepper 2 tbsp diced green onion 2 tbsp ham or meat of your choice 1/4 cup shredded cheese ​ Instructions 1. Beat eggs in a bowl with a whisk. 2. Add canna-milk and season with salt and pepper 3. Add any vegetables and/or meat fillings to the eggs and whisk for a few minutes until egg mixture if foamy — beating in air makes the omelette fluffy​ 4. Melt butter in a small, nonstick skillet over medium-low heat. Pour in egg mixture and twirl skillet so the bottom is evenly covered in egg. 5. Cook until egg starts to set. Lift the edges with a spatula and tilt the skillet so uncooked egg mixture can run towards the bottom of the skillet to set Repeat until no visible liquid egg remains 6. Carefully flip omelette and cook another 30 seconds to 1 minute 7. Sprinkle cheese in one line in the middle of the omelette and fold it in half, cook another 20 seconds them slide the omelette on to the plate This recipe is available for download HERE Original recipe from the Canna School [...] Read more...
August 3, 2023Ingredients -1.5 cups all-purpose flour -1 Tbsp sugar (canna-sugar may be substituted to increase potency) -1 Tbsp baking powder -1 Tsp salt -1 large egg -1.25 cups whole milk (canna-milk may be substituted to increase potency) -3 Tbsp of melted canna-butter or oil -​1 teaspoon vanilla extract (optional) Instructions 1. In a bowl, combine dry ingredients 2. In another bowl, combine wet ingredients 3. Stir the wet ingredients into the dry ingredients until just combined ​Do not over-mix, batter will be thick and slightly lumpy 4. Heat a large frying pan with with a small amount of butter or oil 5. Pour 1 cup of batter in the center of the pan. Fry 2–3 minutes before flipping 6. Fry an additional 3–5 minutes or until pancake reaches your preferred doneness and remove from pan 7. Garnish with your favorite toppings; powdered sugar, syrup, butter, chocolate chips or whatever you might enjoy! Original recipe from cannabis wiki [...] Read more...